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University of Pittsburgh, 2011 
 
In response to in utero insults, male vs. female infants have greater disadvantages in 
pregnancy outcome. We asked if this differential impact of fetal sex might extend to fetal growth 
in utero during preeclampsia.  We first investigated the influence of relevant variables in 
normotensive pregnancy. We evaluated whether the impact of maternal pre-pregnancy body 
mass index (BMI), smoking and socioeconomic status were modified by sex and/or race in 
singleton offspring of 8,801 primiparous normotensive women enrolled in the Collaborative 
Perinatal Project. The mean head-to-chest circumference (HCC) decreased more or each 1kg/m2 
increase in pre-pregnancy BMI, while mean birthweight and ponderal index (PI) increased more 
for each 1kg/m2 increase in pre-pregnancy BMI among term females vs. males (p=0.07, p<0.01 
and p=0.08, interaction respectively).  
We then investigated whether the relationship between preeclampsia and fetal growth 
was modified by sex in offspring of 516 preeclamptic and 8801 normotensive primiparous 
women. Male vs. female preterm offspring of preeclamptic mothers had greater reductions in 
mean birthweight, head and chest circumferences (p=0.05, p=0.02, p=0.01; interaction 
respectively). The influence of preeclampsia on growth of term offspring was more modest, and 
the influence of sex was opposite that in preterm infants. 
 v 
Next we investigated placentas from 735 preeclamptic and 21,185 normotensive 
primiparous and multiparous women, to determine which dimensions of placental growth are 
reduced in preeclamptic pregnancies. We then investigated if the relationship between these 
measures and birthweight was constant between offspring of normotensive and preeclamptic 
women, as well as across infant sex. We found that the smaller but not the larger placental 
diameter was an independent predictor of preeclampsia ((smaller diameter <15cm OR 1.27 95% 
CI 1.01, 1.59) and larger diameter <18 cm (OR 1.18 95% CI 0.90, 1.54)). We also found higher 
rates of increase in birth weight at lower placental weight and placental diameters in offspring of 
preeclamptic vs. normotensive women (all p<0.05, interaction). Additionally, we found that 
among the offspring of preeclamptic women, female offspring with smaller diameters above 
20cm, had a reduction in birth weight while males did not (p=0.02, interaction).  
 This work yields meaningful public health findings by providing evidence that 
influences upon fetal and placental growth are different by infant sex. Studies of mechanisms 
affecting fetal growth should investigate interactions with fetal sex. We hope studies of the 
involved biological pathways will direct future research to reduce rates of growth restriction and 
later life chronic diseases.   
 vi 
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1.0 INTRODUCTION 
 
 
 
1.1 SPECIFIC AIMS 
 
Fetal growth restriction (FGR) is the failure of fetus to grow to his/her genetic growth potential 
(1). Fetuses with FGR have an increased likelihood of fetal death, need for assisted ventilation 
(2), cerebral palsy, as well as later life mortality and morbidity(3-8). Sex differences are often 
observed in pregnancy outcome. Spontaneous preterm labor (9) and complications of 
pregnancies (such as fetal distress during labor and non-reassuring fetal heart rate patterns) are 
more common with pregnancies bearing male fetuses compared to female fetuses (10, 11). 
Emerging evidence indicates that the frequency, expression and outcome of illnesses in adults is 
different based on sex (12). For example, males have poorer rates of survival from 
cardiovascular disease (13) and various cancers (14-16)  as well as higher rates of Parkinson’s 
disease (17, 18). Women tend to develop cardiovascular disease later in life compared to men 
and are more likely than men to die within one year of a heart attack (13). Female smokers are at 
a significantly greater risk of developing lung cancer than male smokers at similar levels of 
smoking (19). We hypothesize that this differential risk in disease outcome also exists in utero 
and at birth. 
 2 
Preeclampsia is a pregnancy specific disease that can cause fetal growth restriction (20-
24) and reduced placental growth(25, 26). Based on evidence of sexual differences in several 
pregnancy outcomes with different fetal sex, we suspect that fetal growth in preeclampsia is 
different based on the sex of the infant.   
Small for gestational age (SGA) is the most common marker used to detect abnormal 
fetal growth. It is commonly defined as birthweights below the 10th percentile for babies born at 
the same gestational age in a population, adjusted for sex and race.  However SGA as an 
indicator of reduced growth has several limitations: 1) An SGA infant may not be growth 
restricted, e.g. small individuals have small babies. 2) Growth restricted infants who do not 
exercise their true genetic growth potential may not be small enough to be SGA. Similarly, the 
ratio of fetal weight to placental weight (FPR) is often used as a measure of the efficiency of 
fetal growth relative to placental growth (27).  However this also has limitations. Placentas that 
are large and thin as well as placentas that are small and thick can produce FPRs that are 
consistent with normal proportioned placentas, (27) yet these may have very different 
implications (28). Owing to these limitations of determining impaired fetal growth by just SGA 
and FPR, it will be helpful to use additional anthropometric and placental indicators to 
characterize if fetal and placental growth in pregnancies diagnosed with preeclampsia varies by 
fetal sex. 
Guided by evidence of sexual differences in disease occurrence and severity outside of 
pregnancy and the known differences in several pregnancy outcomes with different fetal sex we 
intend to investigate if the relationship between preeclampsia, fetal growth and placental 
growth is modified by infant sex. 
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To meet the following specific aims, we will use data from the Collaborative Perinatal 
Project (CPP) — a prospective study of over 58,000 women recruited in 1959 to 1965 that 
collected obstetrical, perinatal, and pathological data to investigate neurologic disorders in 
children born to the women in the cohort. 
In order to assess the relationship between preeclampsia, fetal growth and fetal sex we 
first need to better understand the contribution of fetal sex to the markers of fetal growth and 
determine if sexual and/or racial dimorphisms exist among the determinants of fetal growth.  
Specific Aim 1: To determine if maternal pre-pregnancy BMI, smoking and SES contribute 
differently to fetal growth by infant sex or maternal race.   
 
Figure 1: Specific Aim 1 
 
Hypothesis: Similar to the trend with infant birthweight, these markers of growth: 
frequency of SGA, mean ponderal index (PI), mean head to chest circumference (HCC), 
and mean fetal placental ratio (FPR) will be lower for female and Black infants among 
smokers and lower SES groups. Female vs. male and Black vs. White infants will have a 
lower rate of growth with increasing maternal pre-pregnancy BMI.   
Determinant of Fetal 
Growth*  
Infant Sex or 
Maternal Race 
Fetal Growth 
*Determinant= maternal pre-pregnancy BMI, Smoking or SES. 
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After characterizing the relationship of fetal sex to ponderal index, head-chest circumference 
ratio and fetal placental ratio in normotensive pregnancies, we will then compare the influence of 
fetal sex in preeclampsia on the same outcomes. Small-for-gestational age categorization may 
underestimate the influence of reduced growth; therefore additional markers of growth will also 
be evaluated. 
Specific Aim 2: To investigate if the relationship between preeclampsia and fetal growth is 
modified by infant sex.   
 
Figure 2: Specific Aim 2 
 
Aim 2a: This study aims to investigate whether the relationship between preeclampsia 
and fetal growth is different by fetal sex among term infants using these markers of fetal 
growth: frequency of SGA, mean ponderal index, mean head to chest circumference and 
mean fetal placental ratio.  
Hypothesis: Term infants born to preeclamptic women will have smaller mean ponderal 
indices, smaller fetal placental ratios and higher head to chest circumference ratios 
compared to infants born to normotensive women. Reduced growth will be more 
profound among term male offspring of preeclamptic vs. normotensive women than 
among term female offspring of preeclamptic vs. normotensive women.  
Preeclampsia Fetal growth 
 
Infant Sex 
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Aim 2b: This study aims to investigate whether the relationship between preeclampsia 
and fetal growth is different by fetal sex among preterm infants. 
Hypothesis: Reduced growth will be more profound among preterm male offspring of 
preeclamptic vs. normotensive women than among preterm female offspring of 
preeclamptic vs. normotensive women.  
Specific Aim 3a: To investigate which dimensions of placental growth (thickness, small and 
large diameters and ratio of the diameters) are reduced in association with preeclampsia. 
Hypothesis: The risk of preeclampsia will increase with decreasing placental growth in all 
four placental dimensions. 
Specific Aim 3b: To investigate if the relationship between measures of placental growth and 
birth weight were constant between offspring of normotensive and preeclamptic women.  
Specific Aim 3c: To investigate if the relationship between the measures of placental growth and 
birth weight was constant across male vs. female offspring of normotensive and preeclamptic 
women. 
Hypothesis: In comparison to offspring of normotensive women, the trends in the 
relationship between birth weight and placental growth (specifically growth of the 
smaller diameter and larger placental diameter) will be different in preeclamptic 
pregnancies, as well as by infant sex. 
This research intends to bridge the gap in our understanding of fetal growth in normal 
pregnancy, fetal and placental growth in preeclampsia and the influence of fetal sex on these 
markers of fetal and placental growth. These relationships may be beneficial in directing future 
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research to interpret the mechanisms of fetal growth, placental structure/function, the 
pathophysiology of preeclampsia and the influence of fetal sex on these markers of growth. 
 
1.2 BACKGROUND  
 
 Preeclampsia 1.2.1
 
 Significance of preeclampsia 1.2.1.1
 
Preeclampsia is an important public health issue; preeclampsia is among the leading global 
causes of maternal and infant death. The World Health Organization (WHO) estimates that 
preeclampsia occurs among 3.2% of live births globally resulting in approximately 4 million 
cases annually with 72,000 being fatal among infants (29). Preeclampsia has detrimental effects 
on the infant such as an increased risk of stillbirth, preterm birth, growth restriction (30), and 
cerebral palsy (31) due to the limited oxygen and nutrient transfer during fetal growth (30).   
Preeclampsia can be considered as a 2-stage disease; the first stage is the unsuccessful 
remodeling of the spiral arteries in the uterus (32). This is proposed to result in reduced placental 
perfusion, the root cause of preeclampsia. During normal pregnancy trophoblast cells invade and 
remodel the spiral arteries of the placenta to make the artery walls thinner. With absent smooth 
muscle, the lumen is larger resulting in reduced resistance to blood flow to the placenta (33). The 
second stage, the maternal syndrome, is proposed to be a consequence of inflammation with 
endothelial dysfunction which results in circulatory disturbances in the various organ systems of 
the mother, including the renal, hepatic and central nervous systems (34). This second stage 
 7 
includes an interaction with maternal constitutional factors such as genetics, obesity or diet that 
leads to the systemic pathophysiological changes including hypertension and proteinuria in the 
mother (32).  
 Epidemiology of Preeclampsia 1.2.1.2
 
Preeclampsia is a pregnancy specific disorder, which is diagnosed by new onset proteinuria and 
gestational hypertension (increased blood pressure) occurring after 20 weeks gestation. 
Preeclampsia is different from gestational hypertension which is recognized as blood pressure 
>140/90 mmHg for the first time after 20 weeks of gestation, without proteinuria in previously 
normotensive women (35).  Offspring of preeclamptic women have a 5-fold increased risk of 
mortality compared to non-preeclamptic women (36).  Several studies suggest that there is at 
least a two-fold increased risk of fetal growth restriction (FGR) among infants of 
preeclamptic women compared to normotensive women. (21, 23, 24). Reduced placental 
perfusion is a characteristic of both FGR and preeclampsia. However only about a third of 
infants from preeclamptic pregnancies are growth restricted (22). It is postulated that the 
metabolic changes of preeclampsia represent an appropriate response of the fetus to reduced 
placental perfusion(37). Metabolic changes are absent in FGR pregnancies without preeclampsia. 
Therefore it is theorized that FGR occurs in preeclamptic cases when the metabolic adjustments 
are inadequate to overcome profoundly reduced placental perfusion (33, 38).  
 
 Preterm Preeclampsia 1.2.1.3
 
Preterm preeclampsia is defined as preeclampsia that results in delivery prior to 37 weeks of 
pregnancy while term preeclampsia is preeclampsia with delivery at 37 weeks or beyond (39). 
Preterm preeclampsia is associated with a greater maternal and fetal morbidity (40), as well as 
 8 
higher rates of recurrence of the disease and  higher rates of small for gestational age infants 
compared to term preeclampsia (41).  Furthermore, later life cardiovascular disease is more 
common in women with preterm than term preeclampsia (42). Our study will examine preterm 
and term status separately as these findings imply that it is important to stratify preeclampsia by 
preterm and term status.  
 
 Risk factors for Preeclampsia 1.2.1.4
 
Extensive research indicates that there are several important risk factors for preeclampsia. The 
following table summarizes data from multiple studies that identify the common risk factors for 
preeclampsia (Table 1). Preeclampsia in a previous pregnancy (OR range 5.0-21.5) and pre-
existing hypertension (OR range 4.45-8.97), are among the strongest risk factors for 
preeclampsia. Obese and overweight women have a 2 to 5 fold increase in the risk of having a 
preeclamptic pregnancy. Obesity as a risk factor for preeclampsia is a major public health 
concern due to the global epidemic of obesity. The Centers for Disease Control (CDC) reports 
that over a third of adults in the United States (over 72 million) were obese in 2005-2006 and 
that 35.3 percent of women are obese (43).  Older maternal age and pre-existing diabetes are 
moderately strong risk factors accounting for approximately two- to five-fold increase in the risk 
for preeclampsia. It is proposed that vascular endothelial damage is a natural process of aging 
and plays a role in increasing the risk of preeclampsia among women over 40 years of age (44). 
Nulliparity vs. multiparity triples the risk for preeclampsia. The increased risk of preeclampsia 
among first pregnancies (44-48) is consistent with the hypothesis which suggests that an immune 
maladaptation response towards invading cells of the fetus may influence preeclampsia(49). This 
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maladaptation is reduced by exposure to paternal antigen as occurs with the fetal maternal 
hemorrhage that normally accompanies delivery(50).   
Maternal cigarette smoking during pregnancy is associated with adverse outcomes such 
as increased risk of spontaneous abortion, low birth weight, preterm birth, fetal growth restriction 
and perinatal death (51, 52). Paradoxically however, the risk of preeclampsia is lower among 
smokers compared to non-smokers (53-55). 
The etiology of the Black-White racial disparities in adverse pregnancy outcomes is not 
fully understood (56). Black race is associated with an increased risk of preeclampsia (45) (57) 
as well as related severe complications (58).  In addition, infants born to Black mothers are 
smaller and have higher rates of growth restriction as well as preterm delivery compared to 
infants born to White mothers (59-62). Adjustment for social and maternal risk factors does not 
fully explain the racial disparity in adverse pregnancy and birth outcomes (63, 64).  
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Table 1: Selected Studies of Common Risk factors of Preeclampsia and Fetal growth Restriction 
Risk Factors Preeclampsia Comparison group Reference 
History of 
preeclampsia* 
 
 
21.5 (9.8-47.2) a 
11.2 (9.0-14.0)a 
6.3 (4.4-9.2) a 
5.0 (1.7-17.2) a  (severe) 
7.2 (2.74-18.74) a (severe)                                
Non-preeclamptic women 
Women with no prior preeclampsia 
Normotensive women 
Women without severe preeclampsia 
Normotensive women 
(46) 
(65) 
(44) 
(47) 
(57) 
Pre-existing 
hypertension 
8.97 (8.06-9.99)c  
4.4 (2.8-4.1)b 
1.99 (1.78-2.22) c 
Women without chronic hypertension 
Women without chronic hypertension 
Women without chronic hypertension 
(66)  
(65) 
(67) 
Pre-pregnancy BMI  
(kg/m2) 
7.6 (4.2-13.7)c (severe) 
5.3 (2.9-9.7)c (severe) 
3.5 (1.68-7.46) a 
2.8 (1.4-5.7)b 
2.6 (2.3-2.9)b 
2.4 (1.8-3.1) a   
BMI=35kg/m2 vs. BMI=20kg/m2 White women 
BMI=35kg/m2 (Black) vs. BMI=20kg/m2 (White)  
BMI ≥32.3 kg/m2  vs. <32.3 kg/m2   
BMI =35 kg/m2  vs. 21 kg/m2   
BMI ≥30 kg/m2  vs. <25 kg/m2   
BMI >24.2 kg/m2  vs. 19.8-24.2 kg/m2  
(68) 
(68) 
(57) 
(69) 
(65) 
(44) 
Maternal Age  
≥40 years  
5.48 (1.62-18.5)a    
4.39 (2.05-9.37) c     
1.9 (1.2-2.9)b  
1.8 (1.3-2.6) a  
Vs. women 20-30 years    
Vs. women  20-30 years    
Vs. women 20-29 years    
Vs. women 20-29 years   
(70) 
(70) 
(71) 
(71)             
Pre-existing Diabetes 5.58 (2.72-11.43) b 
2.77 (2.22-3.47) c 
2.1 (1.4-3.0)b 
Type 1 vs. Non diabetic women (<35 years) 
Non diabetic women 
Non diabetic women 
(72) 
(66) 
(65) 
Nulliparity 3.9 (3.0-5.2)  
3.6(2.6-5.0)  
3.8 (1.7-8.3) (severe) 
1.3 (1.2-1.5) 
nulliparous vs. multiparous 
nulliparous vs. multiparous 
nulliparous vs. multiparous 
nulliparous vs. multiparous 
(45) 
(46)  
(47) 
(44) 
Black Race 3.59 (1.54-8.38) a 
2.0 (1.2-3.4)c       
Black/Hispanic vs. White women 
Black vs. White women 
(57) 
(45) 
Smoking  in 
pregnancy 
0.6 (0.50-0.60) (mild)b 
0.5 (0.50-0.60) (severe)b 
0.51 (0.44, 0.58) c 
0.84 (0.78, 0.91)c 
Daily vs. nonsmokers at 1st antenatal visit 
Daily vs. nonsmokers at 1st antenatal visit 
>9 cigarettes/day vs. no tobacco use 
Ever vs. never smoked during pregnancy 
(54) 
(54) 
(73) 
(74) 
Adjusted relative risk or odds ratio (95% confidence interval) *History of preeclampsia in a prior pregnancy  
 a Multiparous women    b Nulliparous women   c Nulliparous and  multiparous women       
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 The Influence of Sex on disease 1.2.2
 
 Epidemiological studies of the influence of Sex upon Disease 1.2.2.1
 
Emerging evidence suggests that the frequency, expression and outcome of illnesses in adults is 
different based on sex (12). For example, the risk of a heart attack is greater among men; 
however women have an increased risk of dying within a year of an attack (13). Males have 
poorer rates of survival from various cancers (14-16)  as well as higher rates of Parkinson’s 
disease (17, 18) compared to women. Several mechanisms, including sex steroids affect 
differential sex outcome. Sex steroids play a role in the expression and outcome of diseases such 
as heart disease. Both testosterone (75-79) and estrogen (78, 80, 81) promote vasodilation of 
blood vessels and influence vascular function.  Low testosterone levels predict stroke (82), 
ischemic attack (82) and cardiovascular mortality (83, 84) in older men,  while the large 
Framingham study reported that the rate of cardiovascular disease increases after menopause in 
women (85). This suggests that sex hormones may play a role in the pathogenesis of 
cardiovascular and other later life diseases. Based on this evidence, we posit that differential risk 
by sex for disease exists as early as in uterine development.  
 
 Fetal Sex and Pregnancy Outcome 1.2.2.2
 
The majority of the current literature suggests that males are at a disadvantage at birth (Table 2). 
As a result, male excess morbidity at birth is of concern in the global medical community (86). A 
retrospective study of 75,725 births in a United Kingdom hospital found that spontaneous 
preterm birth is more common among women carrying male fetuses than when carrying female 
fetuses (9). A retrospective study in Dublin of 8,075 births among first pregnancies, reported that 
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women who experience spontaneous preterm labor as well as women who deliver at term are 
more likely to encounter complications requiring mechanical/instrument assistance if the infant 
is male (87). Other large studies show that complications during labor such as failure to progress 
(10, 88), true knots of the umbilical cord (88, 89), low Apgar scores (11, 88), fetal distress (11, 
90, 91) as well as higher rates of perinatal mortality (11, 91) are more common among male than 
female infants. The literature review revealed one study which reported no difference by sex for 
adverse outcomes among FGR infants, however this study was underpowered to detect the odds 
ratios reported in the previously cited studies (92). Many studies on the male disadvantage fail to 
separate the morbidities based on physical/mechanical or a biological disadvantage. Male infants 
are on average larger and heavier than female infants. This explains complications in pregnancy 
related to longer periods of labor and instrument or operative delivery. However the larger size 
of male infants does not explain the greater incidence of preterm birth, fetal distress or death. 
This suggests that other factors related to the sex of the infant may explain this sexual 
dimorphism.  
 
 Potential Biological Mechanisms 1.2.2.3
 
Little is known about the biological mechanisms responsible for the differential adverse 
outcomes in pregnancies by sex. However, a few mechanisms including gene and steroid 
pathways have been proposed. Gene pathways: Male infants have a XY chromosome while 
females have a XX chromosome. Among females, one X is inactivated during embryogenesis. 
The chorionic villi of the placenta have the ability to reactivate the inactive X-chromosome (93). 
The reactivated X-chromosome is theorized to play a role in increasing the survival of female 
fetuses in compromised uterine environments through conservative reduction in placenta growth 
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that is insufficient to cause  fetal growth restriction (94). Gene expression of immune receptors in 
the placenta has been found to vary by fetal sex. This is believed to play a role in the differential 
response to inflammation or infection as well as growth and development by fetal sex (95). 
Steroid pathway:  Fetal glucocorticoids play a role in fetal organ development (96). Exogenous 
glucocorticoids administered to women at risk for preterm delivery reduce the risk of neonatal 
respiratory distress and accelerate tissue maturation (96). However, high levels of 
glucocorticoids are harmful to the fetus. Placental 11β-hydroxysteroid dehydrogenase type 2 
(11β-HSD2) metabolizes glucocorticoids. Stark and colleagues performed a study on women at 
risk for preterm delivery who were treated with the glucocorticoid betamethasone. He found a 
sex specific autoregulation of 11β-HSD2 among infants born within 72 hours of treatment with 
betamethasone. He hypothesized that the placental adjustment (suppression) of the 11β-HSD2 
response among female infants decreased the metabolism of betamethasone. This allowed for the 
greater prophylactic effect of betamethasone among female infants. The adjustment of the 
response to glucocorticoids in female and the lack of adjustment in male infants may explain the 
greater morbidity and mortality observed among male infants (97). 
 
 Differential Outcome by Fetal Sex in Response to in utero Insults. 1.2.2.4
 
There is evidence that in response to in utero insults, male vs. female infants are at a greater 
disadvantage in pregnancy outcome. Bracero performed a study of 107 pregnant diabetic women 
found that male infants had higher morbidity than female infants at birth. Males had more 
hypoglycemia (p=0.01) and longer stays in intensive care (p=0.01) than female infants (98). 
Despite the fact that the Bracero study adjusted for maternal race, it failed to report data on the 
race of the mothers. Maternal race is known to influence fetal outcome. Another recent study of 
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323 diabetic women reported that male offspring of diabetic women were 3.5 times more likely 
to have a congenital malformation than female infants (OR 3.5 (95% CI 1.3–10.0); P = 0.02) 
(99). In a Swedish population study, 4749 women were diagnosed with chronic hypertension. 
These women had a 3 fold increase in intrauterine death (OR 3.07 (95% CI 2.12-4.46) compared 
to normotensive women, if the offspring was male. Female infants had no increased risk of 
intrauterine death (OR 0.98 (95% CI 0.51–1.89) (100).  
 Murphy found that among pregnant asthmatic women who did not use inhaled steroid for 
treatment of asthma, the female fetuses showed greater reductions in birthweight (p=0.02), while 
the growth of the males were unaffected (p=0.19) (101). However, among pregnant asthmatic 
women with severe exacerbations that required hospitalization, male infants had greater 
reductions in birth weight (p<0.05)(102). This is consistent with the theories proposed by 
Clifton(94)  and Eriksson(103) that when faced with maternal insults, males maximize continued 
fetal growth while females reduce growth to increase chances of survival. However when faced 
with continued or increased in utero insult, males are at greater risk for adverse outcome because 
they have exhausted their placental reserves (94, 103).  The Zetterstrom, Evers and Murphy 
studies were limited by little ethnic diversity in the study populations. Our study will analyze if 
the influence of fetal growth is modified by infant sex and race in a large Black and White 
population. 
Preeclampsia  is associated with an intrauterine enviroment that increases the risk of 
growth restriction and stillbirth (36). A case control study of premature deliveries at <32 weeks, 
at a university hospital reported that male fetuses were more likely to be associated with 
placental lesions that had chronic inflammation. This inflammation is indicative of a maternal 
immune response against the invading interstitial trophoblast (104). Therefore we propose that 
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the uterine insult in preeclamptic pregnancies may subject the already disadvantaged male 
offspring to a greater risk of growth restriction compared to female offspring.  
 
 Differential Outcome by Fetal Sex in Preeclampsia. 1.2.2.5
 
There is also evidence suggesting that there are differences in the outcomes of preeclamptic 
pregnancies depending on offspring sex. In contrast to the general population (105-107) where 
male fetuses are more common in preterm deliveries than at term, at least two studies indicate 
that male offspring were less common among preterm preeclamptic pregnancies, than among 
term preeclamptic pregnancies (106, 108).  
 Two small studies by Stark and colleagues found vasodilation and blood flow differences 
in preeclamptic women and their term offspring compared to normotensive women and their 
term offspring. The first study reports that the response to corticotrophin releasing hormone 
(CRH) was different in preeclamptic women with male but not female fetuses: the preeclamptic 
women bearing male offspring had reduced vasodilation in their peripheral microvascular and 
skin tissues while there was no difference among preeclamptic women bearing female offspring 
(109).  In the second equally small study of 38 offspring of normotensive and 33 offspring of 
preeclamptic women, blood flow in the peripheral microvascular and skin tissues was different in 
male and female infants of preeclamptic mothers after birth (110).  In both studies some of the 
preeclamptic women received anti-hypertensive medication which may have influenced 
microvascular function. However, the equal numbers of male and female infants exposed to the 
medication reduced the bias introduced by the medication in interpreting the influence of fetal 
sex on microvascular function.  Because the systemic vasculature of both the fetus and mother is 
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influenced by fetal sex, we also suspect that fetal sex may influence the placental vasculature, 
shape of the placenta, and fetal grow in the setting of preeclampsia.  
There is evidence to suggest that fetal sex affects maternal blood pressure, and 
hemoglobin concentration. Early gestational blood pressure was significantly higher in a large 
study of women who had gestational hypertension bearing male offspring than women with 
female offspring. Women with gestational hypertension also had lower third trimester 
hemoglobin values and less frequent proteinuria if their offspring was male. Surprisingly, 
however, Naeye reported that there were fewer syncytial knots (placental result of low 
uteroplacental blood flow) among the placenta of male fetuses (111). The Naeye study defined 
preeclampsia as 2 or more diastolic blood pressures that exceeded 90mmHg. This definition is 
more consistent with the definition of gestational hypertension than preeclampsia in our study 
and was re-defined for the purposes of this literature review as gestational hypertension. 
Increased blood pressure and gestational hypertension are signs of preeclampsia. These 
combined with low hemoglobin levels suggest that male sex may influence preeclampsia.  
Differential fetal sex outcome is not a well-studied area. To our knowledge, there are no 
previous studies that have investigated differential growth by fetal sex in preeclampsia. Our 
study is specifically designed to expand this area.  
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Table 2:  Summary Table of Selected Studies showing that Women with Male Fetuses are 
at Greater Risk for Perinatal Complications. 
 
Study population  Males vs. Females Reference  
423,033 singleton 
pregnancies in the 
Netherlands 
Increased risk of:  
Fetal Distress during labor         1.48 (1.44-1.51) 
Apgar score  at 5 min ≤3            1.27 (1.20-1.34) 
Perinatal death                            1.27 (1.20-1.34) 
 
(11) 
75,725 deliveries in UK 
teaching hospital over 11 
years 
Increased risk of:  
Preterm delivery                         1.13 (1.06-1.20) 
Spontaneous preterm delivery    1.30(1.19-1.42) 
(9) 
 
1,158,276 infants born in 
Sweden 1990-2001 
Maternal Risk of:  
Preeclampsia> 28 wks GA           1.02 (1.00-1.04) 
(108) 
55,891 male and 53,104 
female neonates in Negev 
Israel 1988-1999 
Increased risk of:  
Vacuum delivery                         1.5 (1.4-1.6) 
Apgar at 1 min <7                         1.3 (1.3-1.4) 
Birthweight>4kg                            2.0 (1.8-2.1) 
Failure to progress to *2nd stage    1.4 (1.3-1.5) 
 
(88) 
4 datasets and 20 populations Increased risk of Preterm birth <37 weeks: 
EUROPOP                                   1.14 (1.06-1.22) 
SSD Registry                               1.14 (1.03-1.27) 
FNPS                                            1.13 (1.01-1.27) 
(107) 
 
866,188 women with 
singleton pregnancies 
from the Swedish Medical 
Birth Registry 1992–2004. 
Males of chronic hypertensive mothers vs. 
normotensive had increased risk of:  
Intrauterine death                         3.07 (2.12-4.46) 
Neonatal death                             2.99 (1.84-4.85) 
(100) 
Adjusted relative risks or odds ratio (95% CI) reflect males vs. females        
*2nd Stage= dilation of cervix to delivery of infant. 
 
 
 Fetal Growth  1.2.3
 
 Normal Fetal Growth 1.2.3.1
 
Fetal birthweight is a key predictor of perinatal outcome (112). The fetus achieves only 10% of 
its final birth weight in the first 20 weeks of gestation. During the first half of pregnancy fetal 
development is directed at organogenesis rather than growth. Around 28 weeks of gestation 
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exponential fetal growth begins and is accompanied by fetal weight gain of approximately 
200g/week(113). 
 
 Determinants of Fetal Growth 1.2.3.2
 
Several modifiable and non-modifiable risk factors that influence fetal growth are presented in 
the table below (Table 3). These illustrate that the study of preeclampsia is complex based on the 
fact that several risk factors common to preeclampsia and fetal growth restriction behave 
differently in each setting.  Similar to risk factors for preeclampsia (Table 1), older maternal age 
and black race are associated with an increased risk of fetal growth restriction (Table 3). Biologic 
determinants such as race reflect the genetic environment of the fetus. Infants born to Black 
mothers are smaller and have higher rates of growth restriction as well as preterm delivery 
compared to infants born to White mothers (59-62).  
 However, there are other risk factors that show an influence in the opposite direction for 
preeclampsia compared to growth restriction. Maternal smoking during pregnancy is a 
modifiable risk factor that increases the risk of fetal growth restriction two to threefold compare 
to non-smokers. Paradoxically however, the risk of preeclampsia is lower among smokers 
compared to non-smokers. Pre-pregnancy BMI and pregnancy weight gain are important 
modifiable risk factors that impact fetal growth. As maternal BMI increases the risk of fetal 
growth restriction decreases and birth weight increases. Underweight mothers and normal-weight 
mothers are more likely to give birth to growth restricted infants, while obese mothers are likely 
to give birth to large for gestational age infants. However, obesity is associated with an increased 
risk of preeclampsia.  
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Table 3: Selected Studies of Risk Factors for Fetal Growth Restriction and Preeclampsia 
 
Determinants  
of Growth 
Growth  
Restriction 
Comparison group Refere
nce 
Excess Growth 
(LGA) 
Comparison 
group 
Refe
renc
e 
Risk for 
Preeclampsia 
Comparison group Refe
renc
e 
Same Direction 
Maternal 
Age 
2.09 (NR) 
1.3 (1.0-1.6) 
1.13(1.06-1.20) 
 
>40 vs.20-29 years 
>35 vs. 20-34 years 
>35 vs. 21-25 years 
 
(114) 
(59) 
(115) 
 
   5.48 (1.62-18.5) 
4.39 (2.05-9.37)      
1.9 (1.2-2.9) 
1.8 (1.3-2.6) 
≥40 vs.20-30 years b 
≥40 vs.20-30 years b 
≥40 vs.20-29 yearsa 
(70) 
(70) 
(71) 
(71)             
Black Race 2.6 (1.8-3.7) 
1.4 (1.1-1.7) 
 White  
Non-Hispanic White 
(116) 
(59) 
2.8 (2.2-3.8) 
 risk of LGA 
among preterm 
infants  
 Non-Hispanic 
White 
(59) 2.22 (1.37-3.62) s 
2.0 (1.2-3.4)   
Black/Hispanic vs. Whitec 
Black vs. White c 
 
(57) 
(45) 
Opposite Direction 
Maternal 
Smoking 
3.31 (3.19-3.44) 
2.89 (2.00-4.20) 
2.87 (2.24-3.68) 
2.6 (2.2-3.2) 
2.28(2.14, 2.43) 
Smoke in pregnancy vs. no  
Each 25 cig/day increase  
Smoker: yes/no                       
10+/day vs nonsmoker 
Smoker at 1st antenatal visit 
vs. nonsmoker 
(115) 
(52) 
(117) 
(59) 
(51) 
   0.73 (0.71-0.75) 
0.5 (0.50-0.60) 
Smoker vs. nonsmoker 
Smoker vs. nonsmoker (at 
registration) 
(118) 
(54) 
Gestational 
weight gain  
      1.54 (1.46-1.63) <41lbs vs. ≥41 lbs (66) 
Maternal 
Pre-
pregnancy 
Body Mass 
Index (BMI) 
1.69 (NR)c 
 
<18.3 vs 18.3-28.8kg/m2 c (114) 1.66(1.20-2.30) 
1.04(1.01-1.08) 
≥25 vs. 
<25kg/m2 
>30 vs. 18.5-25 
kg/m2  
(119) 
(120) 
7.6 (4.2-13.7)c s  
5.3 (2.9-9.7)c s 
3.5 (1.68-7.46) b 
2.8 (1.4-5.7)a 
2.6 (2.3-2.9)a 
2.4 (1.8-3.1) b  
35 vs. 20kg/m2 (White)  
35(Black) vs.20kg/m2 (White)  
≥32.3 vs. <32.3 kg/m2   
35 vs. 21 kg/m2   
≥30 vs. <25 kg/m2   
>24.2 vs. 19.8-24.2 kg/m2 
(68) 
(68) 
(57) 
(69) 
(65) 
(44) 
NR= Not Reported,  
a primiparous women 
b multiparous women 
c primiparous and multiparous women 
s severe preeclampsia 
 
  Abnormal Fetal Growth 1.2.3.3
 
Normal fetal growth is essential for appropriate fetal outcome following pregnancy. It is well 
recognized that abnormal growth at both extremes of the fetal weight distribution is associated 
with an increased risk for perinatal morbidity and mortality. As a result, abnormal growth is a 
major public health issue. These adverse events include necrotizing enterocolitis, and respiratory 
distress syndrome in reduced growth cases (121), while trauma, fractures and facial paralysis can 
occur in cases with large for gestational age infants (122). Fetal growth restriction (FGR) is 
defined as the failure of fetus to grow to his/her genetic growth potential (1). A recent study that 
compared 3 definitions of FGR revealed that FGR infants have a  2.5-3.5 fold increased 
likelihood of fetal death, and a 1.5-2.0 fold increase in the likelihood of requiring assisted 
ventilation 28 days after birth, regardless of the definition (2). Fetal growth restriction is also 
associated with a two fold increase in the likelihood of an infant with cerebral palsy (OR 2.3 
(95% CI 1.8–3.0) (123). Additionally, fetal growth restriction is associated with consequences 
for the fetus later in life (3). These include an increased risk of hypertension, cardiovascular 
disease and mortality (124), and type 2 diabetes mellitus (125).  Growth restriction early in 
pregnancy results in a symmetric reduction in length, weight and head size.  This is consistent 
with the genesis of growth restriction at this time, which is related to viral infection and 
congenital abnormalities resulting in a net decrease in cell number.   Restriction  later in 
pregnancy is associated with reduced nutrient availability for the fetus and results in reduction in 
weight, length, fat mass and is often accompanied by “brain sparing” growth (normal head 
circumference) (126) except in the most severe cases in which compensatory mechanisms are 
overcome and all organ growth is reduced (127-129). SGA is a reasonably effective indicator of 
 21 
fetuses that are at risk for perinatal morbidity and mortality.  However studies of growth have 
been limited by the analysis of only SGA as the sole marker of fetal growth restriction, and it is 
possible that the impact of preeclampsia on fetal growth has been underestimated. It is essential 
to therefore investigate additional indicators of fetal growth to determine the combined effect of 
sex and preeclampsia on growth. 
 
 Fetal Growth and Adult Disease 1.2.3.4
 
The Fetal Origins of Adult disease hypothesis suggests that reduced fetal growth is associated 
with offspring risk for cardiovascular and other chronic diseases later in life (130). Barker 
proposed that in response to a reduced nutrient supply the fetal system alter metabolic processes 
and organs to adapt (fetal programming). He theorizes that this fetal programming is permanent 
and predisposes the infant to heart disease and diabetes in adulthood (130). Barker also posits 
that over-nutrition of these infants post-partum may also further contribute to later adult disease 
based on the increased demand on the reduced functionality of organs such as the kidney and 
heart (131).  Ensuing follow-up studies by Barker and other researchers have provided evidence 
to support the hypothesis:  Low birth weight and reduced fetal growth is associated with an 
increased risk of cardiovascular disease (5), hypertension (6) and Type 2 diabetes (7, 8) in later 
life. Based on the Developmental Origins of Adult Disease hypothesis, a compromised uterine 
environment in the presence of preeclampsia may be a mechanism that predisposes the infant to 
disease later in life. Observational human studies support this theory:  Kajantie analysed risk for 
hypertension and cardiovascular disease among adult offspring of 284 preeclamptic women who 
were enrolled in the Helsinki Cohort Study, and found that the risk of hypertension was 
increased by 50% (RR 1.5; 95% CI 1.1-2.3), while the risk of stroke increased 2-fold (RR 2.2; 
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95% CI 1.2-4.1) among offspring of women with severe preeclampsia compared to offspring of 
normotensive women (132). A second study investigated the day and night ambulatory blood 
pressure (ABP) among 57 age and sex matched pairs of 12 year old offspring of preeclamptic 
and normotensive pregnancies. This study found that for both night and day time readings, the 
offspring of preeclamptic women had significantly higher mean 24-hour systolic and diastolic 
ABPs compared to the offspring of normotensive women. (133).  
A few researchers have challenged the fetal origins of adult disease hypothesis. They cite 
statistical errors or inappropriate adjustment for current weight and confounders as flaws in the 
interpretation in studies of the relationship between birthweight and later life disease (134-136). 
However, evidence from animal studies of fetal programming provides biological support for the 
fetal origins of adult disease hypothesis. These animal studies also show sex differences in 
response to fetal programming. Alexander investigated if FGR rats from induced placental 
insufficient pregnancies showed elevated mean arterial pressure. She found that induced 
placental insufficiency in late pregnancy resulted in elevated mean arterial pressure in male and 
female growth restricted rats (137). However at 12 weeks the blood pressure of the female 
offspring became normal (i.e. blood pressure was not significantly different from control female 
rats) while the male offspring remained hypertensive (137).  A study by Woods et.al investigated 
the effect of moderate protein diet restriction during pregnancy of rats on mean arterial pressure 
of adult offspring. The study found a greater increase in blood pressure and vascular 
abnormalities in peripheral arteries of male but not female offspring (138). In addition to this 
finding, severe protein restriction results in hypertension and changes to the structure of the 
kidney in both male and female adult offspring (139, 140). These animal studies suggest that 
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male infants may be more susceptible to in utero insults than female infants to the maternal 
environment during pregnancy and that the results of fetal programming differ by infant sex. 
Based on evidence from these observational and animal studies, it is important to 
understand the mechanisms by which fetal growth restriction and preeclampsia are associated 
with long term offspring risk for cardiovascular morbidity and mortality. Human observational 
studies have not commonly evaluated the effect of infant sex on their findings. Studying the 
influence of sex on the health of offspring of preeclamptic women may provide early markers of 
individuals who should be targeted for interventions before clinical manifestation of later life 
disease. 
 
 Additional Indicators of Fetal Growth 1.2.4
 
 Small for gestational age (SGA) is defined as birthweight below the 10th percentile for babies of 
the same gestational age from the internal or an external referent population and is often used to 
measure FGR. SGA can be adjusted for factors such as race, infant sex and parity(141).  Kramer 
studied 11.5 million Black and White singleton live births greater than 22 completed weeks of 
gestation and birthweight greater than 500 g, in the United States from 1998 to 2000(142). He 
found that the risk of SGA among Blacks vs. White infants was 2-fold when he used a non-race 
specific standard (HR 2.05; 95% CI 2.04-2.06) and that the greater risk of SGA among Black 
infants was lost when he used a race-specific standard (HR 1.05; 95% CI, 1.04-1.06)(142).  
Given the well-established lower mean birthweight and higher mortality rate among Black vs. 
White infants, it is reasonable to expect that growth restriction and not physiology contributes to 
these higher rates in Blacks. Therefore in our study we will not adjust the SGA charts for race.  
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Because there are limitations of SGA to determine impaired fetal growth it is helpful to 
utilize additional growth indicators such as ponderal index (PI), head to chest circumference 
(HCC) ratio and the fetal placental ratio (FPR) to further characterize fetal growth. We will 
utilize these markers along with SGA to characterize growth in normal pregnancy as well as 
pregnancies complicated by preeclampsia to assess if growth is modified by fetal sex. 
 
 Ponderal index 1.2.4.1
 
Ponderal Index provides an estimate of relative thinness of the fetus. It is defined as Weight 
(gm)/Length (cm)3 x 100. A low ponderal index is an indicator of asymmetric fetal growth. 
Ponderal index increases with gestational age. Ponderal index values of < 2.0 between 29 and 37 
weeks and <2.25 beyond 37 weeks are indicative of fetal growth restriction (143) (Table 4).  
Offspring of early onset preeclamptic women have lower birthweight and lower ponderal indices 
compared to offspring of normotensive women. However in late onset preeclampsia there was no 
significant difference between the preeclamptic and normotensive offspring (144)  There is 
evidence to suggest that the growth of the chorionic plate area affects fetal body proportion: 
ponderal index appears to be directly proportional to chorionic plate area, however disc thickness 
did not appear to have an effect on ponderal index (27).  Our study will initially characterize 
ponderal index by race and sex and gestational age at birth in uncomplicated pregnancies. We 
will then be able to compare normal fetal growth to fetal growth in pregnancies complicated by 
preeclampsia and determine if these associations are modified by offspring sex.  
Contribution to understanding fetal growth: Ponderal index will be able to identify 
cases of growth restriction than may have been missed using birth weight for gestational age 
alone(145). A study which compared the traditional definition of FGR (birthweights <10th 
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percentile) to low ponderal index (defined as PI below the 10th percentile after 36 weeks of 
completed pregnancy) found that the rates of fetal distress and caesarean deliveries were 
significantly higher in the low PI group compared to the SGA group (p=0.02 and p=0.0 
respectively). This study confirmed the finding of 3 previous reports which suggest that PI may 
provide additional information in identifying cases of FGR than birth-weight percentiles alone 
(145-147).  Ponderal index measures proportionality of skeletal to soft tissue growth. It indicates 
those infants who attained insufficient or excess soft tissue growth relative to the skeletal growth. 
Used in conjunction with SGA, PI will be a valuable contribution to understanding fetal growth. 
In SGA cases, the ponderal index is proposed to distinguish between inappropriate and 
appropriate soft tissue to skeletal growth.  In cases where the weight is appropriate for 
gestational age, but the infant is disproportionate in length for given weight and age, the ponderal 
index would be able to detect that the infant has inappropriate soft tissue to skeletal growth 
which is an indicator of abnormal growth.    
 
 Head circumference to chest circumference (HCC) ratio. 1.2.4.2
 
HCC is defined as the head circumference in centimeters divided by the chest circumference in 
centimeters. HCC is an indicator of growth restriction (Table 4). The underlying theory is that 
in the presence of growth restriction, visceral organ growth is compromised earlier and 
brain growth is compromised later. As a result HCC is indicative of symmetric or 
asymmetric growth (148). In normal growth HCC is inversely proportional to gestational age. 
Ounsted et.al. found that among SGA infants, males had higher ratios than females, while first 
born infants and offspring of preeclamptic women had significantly higher ratios compared to 
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SGA infants of normotensive mothers (149). Women with severe preeclampsia are at greater risk 
of delivering an asymmetric fetuses compared to a symmetric fetus (150). 
The previously mentioned Stark paper which analyzed peripheral microvascular blood 
flow in offspring of preeclamptic women also analyzed infant symmetry. They reported that 
female fetuses exhibited asymmetric growth accompanied by reduced birth weight, while the 
male fetuses maintained symmetric growth in the presence of preeclampsia (110). However the 
study failed to report how symmetry was assessed. Our study will characterize HCC ratio and 
ponderal index by race and sex and SGA in 9,551 uncomplicated pregnancies and thus be able to 
compare growth in normal versus preeclamptic pregnancies.  
Contribution to understanding fetal growth: HCC can be used to categorize infants as 
symmetric or asymmetric (disproportionately lagging in abdominal growth) in order to 
categorize the type of reduced growth (151). Small fetuses that are symmetrical may be small 
because they are normally grown (constitutionally small) or due to severe growth restriction in 
which the growth of the head has slowed to match the abdominal circumference.   Symmetrically 
small infants are regarded as less common (150) and are considered to have worse perinatal 
outcomes compared to asymmetric growth restricted infants (150, 152). However two studies 
suggest that asymmetric growth restriction is associated with an increased risk of neonatal 
morbidity compared to symmetric SGA infants if congenital anomalies are removed (151, 153). 
The lower rates of neonatal morbidity among symmetric SGA infants without anomalies, 
suggests that this group also includes constitutionally small infants.  Similar to PI, HCC will also 
be better able to identify growth restriction than using birth weight for gestational age alone. 
Used in conjunction with SGA, HCC will not only be able to confirm SGA, but will also 
determine if fetal growth was symmetric or asymmetric. In cases where the weight is appropriate 
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for gestational age, but the infant is disproportionate in the circumference of the chest relative to 
that of the head for the given gestational age, the HCC would be able to detect that the infant has 
compromised organ growth relative to brain growth which is an indicator of abnormal growth.    
 
Table 4: Summary of Anthropometric Markers of Growth. 
 
Fetal Marker What it indicates 
What indicates Growth 
Restriction 
Small For Gestational 
Age (SGA) 
FGR 
<10th percentile for 
gestational age 
Ponderal Index (PI) 
Symmetric/Asymmetric 
Growth 
< 2.0 between 29 & 37 
weeks of gestation 
 
<2.25 beyond 37 weeks of 
gestation 
Head to chest 
circumference (HCC) 
Symmetric/Asymmetric 
Growth 
Elevated 
(Normal is approx 1.0) 
 
 
 Placental Growth 1.2.5
 
 Placental Function and Growth.  1.2.5.1
 
The placenta is the main source of nutrient supply to the fetus. It acts as a nutrient and waste 
exchange system. The placenta supplies the fetus with nutrients from the blood of the mother and 
transports waste products to the blood of the mother (154). Normal placental growth and 
function is essential for growth of the fetus.  Studies show that abnormal placental growth is 
associated with increased risk of morbidity and mortality and adverse lifelong consequences such 
as mental, visual and hearing impairment, autism and cerebral palsy (155, 156). 
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 The growth of the placenta is an important factor in the growth of the fetus. Fetal 
growth is controlled by the nutrient supply of the mother and the placenta. In pregnancy, 
maternal blood is delivered to the placenta via the spiral arteries, where it bathes the chorionic 
villi in the intervillous space. The fetus sends blood to the placenta via two umbilical arteries. 
The fetal arteries branch within the chorionic villi providing a large surface area for nutrient and 
waste exchange with the maternal blood (157).  Placental growth follows an S-curve (158). The 
rate of growth of the placenta is greater than fetal growth in the first 16 weeks of pregnancy 
resulting in the weight of the placenta being greater than the fetal weight during this period. 
However the placental and fetal weights are similar between 17 and 28 weeks. At approximately 
27 weeks of pregnancy the placenta weighs approximately 50% of its term weight while the fetus 
has only achieved 30% of its term weight. During maximum fetal growth (28-38 weeks) the rate 
of growth of the placenta is lower than the fetal growth and is observed to decelerate after 38 
weeks (113). The placenta plays a crucial role in supplying the fetus with nutrients as well as 
producing growth hormones. These hormones for e.g. insulin-like growth factors (IGF-1 and 
IGF-2) which plays a major role in controlling growth of fetus and placenta and vascular 
endothelial growth factor (VEGF) which is responsible for proliferation of trophoblasts and 
vasculogenesis are important for fetal and placental growth(113).  
 
 Compensatory Mechanism of the Placenta 1.2.5.2
 
Understanding the growth of the placenta is essential in understanding the growth of the fetus.  
Studies indicate that term offspring of preeclamptic women have had fetal growth similar to 
offspring of normotensive women (110, 159, 160). Molteni suggests that diseases such as 
preeclampsia can inhibit proper placental growth by limiting placental blood flow, and this may 
cause the placenta to slow its growth progression. He suggests however that fetal weight may be 
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maintained provided that there is sufficient placental reserve to sustain fetal growth (161). The 
placenta can survive the functional loss of 30-40% of the placental villi without compromising 
fetal growth and also has the capacity for compensatory growth (4). As a result it is imperative to 
investigate the growth of the placenta as fetal weight may be sustained while the placenta is 
compromised. Even with apparent normal fetal growth, the compromised placental growth and 
its adaption to the restrictive environment may result in fetal programming which places the 
infant at risk for disease later in life. Compromised placental growth is indicative of underlying 
risk factors for disease later in life such as hypertension (6, 162), (as discussed in previously in 
the fetal growth section). Eriksson and colleagues reported that hypertension in men was 
associated with a shortened smaller diameter of the placenta. However, hypertension in women 
was associated with a small placental area (103). In addition, they also found that at birth, males 
had larger placentas compared to females. However, the male placentas were smaller in 
comparison when compared to birthweight and may indicate lower reserve capacity (103).  The 
study cohort was born during the Second World War during a time of severe food 
shortages(163). This suggests that growth of the placenta in response to in utero insult or reduced 
nutrient supply is different based on infant sex. Our study will investigate the morphometric 
features of the placenta in order to better understand placental growth in offspring of 
preeclamptic women, and determine if this growth is modified by offspring sex. This can provide 
an early marker of persons who should be targeted for interventions before clinical manifestation 
of disease. 
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 Determinants of placental growth 1.2.5.3
 
There are several risk factors associated with abnormal placental growth. Similarly to FGR and 
preeclampsia, Baptiste-Roberts reported that Black race is associated with an increased risk of 
placental growth restriction (growth that is <10th percentile of the respective placental growth 
measure). In the CPP, Black compared to White race was associated with a 66% increase in the 
likelihood of low placental weight (OR 1.66; 95 % CI 1.51-1.82), a 3-fold increase in the 
likelihood of small placental disk thickness (OR 3.22; 2.90-3.58) and a 36% increase in the 
likelihood of restricted growth of the chorionic plate area (OR 1.36; 95% CI 1.24-1.49). The 
study also found that hypertensive disease beyond 24 weeks of pregnancy increased the 
likelihood of growth restriction for the placental weight and chorionic plate area approximately 
2-fold (OR 1.98; 95% CI 1.54-2.55, and OR 1.86 95% CI 1.46-2.37 respectively).  Similar to 
FGR, Baptiste-Roberts found that each 1kg/m2 increase in pre-pregnancy BMI was associated 
with a reduced likelihood of low placental growth (164).  
 
 Markers of placental growth 1.2.6
 
Studies of placental growth are limited by their analysis of placental weight as the sole marker of 
placental growth (25, 162). The ratio of fetal weight to placental weight (FPR) is another marker 
that is used as a measure of the efficiency of placental growth relative to fetal growth (27, 112). 
The fetus and the placenta share the same genetic material (165) thus fetal weight relative to 
placental weight may be a better predictor of fetal and placental growth because it avoids the 
influence genetic  factors.  There are, however, limitations to this approach. Placentas that are 
large and thin as well as placentas that are small and thick can produce FPRs that are consistent 
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with normal proportioned placentas (27). These different placental proportions may result in 
functionally different placentas (28). Based on these limitations, it is advantageous to employ 
alternate placental measures. The larger and smaller placental diameters, ratio of the diameters, 
thickness and FPR, will be better able to ascertain placental growth beyond placental weight.  
 
 Fetal Placental Ratio 1.2.6.1
 
FPR increases with fetal growth and gestational age. Appropriate for gestational age (AGA, 
birthweight between 10th and 90th centiles) and large for gestational age (LGA, birthweight >90th 
centile), infants have consistent placental growth up to 42 weeks of gestation, while among small 
for gestational age infants (SGA) (birthweight <10th centile), placental growth tends to stop at 
around 34 weeks, but fetal growth may continue until term (161).   
SGA infants tend to have lower fetal placental ratios (112, 161) (Table 5). When 
comparing FPR in uncomplicated pregnancies to pregnancies complicated by gestational 
hypertension or fetal growth restriction using LGA, AGA, and SGA categories, as expected, it 
was found that the FPR was smallest among the SGA group and largest among the LGA group 
(166). FPR in SGA pregnancies is lower and FPR in LGA pregnancies are higher than FPR in 
AGA pregnancies throughout gestation.  
A low FPR (low fetal weight relative to placental weight) is suggestive of a less efficient 
placenta and occurs in impaired environments such as maternal anemia (167), maternal smoking, 
low socioeconomic status (168) and obesity (169). The work of Lao and Wong suggest that the 
reduced FPR among SGA infants is due to the combined result of continued placental growth 
(increase in placental size) and deceleration of fetal growth (170).  
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It is interesting to note that high FPRs also are associated with growth restriction: 
High FPRs are indicative of a small placenta relative to the fetal weight. Molteni points out that 
placental growth may stop at 34 weeks, however if there is sufficient placental reserve, then fetal 
growth may continue (161), and the FPR will be high. High FPRs suggests that the placental 
reserve has been exceeded and is unable to sustain optimal fetal growth (171) and place infants at 
hypoxic risk during delivery (161). FPRs greater than 10.35 are associated with the risk of fetal 
distress at birth or stillbirth (161, 172) (Table 5). This indicates that it is important to analyze 
both extremes of the FPR distribution to ascertain growth.  
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Table 5: Summary of reported mean fetal placental ratio (FPR) from selected Studies.  
Study population  Mean FPR (SD) Reference  
11,141 uncomplicated single term 
pregnancies 37-42 weeks of 
gestation 
37 weeks 
5th percentile=4.27 
50th percentile= 5.68 
95th percentile=7.58 
40 weeks 
5th percentile= 5.03 
50th percentile= 6.41 
95th percentile=8.20 
 
 
(173) 
16,616 uncomplicated singleton 
pregnancies with 1569 small for 
gestational age (SGA) and 15,047 
appropriate for gestational age 
(AGA) infants between 32 and 42 
weeks 
SGA 
32 wks=4.68 
36 wks= 5.71 
40 wks= 6.93 
AGA 
32 wks=4.78 
36 wks= 6.30 
40 wks= 7.05 
(112) 
29,710 full term, 2675 SGA and 
27,035 AGA infants from the 
collaborative perinatal project 
(CPP). 
SGA =6.94 
AGA=7.35 
(174) 
238 normal pregnancies, 36th-40th 
gestational weeks. 
Median 
36 weeks = 5.16 
37 weeks=5.99 
38 weeks=6.01 
39 weeks=6.07 
40 weeks= 6.20 
(175) 
High Fetal Placental Ratios 
417 low risk infants 38-42 weeks of 
gestation 
FPR ≥11 
= increased risk of fetal distress 
=increased risk of Agar score ≤6 
(172) 
Not reported. FPR≥10.35 
=increased risk of fetal distress 
=increased risk of stillbirth 
(176) as cited 
in (161) 
*GA= gestational age, SGA= small for gestational age, AGA = appropriate for gestational age, 
LGA=Large for gestational age 
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 Larger and Smaller Placental diameters. 1.2.6.2
 
Placental growth is expected to be centripetal around the umbilical cord (171, 177). The largest 
and smallest placental disk diameters determine the surface area available for spiral arteries from 
the uterine wall to perfuse the placenta (Table 6). Placentas that are wide in both diameters are in 
contact with more spiral arteries than a smaller disk (27). The extent of the lateral growth of the 
placenta on the uterine wall determines the number of spiral arteries that are available for 
conversion by the placenta (171).  
Salafia suggests that a chorionic plate that is wide in both diameters (with a large 
vascular tree) that is thin (with fewer villus branching) may present a very different fetal 
cardiovascular burden than a chorionic disc that is small in surface area but very thick (28). A 
large retrospective study by Kajantie on subjects born in the Helsinki Birth Cohort (1934-1944) 
found that smaller placental surface area was associated with preeclampsia. When the larger and 
smaller diameters of the placenta were analyzed together, preeclampsia was strongly associated 
with the length of the smaller diameter, but not the larger diameter (p<0.0001). He also found a 
dose-response effect- the shorter the smaller diameter, the greater the risk and severity of 
preeclampsia (178).  
A large retrospective study was performed by Misra using offspring from the 
Collaborative Perinatal Project (1959-1965). Misra found that the birthweight and fetal placental 
ratio of females compared to males was more sensitive to changes in the placental area for 
female vs. male infants (179). We posit that fetal programming of the placenta in the presence of 
preeclampsia will be different by infant sex. We propose that the size of the placenta reflected by 
the larger and smaller diameters (surface area) is an indicator of the nutrient supply to the fetus 
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and as a result can be used as a proxy to compare the available vasculature system that facilitates 
delivery of nutrients for growth between offspring of preeclamptic and normotensive women. 
The diameters should provide additional information on the vasculature in the cases where the 
placentas may be proportionate, large and thin, or small and thick.  We propose and will test 
therefore that the diameters of the placenta will be related to preeclampsia and birth weight in a 
manner not solely explained by placental weight. We theorize that the relationship of birth 
weight to growth of the placental diameters will be different among offspring of preeclamptic 
women compared to offspring of normotensive women by infant sex. Understanding the 
influence of fetal sex on the relationship between preeclampsia and fetal growth may help to 
explain why morbidity and mortality rates differ by sex in pregnancy complications. 
 
 Ratio of the diameters 1.2.6.3
 
The ratio of the diameters indicates the asymmetry of placental growth (171), which is expected 
to be centripetal around the umbilical cord (171, 177) (Table 6). Placental underperfusion may 
cause early onset or excess blood flow to the placenta resulting in excessive oxidative stress, that 
leads to asymmetric placental shape(180).  Asymmetric shapes may also be caused by reduced 
growth of the placental tissue during the second and third trimesters due to chronic oxidative and 
other stresses that may have been induced through underperfusion of the placenta(180).  
In a previously mentioned study, Kajantie found a dose-response relationship between 
placental asymmetry and preeclampsia. As the placental became less symmetric (more oval-
shaped) the association with preeclampsia increased (178). We theorize that the relationship of 
birth weight to growth of the ratio of the placental diameters will be different among offspring of 
preeclamptic women compared to offspring of normotensive women by infant sex. 
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Understanding the relationship between birth weight and asymmetry of the placenta in the setting 
of preeclampsia may bring us closer to understanding the pathophysiology of preeclampsia as 
well as mechanisms for sex differences in pregnancy outcome.  
 
  Placental disk thickness 1.2.6.4
 
The thickness of the placenta is an indicator of the villus volume available for nutrient transfer to 
the fetus (Table 6).  The branching of the placental villi increases its thickness (27).  Kajantie 
found that the mean thickness of placentas from women diagnosed with preeclampsia was 
greater than in normotensive pregnancies (178). This may indicate compensation for the smaller 
mean placental area found among the preeclamptic vs. normotensive women in his study (178). 
He also found that the relationship between disk thickness and birth weight was different in male 
vs. female infants. We propose that similarly to the smaller and larger diameters, the disk 
thickness will provide additional information about the vasculature in the cases where the 
placentas may be proportionate, large and thin or small and thick. We theorize that the 
relationship of birth weight to growth of the placental diameters will be different by sex among 
offspring of preeclamptic women vs. normotensive women. Based on the Barker hypothesis we 
theorize that these compromised cases may indicate increased risk for disease later in the life of 
the offspring (130). 
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Table 6: Summary of Placental Markers of growth 
 
Placental Marker What it indicates 
Smaller and Larger 
disk diameters 
Surface area available for 
spiral arteries 
Ratio of the diameters reflects the asymmetry of 
placental growth 
Disk thickness Area available for nutrient 
transfer 
 
 
 
  Summary of the interrelationship among preeclampsia, fetal sex, fetal growth and 1.2.7
placental growth.  
 
The risk of FGR is greater among offspring of preeclamptic women compared to offspring  of 
normotensive women (22). Preterm preeclampsia is more severe than term preeclampsia, it is 
associated with a greater maternal and fetal morbidity (40). The fact that males are more 
common in preterm normotensive pregnancies than in preterm preeclamptic pregnancies (106, 
108), may indicate increased stillbirths among preterm male offspring of preeclamptic women.  
In preeclamptic pregnancies there is evidence that that male sex affects vasodilation in both the 
mother (109) and the fetus (110), also pregnant women with male fetuses have increased blood 
pressure and weight gain (111).  These indicate that male sex has the potential to influence the 
effect of preeclampsia on fetal development.  Male offspring of preeclamptic women tend to fare 
worse in perinatal outcomes (11, 100, 102). Based on these observations, which state that males 
are already disadvantaged in pregnancy and can influence the outcome of preeclampsia, we 
expect to find results consistent with reduced fetal and placental growth among preterm male 
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offspring of preeclamptic women that will be more severe than similar changes in female fetuses. 
Several studies that have investigated sex differences in preeclampsia were limited to SGA 
infants. Our study intends to analyze the population in the CPP data to characterize growth in the 
offspring and placenta of the preeclamptic versus the normotensive population, and will not be 
limited to SGA infants.  Also, very few studies have investigated the influence of sex on 
placental morphometry. Our study will address the limitations of SGA while determining the 
influence of sex on the relationship between preeclampsia and growth restriction in the fetus and 
the placenta. 
 
 Gaps in our current knowledge. 1.2.7.1
 
Gaps in our current knowledge of the role that fetal sex plays in fetal growth, the growth of the 
placenta and preeclampsia will begin to be filled by our proposed study.  Our literature review 
revealed limited information describing normal growth using FPR, PI and HCC by race and sex. 
We intend to fill the gap in this knowledge by using the large cohort of the CPP to characterize 
normal anthropometric growth among offspring of normotensive women. The alternative 
markers used in our study will confirm SGA (for fetal growth) and provide more information 
about reduced fetal/placental growth in pregnancy. Using a racially diverse population, our 
proposed study will also allow us to describe the contribution of fetal sex to fetal and placental 
growth in the presence of preeclampsia.  
The compensatory mechanisms of the placenta (4), the fetal origins of adult disease 
hypothesis (130), and the limitations of SGA and FPR, led us to theorize that even though an 
infant may be characterized at birth as normally grown, a fetus or placenta with reduced growth 
indicated by our alternative indicators of growth (fetal: ponderal index, head to chest 
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circumference); (placental: placental weight, smaller diameter, larger diameter, and disk 
thickness) may reveal growth reductions by sex that may be associated with early and/or later 
life consequences.  
Fetal sex differences that influence placental, fetal and maternal physiology may bring us 
closer to understanding the pathophysiology of preeclampsia as well as explain why morbidity 
and mortality rates differ by sex in pregnancy complications.  Fetal sex differences may be 
beneficial in directing future research to interpret the relationship between fetal growth, placental 
structure/function and the pathophysiology of preeclampsia 
 
  
1.3  BIOLOGICAL VS. STATISTICAL INTERACTION 
 
 
Our study aims to determine if the relationship between preeclampsia and fetal growth is 
modified by infant sex. We will use statistical interaction to detect this biological interaction. 
Biological interaction implies that two or more risk factors of a disease together influence 
disease risk. Statistical interactions are used to as a proxy to measure/detect the presence of 
biological interaction. Statistical interaction refers to a product term in a regression model that 
detects if the relationship between two variables varies as a function of a third variable (181).  
Statistical interaction can be measured on an additive or multiplicative scale (182, 183).  
True biological interaction indicates a biological pathway or causal mechanism. Rothman 
illustrates that cases of exposure to two risk factors can be divided into four potential categories 
of causal mechanisms. Biological interaction can then be estimated from the additivity of risk 
differences or risk ratios of these categories(184).  Therefore it has been argued that measuring 
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statistical interaction in the additive scale is a better predictor of biological interaction because 
the additive scale measures synergism of effects(185).  
Synergism or positive interaction occurs when the sum of the individual effects is greater 
than the combined effect (186). This indicates that individuals with both exposures have an 
increased risk for the outcome, beyond the risk expected from the sum of the exposures. 
Antagonism or negative interaction occurs when the sum of the individual effects is less than the 
combined effect (186). This indicates that individuals with both exposures have a decreased risk 
for the outcome, below the risk expected from the sum of the exposures. The synergy index (SI) 
can be used to measure departure from additivity of effects in multiplicative models. The SI is 
calculated as the ratio between the combined effect and individual effects(187). We used the 
synergy index to estimate the effect of interactions in the additive scale from our SGA models 
(multiplicative models).   SI ranges from 0 to infinity; the SI equals 1 if there is no interaction 
(exactly additive), values greater than 1 indicate synergism, while values less than 1 indicate 
antagonism (188). 
 
 We will use linear regression models and the synergy index (for the multiplicative 
models) to detect biological interaction. We will use separate regression models for each marker 
of fetal and placental growth to evaluate whether fetal and placental growth are modified by 
infant sex. Multiple fetal and placental markers will enable us to determine whether our findings 
are consistent and reliable. The results will be reported separately for each sex to interpret the 
influence of infant sex.  
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2.1 ABSTRACT 
 
It is unknown if fetal sex and race modify the impact of maternal pre-pregnancy body mass index 
(BMI), smoking and socio-economic status (SES) on fetal growth. We studied markers of growth 
in offspring of 8,801 primiparous, normotensive women with singleton pregnancies, enrolled in 
the Collaborative Perinatal Project. We tested for departures from additivity between sex/race 
and each determinant. The head-to-chest circumference ratio (HCC) decreased more, while 
birthweight and ponderal index (PI) increased more for each 1kg/m2 increase in pre-pregnancy 
BMI among term females vs. males (p=0.07, p<0.01 and p=0.08, interaction respectively). For 
term offspring of White compared with Black women, smoking independent of “dose” was 
associated with larger reductions in growth (165g vs. 68g reduction in birthweight), greater 
reduction in the fetal placental ratio (p<0.01, interaction), PI (p<0.01, interaction), and greater 
increase in HCC (p=0.02), respectively). The relationship between SES and fetal growth was not 
modified by fetal sex. The association of BMI and smoking with fetal growth appeared to be 
reversed in term compared to preterm infants. Our study provides evidence that the associations 
of pre-pregnancy BMI and smoking are not constant across fetal sex and race. This may be 
relevant to sex and race differences in neonatal and long term health outcomes.   
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2.2 INTRODUCTION 
 
Male infants are significantly heavier and have larger head circumferences at birth compared to 
female infants (4, 189, 190). Nonetheless males have lower Apgar scores and higher rates of  
fetal distress (11), are more likely to need resuscitation, have higher rates of perinatal mortality 
(91) and higher rates of later life disease (191, 192). In addition, infants born to Black mothers 
are smaller and have higher rates of growth restriction as well as preterm delivery compared to 
infants born to White mothers (59-62).  
Social, behavioral and environmental factors impact fetal growth (193-196).  Pre-
pregnancy body mass index (BMI) is a useful indicator for evaluating maternal nutritional status 
near conception (197) and is a predictor of infant birthweight(197, 198). Socio-economic status 
(SES) is an index of maternal resources to support fetal growth (115, 195), while maternal 
smoking is an environmental factor that impairs fetal growth(199-201).  However little is known 
about whether maternal pre-pregnancy BMI, SES and smoking interact with maternal race and 
infant sex to impact of fetal growth. To improve our understanding of factors affecting fetal 
growth we designed a study to evaluate whether the impact of maternal BMI, smoking and SES 
on fetal growth are modified by fetal sex and maternal race. 
Appropriate growth is essential for both immediate and long term health of the infant. 
Low birthweight is associated with both acute and later life mortality and morbidity for the infant 
(4-8). Small for gestational age (SGA) is the most common marker used to detect abnormal 
growth. It is commonly defined as birthweights below the 10th percentile for babies born at the 
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same gestational age in a population.  An SGA infant however, may not be growth restricted, e.g. 
small individuals have small babies. Growth restricted infants genetically destined to be large; 
who do not exercise their true genetic growth potential may not be small enough to be SGA. To 
address these limitations, additional anthropometric indicators of growth such as ponderal index, 
head to chest circumference ratio and fetal placental ratio may allow better characterization of 
impaired fetal growth. 
In addition to SGA, our study analyzed these markers of fetal growth among infants born 
to primiparous normotensive women. The study was designed to evaluate whether the impact of 
maternal BMI, smoking and SES on fetal growth are modified by fetal sex and maternal race. 
This may bring us closer to understanding why female and White offspring have a greater 
resilience and male and Black offspring are at a disadvantage in pregnancy outcomes and long 
term health consequences. 
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2.3 METHODS 
 
 Study population 2.3.1
 
The subjects were pregnant women and their offspring who were enrolled in the Collaborative 
Perinatal Project (CPP), a prospective study of neurologic disorders and other conditions in 
children. The CPP collected data on 54,681 births to pregnant women enrolled at 12 study 
centers during 1959 to 1965, about half of whom were African American (202, 203).  
Of the 54,681 births in the Collaborative Perinatal Project, 16,523 were primiparous with 
singleton births (Figure 3). Multiparity is associated with increased birth weight in subsequent 
pregnancies(204). The risk for adverse pregnancy outcomes also changes with increasing parity 
(205). Limiting the study to primiparous women removed these confounding effects of parity. 
We excluded 750 women diagnosed with preeclampsia, 3,425 women diagnosed with proteinuria 
only, or chronic or transient hypertension (gestational hypertension without proteinuria (206)), 
103 that were missing hypertension status and 179 women with diabetes mellitus. These women 
were excluded to examine the relationship between the predictors of fetal growth and their 
interaction with sex/race among women that were otherwise healthy. We also excluded stillbirths 
(n=177), those missing the covariates of interest (n=1,167), Hispanics and Asians (n=706) as 
well as births less than 25 or greater than 42 weeks or those missing gestational ages (n=1,215). 
Hispanics and Asians were excluded because of small numbers. The final population was 8,801 
normotensive women and their offspring.  
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Gestational age was calculated based on the last menstrual period of the mother. This 
method is known to be subject to error (207-209). Women with long cycles are more likely to 
have their gestation length overestimated and misclassified as term (210) while women with 
short cycles are more likely to have their gestation length underestimated and misclassified as 
preterm. To address this limitation, gestational age was defined as reliable in a subgroup of 
women (n=4,905) with a last menstrual period that was 26 to 35 days following the beginning of 
the previous menstrual period (211, 212). Analyses were repeated in this group. To further 
determine if possible bias introduced by misclassification of preterm/term infants affected our 
results, we performed a second analysis among infants with gestational ages 39-42 weeks. The 
results were unaffected when we performed both secondary analyses. Therefore the results 
reported are for the full study sample.  
 
 Fetal growth Variables   2.3.2
  
Birthweights(213), birth lengths (213), head (214, 215) and chest circumferences (215) were 
checked for plausibility using comparative reference populations. The models met the 
assumptions for normality after Tukey’s severe outlier criterion was used to remove biologically 
implausible data (216). Among the term infants, 1-19 observations were removed from each 
growth measure. Among the preterm infants, 0 to 8 outliers were removed from each growth 
measure. The results of the fetal growth models were not different with the removal of outliers. 
The fetal growth variables were SGA, head to chest circumference ratio, ponderal index 
and fetal placental ratio. SGA was defined as birthweight below the 10th percentile for 
gestational age and sex from the CPP population. Ponderal index, (100 x [birthweight (g)/crown-
heel length (cm)3] is similar to BMI in adults. It indicates those infants who attained insufficient 
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(low ponderal index) or excess soft tissue growth (high ponderal index) relative to the skeletal 
growth. Head to chest circumference ratio (HCC), (head circumference (cm) / chest 
circumference (cm)), indicates compensatory growth resulting in a higher head to chest 
circumference ratio (148). The fetal placental ratio (FPR) (birthweight (g) / placental weight (g)) 
is often used as a measure of the efficiency of fetal growth relative to placental growth (27). 
Growth restricted infants tend to have lower fetal placental ratios (112, 161). In cases where fetal 
weight appears appropriate for gestational age, these measures may indicate impaired growth in 
the absence of SGA conversely they may also indicate normal growth in SGA infants. Our study 
population had large numbers of missing placental weight and chest circumference measures. 
Women missing placental data (n=1,101, 14.5%) were more likely to be of lower SES, Black and 
non-smokers, while mothers of offspring missing chest circumference data were more likely to 
be of higher SES, and White. 
 
 Sociodemographic variables 2.3.3
 
Maternal smoking, SES and race were collected via self-report at the initial interview. BMI was 
calculated from measured height and self-reported pre-pregnancy weight at admission to the 
prenatal clinic. Maternal smoking status at intake visit was coded as a yes/no dichotomous 
variable. The number of cigarettes smoked per day at intake visit was also analyzed as a 
continuous variable using 5 cigarette increments. The socioeconomic status variable was a 
combined score based upon education, occupation and income (202, 203) and was categorized as 
low, middle and high SES.  Maternal pre-pregnancy BMI and gestational age were analyzed as 
continuous variables. Gestational weight gain may be a mediator on the biological pathway 
between maternal pre-pregnancy BMI and fetal growth. To measure the total influence of BMI 
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on fetal growth, it is important not to block any effect that acts through a mediating variable 
(217), therefore we did not control for gestational weight gain. 
 
 Statistical analysis 2.3.4
 
Chi-square tests were used to test for association between variables. Separate multivariable linear 
regression models were used to evaluate the influence of maternal pre-pregnancy BMI, smoking 
and SES on fetal growth. Normality and linearity assumptions were tested using histograms of 
the residuals, q-q plots and residuals vs. fitted values for each model and outliers removed as 
previously described.  
 Separate linear and logistic regression models were fitted by sex and race to show the 
estimate of the relationship between each determinant and fetal growth. Growth restriction early 
in utero is typically symmetric while growth restriction later in utero tends to be 
asymmetric(126). In addition, the risk factors for growth restriction differ among preterm and 
term infants(218). Therefore we analyzed the influence of maternal pre-pregnancy BMI, 
smoking and SES on fetal growth separately in preterm and term infants. The results were 
reported as point estimates of the mean and standard error or estimated odds ratio and 95% 
confidence interval. 
Statistical interaction terms between sex and each determinant as well as race and each 
determinant were used to test if the influence of maternal pre-pregnancy BMI, smoking and SES 
varied by sex or race.  Models with and without interaction terms were compared using the 
partial F test for linear models and the likelihood ratio test for logistic models (P<0.10). It is 
proposed that departures from additivity (interaction in the additive scale) are more meaningful 
for interpreting the public health and biological significance than departures from 
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multiplicativity (interaction on the multiplicative scale) (185, 219, 220). Therefore departures 
from additive effects in the SGA models were also evaluated by calculating the synergy index 
(SI) (a test of interaction) (221) and its 95% confidence interval (222).  The SI was calculated as 
the ratio between the combined effect and the sum of the individual effects of the risk factors 
(187). 
The synergy index was originally designed to measure risk factors rather than preventive 
factors(187). Therefore, we modeled maternal pre-pregnancy BMI with a 1 unit decrease using 
the World Health Organization categories (Obese (>30kg/m2) (referent), Overweight  (25.0- 29.9 
kg/m2 ), Normal (18.5-24.9 kg/m2) and Underweight (<18.5 kg/m2).  
Stata Software, version 11 (StataCorp, College Station, TX) was used to calculate 
departures from additivity for the SGA logistic regression models. All other statistical analyses 
were performed using SAS 9.2 software (SAS Institute, Cary, N.C.). A P value of <0.05 was 
considered statistically significant. We repeated the analysis in the preterm and term infants as 
well as in infants born to women who had reliable menstrual cycles to investigate if the results 
were consistent. 
  
2.4 RESULTS 
 
Table 7 shows the characteristics of the normotensive women stratified by maternal race and 
infant sex. Among the births, 1,219 (14%) of the infants were preterm (25 to 36 weeks 
gestation). There were no meaningful differences in maternal race, smoking status, SES or rates 
of preterm birth by offspring sex. White mothers were older and smoked more compared to 
Black mothers (P<0.01). Black mothers had more preterm infants, lower SES and were 
significantly more overweight and obese compared to White mothers (all P<0.01). 
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As expected, the mean birthweight, head to chest circumference, and fetal placental ratios were 
all higher among male compared to female offspring (P<0.01) (Table 8). Among offspring of 
Black compared to White women, mean birthweight and ponderal index were lower (P<0.01), 
while the mean head to chest circumference ratio was higher (P<0.01). Males compared to 
females had an 18% greater risk of SGA, while Blacks compared to Whites had a 78% greater 
risk of SGA (males vs. females OR 1.18 (95% CI: 1.02, 1.36) p=0.02 and Blacks vs. Whites OR 
1.78 (95% CI: 1.51, 2.10) P<0.01 respectively) using non-race adjusted charts. Importantly, 
when we compared the risk of SGA in Black and White infants using race adjusted charts(141, 
142), SGA rates were similar in Blacks and Whites despite the other markers of reduced growth 
we found in Black infants. 
 
 Fetal sex, Maternal Pre-pregnancy BMI and fetal growth 2.4.1
 
The influence of pre-pregnancy BMI on fetal growth was modified by fetal sex.  Growth among 
term female infants was greater with increasing maternal pre-pregnancy BMI than that of term 
male infants (Table 9). The head to chest circumference ratio decreased more and the ponderal 
index increased more in term females compared to term males for each 1kg/m2 in maternal pre-
pregnancy BMI (P=0.07 and P=0.08, additive interaction respectively).  This was driven by a 
significantly larger increase in the chest circumference (P<0.01, additive interaction) and 
birthweight (P<0.01, additive interaction) for each 1kg/m2 increase in the maternal pre-
pregnancy BMI for females compared to males. For the SGA models we used the World Health 
Organization categories (Underweight (<18.5 kg/m2), normal (18.5-24.9 kg/m2), overweight  
(25.0- 29.9 kg/m2 ) and obese (>30kg/m2).We found an increase in the risk of SGA for females 
but not males for each 1 category decrease in the mother’s pre-pregnancy BMI (OR 1.15 
(95%CI; 0.94, 1.41 vs. OR 1.76 (95% CI; 1.41, 2.21) male vs. female infants respectively). 
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Consistent with the additive models, the synergy index (synergy index 0.55 (95% CI 0.30, 0.79)) 
indicated that males were less sensitive to the influence of maternal pre-pregnancy BMI on SGA 
risk.  
We examined the same relationships among preterm births. Precision was compromised 
by the smaller sample size resulting in changes that were not statistically significant. 
Nonetheless, the influence of fetal sex and BMI on fetal growth appeared to be opposite that 
observed in term pregnancies (all P>0.19, interaction), with fetal growth being influenced more 
by increasing maternal BMI in male vs. female fetuses.  
  
 Maternal race, smoking and fetal growth 2.4.2
 
Smoking was associated with a larger reduction in birthweight in term offspring of White 
compared to Black women (165 vs. 68 g reduction, respectively) (Table 10). There was also a 
greater reduction in fetal placental ratio (P<0.01, additive interaction), a larger increase in the 
head to chest circumference ratio (P=0.02, additive interaction) and a reduction in the ponderal 
index (P<0.01, interaction) in the term offspring of White compared to Black smokers. 
Additionally, offspring of White smokers had a higher relative risk of being SGA compared to 
non-smokers than the offspring of Black smokers in the multiplicative scale (OR 2.90 [95% CI: 
2.24, 3.77] versus OR 1.51 [95% CI: 1.24, 1.85]; P<0.01 for multiplicative interaction). The 
borderline significance of the synergy index (synergy index 0.86 (95%CI 0.67, 1.05) was 
consistent with the additive models which indicated that offspring of Black women were less 
susceptible to the influence of maternal smoking.  
White women tended to smoke more heavily than Black women (7.8 compared to 4.0 
cigarettes per day respectively; P<0.01). Even after accounting for smoking ‘dose’ there was still 
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a greater reduction in birthweight, crown-heel length, and fetal placental ratio and a greater 
increase in the risk of SGA among offspring of White smokers compared to Black smokers. For 
each five additional cigarettes smoked per day, the decrease in fetal growth was greater in 
offspring of White smokers (birthweight, crown heel length, head circumference, chest 
circumference and fetal placental ratio all P≤0.05, interaction) (Table 11). When the preterm 
births were analyzed, the results again appeared to be opposite to that observed among the term 
infants. With smoking there appeared to be a larger reduction in birthweight in preterm offspring 
of Black smokers than in preterm offspring of White smokers, although the confidence intervals 
of these estimates were wide.  
Among term infants, socioeconomic status did not significantly impact fetal growth in the 
linear regression models for fetal placental ratio, head to circumference ratio (P=0.29, 0.17 
respectively) but was a significant influence on fetal growth as indicated by the prevalence of 
SGA (p<0.001) and ponderal index (P=0.02) models. The risk of SGA was lower among the 
highest socioeconomic group compared to the lowest and middle SES groups. In addition SGA 
risk was lowest among the White vs. Black of the highest SES group.The middle SES group, had 
a lower mean ponderal index, compared to the lowest SES group. However there was no 
difference in the mean ponderal index between the highest vs. lowest SES group. Fetal sex or 
race did not modify the influence of socioeconomic status on ponderal index (data not shown). 
 
 
2.5 DISCUSSION 
 
In this study we identified pre-pregnancy BMI and maternal smoking as factors that influence 
fetal growth differently according to maternal race or infant sex. Our findings indicated greater 
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growth of term female vs. male infants with increasing maternal pre-pregnancy BMI. In addition, 
the growth of term offspring of white smokers was lower compared to term offspring of Black 
smokers. Although the precision of our results was compromised by smaller sample size with 
preterm infants, we observed an opposite relation with increasing maternal pre-pregnancy BMI 
on fetal growth for preterm males compared to females. Also the direction of the influence of 
smoking with preterm births was opposite that in term births. Maternal smoking had a larger 
negative influence among preterm offspring of Black compared to White smokers. These results 
suggest that maternal pre-pregnancy BMI and smoking influence fetal growth through different 
biological pathways at different gestations by sex and race.  
A recent study performed in Chile supports our findings that fetal growth is sex-specific 
and time sensitive in response to maternal anthropometry (223). Lampl reported that birthweight 
in 1,814 male vs. 1,681 female fetuses varied in sensitivity to different maternal weight and 
height combinations at different gestations. Specifically, male fetuses were sensitive to maternal 
height of thin mothers in early pregnancy and maternal weight of short mothers in later gestation. 
Female infants were sensitive to maternal weight of tall mothers early in pregnancy and maternal 
height of thin mothers later in gestation (223). In addition, the greater fetal growth and decrease 
in the incidence of SGA with increasing maternal pre-pregnancy BMI among term females 
compared to male offspring in our study is consistent with a theory proposed by Eriksson. This 
theory suggests that females respond to the mother’s lifetime nutrition and metabolism while 
males respond to her current nutrition(103). This was demonstrated in the Dutch Famine in 
which there was greater increased mortality among adult males than females who were in utero 
during the famine (224). Animal studies also indicate a greater effect of maternal malnutrition on 
male than female rats(138, 225).  The biological mechanisms that may explain these results 
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remain unknown, however gene (94, 95) and steroidal pathways (96, 97) have been shown to 
influence birth outcomes differently by fetal sex.  
In our study, term offspring of White smokers had greater reductions in birthweight and a 
greater likelihood of being SGA than term offspring of Black smokers. This is consistent with a 
prospective cohort study of 925 term Black and White singleton infants (226) and a population 
study of US births in 1995 to 485,905 Black and  681,600 White mothers(199). Both studies 
found greater reductions in growth measurements of White offspring compared to Black 
offspring of smokers (226). In addition, a case-control study of 407 White mothers and 537 
Black mothers found a higher risk of SGA among the offspring of White compared to Black 
smokers as smoking level (200). A few studies have reported that maternal smoking had a 
greater negative impact on offspring birthweight of Black compared to White women (201, 227-
229). These studies were limited to a specific birthweight cut-point (birthweight less than 2500g) 
and did not address smoking “dose”. 
The differential impact of smoking on fetal growth may be explained by innate factors 
associated with race. As an example, tobacco intermediates are detoxified for excretion by 
enzymes such as the glutathione S-transferase family.  A recent study reported that among 
smokers, those with offspring with the GSTT1(del) genotype had a larger mean reduction in 
birthweight than infants without the gene deletion (230). Another study found that the a 
combination of the GSTM1(del) and the GSTT1(del) genotypes intensified the influence of 
maternal exposure to environmental tobacco smoke on birth weight more than the presence of 
either genotype alone(231). The  combination of the GSTM 1(del) and GSTT1 (del) genotypes 
as well as the GSTM1 (del) genotype is more common among US Whites (232), while the 
GSTT1 (del) genotype is more common in US Blacks. More research is needed to determine if 
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there is a race-gene-smoking interaction which influences fetal growth by race among offspring 
of smokers with these genotypes.  
Our study had several strengths. The Collaborative Perinatal Project (CPP) is the only 
study of this scale with fetal measurements in the United States. In the CPP, anthropometric data 
were recorded at birth and were measured using standardized protocols which minimized bias. 
The equal numbers of Black and White women allowed the opportunity to explore the interaction 
between race and smoking on fetal growth in a large number of infants. The consistency in the 
results of reduced growth using several indicators of fetal growth, in addition to SGA, supports 
our findings and indicates true changes in growth that are unlikely due to chance. We found 
lower anthropometric measures accompanied by greater odds of SGA among offspring of Blacks 
compared to Whites in our study. Despite the anthropometric measures indicating reduced 
growth, this different rate of SGA between Black and White infants was not evident using race 
adjusted growth charts. Our findings are consistent with the large body of evidence that offspring 
of Black women are at greater risk for fetal growth restriction than offspring of White women 
(142, 233, 234), and support the use of non-race adjusted growth curves. 
The study was limited to one-time measures of fetal growth taken at birth and as a result 
does not indicate growth throughout pregnancy. Although our determination of gestational age 
and thus term and preterm gestation was based on the mothers last menstrual period, testing the 
results in women with known normal menstrual cycles or delivery dates of at least 39 weeks did 
not change the findings. Despite the fact that obesity is more common today (30% currently 
compared to 9% in CPP), we believe the results are generalizable to a modern population. It 
seems unlikely that the biological mechanism between a 1kg/m2 increase in the maternal pre-
pregnancy BMI and fetal growth would change over time.  
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Women missing placenta weight and chest circumference data differed from women with 
these measures. The findings from the placenta and chest circumference models were consistent 
with the other fetal growth models suggesting that any resulting selection bias is minimal. Given 
the large sample size the bias introduced from missing data should be small. There should be 
little selection bias in our study as the selection criteria were independent of offspring sex.  
Our study is novel in that it provides evidence that the influence of maternal pre-
pregnancy BMI and smoking are not constant across fetal sex and maternal race. This evidence 
suggests that this relationship may operate through different biological pathways by sex and race. 
These subtle race and sex differences in growth are not of a magnitude to justify revisions of the 
current clinical management. However, our findings indicate it is important to incorporate sex 
differences in the study of mechanisms of fetal growth. Additionally our study indicates that in 
addition to SGA, several other indicators of fetal growth capture reduced fetal growth. 
Additionally, these measures confirmed that using non-race adjusted weight for gestational age 
tables are more appropriate than race adjusted tables. Our results may help to explain sex and 
race differences in neonatal and long term health outcomes. The relationship between maternal 
BMI, smoking, fetal growth, fetal sex and race is complex and warrants further study.  
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2.6 Tables and Figures  
 
Figure 3: Study Population (Manuscript 1)
CPP Population 
54,681 
Primiparous 
16,523 
Infants included in 
this study 
8,801 
Term infants 
7,582 
Preterm infants 
1,219 
EXCLUDED 
  Stillbirths n=177 
  Hispanics and Asians n=706 
Offspring of mothers with: 
 Preeclampsia, Chronic &Transient 
Hypertension n=3436 
  Proteinuria n= 739 
  Missing Hypertension status n=103 
  Diabetics = 179 
  Missing Race n=54 
  Missing SES n=341 
  Missing BMI n=732 
  Missing Smoking status n=37 
Offspring with:  
 Missing *GA & *GA <25 & >42 weeks  
n=1,215 
 Missing Sex status n=3 
Multiparous 
38,158 
*GA= Gestational Age 
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Table 7: Baseline Characteristics of Population of Normotensive Primiparous Women 
 
Characteristics N=8801 
 
Males 
(N=4597) 
n(%) 
Females 
(N=4204) 
n(%) 
P-
value  
Blacks 
(N=4126) 
n(%) 
Whites 
(N=4776) 
n(%) 
p-
value 
Maternal Age        
<20 2356 (52.0) 2177 (48.0) 
0.22 
 2800 (61.8) 1733 (38.2) 
<0.01 20-29 2125 (52.8) 1898 (47.2)  1218 (30.3) 2805 (69.7) 
30+ 116 (47.4) 129 (52.6)  79 (32.2) 166 (67.8) 
Maternal Race        
White 2483 (52.8) 2221 (47.2) 
0.27 
   
 
Black 2114 (51.6) 1983 (48.4)    
Smoking        
Nonsmoker 2587 (52.5) 2339 (47.5) 
0.55 
 2542 (51.6) 2384 (48.4) 
<0.01 
Smoker 2010 (51.9) 1865 (48.1)  1555 (40.1) 2320 (59.9) 
Cigarettes/day        
Mean±SD 6.04±12.42 6.17±12.8 0.63  3.99±11.65 7.94±13.09 <0.01 
BMI (kg/m2)        
Underweight 
(<18.5) 619 (53.8) 532 (46.2) 
0.36 
 569 (49.4) 582 (50.6) 
<0.01 
Normal  
(18.5-24.9) 3580 (52.3) 3270 (47.7)  3069 (44.8) 3781 (55.2) 
Overweight  
(25.0- 29.9 ) 330 (50.1) 329 (49.9)  374 (56.8) 285 (43.2) 
Obese  
(>30 ) 68 (48.2) 73 (51.8)  85 (60.3) 56 (39.7) 
Maternal SES score        
1  (low) 1584 (51.4) 1497 (48.6) 
0.49 
 2275(73.8) 806 (26.2) 
<0.01 2 (mid) 1238 (52.4) 1126 (47.6)  1236 (52.3) 1128 (47.7) 
3 (high) 1775 (52.9) 1581 (47.1)  586 (17.5) 2770 (82.5) 
Gestational Age 
(completed weeks)        
 Preterm <37 658 (14.3) 561 (13.3) 
0.19 
 848 (20.7) 371 (7.9) 
<0.01 
Term ≥ 37 3939 (85.7) 3643 (86.7)  3249 (79.3) 4333 (92.1) 
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Table 8: Adjusted Means of the Markers of Growth by Race and Sex for all births (preterm and term) 
Fetal Measures 
 
Male b 
Mean (SE) 
Female b 
Mean (SE) 
Sex 
Difference 
Sex 
Difference 
p 
Black c 
Mean (SE) 
White c 
Mean (SE 
Race 
Difference 
Race 
Difference 
p 
Birthweight (g) 3147.71 (6.53) 3047.38 (6.84) +100.33 <0.01 3009.74 (7.65) 3178.28 (7.05) -168.54 <0.01 
Crown Heel Length 
(cm) a 50.04 (0.04) 49.38 (0.04) +0.66 <0.01 49.42 (0.04) 50.00 (0.04) -0.58 <0.01 
Head Circumference 
(cm) a 33.85 (0.02) 33.28 (0.02) +0.57 <0.01 33.39 (0.02) 33.74 (0.02) -0.35 <0.01 
Chest Circumference 
(cm) a 31.71 (0.03) 31.40 (0.03) +0.31 <0.01 31.26 (0.03) 31.87 (0.03) -0.61 <0.01 
Placental Weight 
(g) a 426.12 (1.37) 421.57 (1.44) +4.55 0.02 414.89 (1.67) 430.78 (1.42) -15.88 <0.01 
Ponderal Indexa 2.507 (0.004) 2.527 (0.005) -0.020 <0.01 2.493 (0.005) 2.537 (0.005) -0.044 <0.01 
Head- Chest 
Circumference Ratioa 1.070 (0.001) 1.062 (0.001) +0.008 <0.01 1.070 (0.001) 1.061 (0.001) +0.009 <0.01 
Fetal Placental 
Weight Ratioa 7.57 (0.02) 7.43 (0.02) +0.14 <0.01 7.48 (0.03) 7.52 (0.02) -0.04 0.36 
SGA  n (%) 492 (10.7) 394 (9.4) - - 530 (12.9) 356 (7.6) - - 
SGA OR (95% CI) 1.18 (1.02, 1.36) d REFERENT d - 0.02 1.78 (1.51, 2.10) e REFERENT e - <0.01 
  Values are means and standard error unless otherwise specified. 
aReduced sample size due to missing values (missing=3% length, PI & head circumference, 12% chest circumference & HCC and 15% placental weight & FPR models). 
bDerived from linear regression models adjusting for maternal age, race, pre-pregnancy body mass index (BMI), smoking, socio-economic status (SES) and 
gestational age at delivery. 
cDerived from linear regression models adjusting for infant sex, maternal age, pre-pregnancy BMI, maternal smoking, SES and gestational age at delivery. 
dDerived from logistic regression models adjusting for  maternal age, race,  pre-pregnancy BMI, smoking and SES. 
eDerived from logistic regression models adjusting for infant sex, maternal age, pre-pregnancy BMI, smoking and SES. 
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Table 9: Influence of 1 kg/m2 increase in BMI by Fetal sex and Race on each Growth Measure. 
Fetal Measures 
Term Male b 
Beta coefficient 
(SE) 
Term Female b 
Beta coefficient 
(SE) 
SEX x BMI 
Interaction p 
Term Black c 
Beta coefficient (SE) 
Term White c 
Beta coefficient (SE) 
RACE x BMI 
Interaction p 
Birthweight (g) 9.83 (2.28)* 20.23 (2.20)* <0.01 15.15 (2.24)* 14.66 (2.23)* 0.78 
Crown Heel Length (cm) a 0.034 (0.012)* 0.060 (0.012)* 0.14 0.061 (0.013)* 0.033 (0.012)* 0.07 
Head Circumference (cm) a 0.024 (0.007)* 0.045 (0.007)* 0.06 0.034 (0.008)* 0.035 (0.007)* 0.89 
Chest Circumference (cm) a 0.032 (0.010)* 0.073 (0.010)* <0.01 0.056 (0.010)* 0.048 (0.010)* 0.63 
Placental Weight (g) a 2.482 (0.504)* 4.234 (0.509)* 0.01 2.865 (0.535)* 3.723 (0.483)* 0.29 
Ponderal Indexa 0.003 (0.002)† 0.008 (0.002)* 0.08 0.004 (0.002)† 0.007 (0.002)* 0.06 
Head- Chest 
Circumference Ratioa -0.0004  (0.0003) -0.001 (0.0003)* 0.07 -0.0009 (0.0003)* -0.0005 (0.0003) 0.35 
Fetal Placental Weight 
Ratioa -0.023 (0.007)* -0.022 (0.007)* 0.92 -0.014 (0.008) -0.029 (0.007)* 0.16 
 
Male d 
OR (95% CI) 
Female d 
OR (95% CI 
P 
Interaction  
Black e 
OR (95% CI) 
White e 
OR (95% CI) 
P 
Interaction  
SGA (<10th percentile)  
Decrease in BMI WHOf 
category 
1.15 (0. 94, 1.41) 1.76 (1.41, 2.21)* <0.01h 1.46 (1.21, 1.77) 1.27(1.00, 1.62) 0.33 h 
SI (decrease in BMI WHOf 
categories from obese to 
underweight) g 
0.55(95% CI; 0.30, 0.79) 
Risk factors= 
decreasing BMI 
and Male sex 
1.49 (95% CI; 0.55, 2.42) 
Risk factors= 
Decreasing BMI 
and Black race 
*=p≤0.01,    †=p≤0.05      The p-values reported are for interaction in additive scale unless otherwise specified 
aReduced sample size due to missing values (missing=3% length, PI & head circumference, 12% chest circumference & HCC and 15% placental weight & FPR models). 
bDerived from linear regression models adjusting for maternal race, age, smoking, SES and infant gestational age at delivery. 
cDerived from linear regression models adjusting for infant sex and gestational age at delivery and maternal smoking, age and SES. 
dDerived from logistic regression models adjusting for  maternal race, age, socioeconomic status (SES), and smoking. 
e Derived from logistic regression models adjusting for infant sex infant and maternal age, smoking and socioeconomic status (SES). 
fWorld Health Organization BMI Categories Underweight (<18.5 kg/m2), Normal (18.5-24.9 kg/m2) Overweight  (25.0- 29.9 kg/m2 ) Obese (>30kg/m2 ) 
g A synergy index of 1.0 = no interaction, <1 indicates antagonism, and >1 indicates synergy.  
h p-value for interaction in multiplicative scale 
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Table 10: Differential Influence of Smoking by race. 
Fetal Measures Non Smoker Mean (SE) 
Smoker 
Mean (SE)  
Nonsmoker 
Mean (SE) 
Smoker 
Mean (SE)  
SMOKE x RACE  
Interaction p 
 Term Blackb Black difference Term White
b White difference  
Birthweight (g) 3105.87 (9.52) 3037.74  (11.99) -68.13* 3332.22 (9.13) 3167.32 (8.96) -164.90* <0.01 
Crown Heel Length (cm) a 49.92 ( 0.05) 49.44 (0.07) -0.48* 50.66 (0.05) 49.98 (0.05) -0.68* 0.06 
Head Circumference (cm) a 33.72 ( 0.03) 33.41 (0.04) -0.31* 34.07 (0.03) 33.75 (0.03) -0.32* 0.80 
Chest Circumference (cm) a 31.65  (0.04) 31.34 (0.05) -0.31* 32.43 (0.04) 31.90  (0.04) -0.52* 0.01 
Placental Weight (g) a 417.01 (2.28) 422.45  (2.75) +5.44 434.47 (1.98) 438.09 (1.96) +3.62 0.68 
Ponderal Indexa 2.497 (0.007) 2.514 (0.008) +0.017 2.562 (0.006) 2.536 (0.006) -0.027* <0.01 
Head- Chest 
Circumference Ratioa 1.067 (0.001) 1.068 (0.001) +0.001 1.053  (0.001) 1.060 (0.001) +0.007* 0.02 
Fetal Placental Weight 
Ratioa 7.627 (0.032) 7.348 (0.039) -0.279* 7.836 (0.028) 7.377 (0.028) -0.459* <0.01 
SGA n (%) 279 (13.6%) 238 (19.5%) - 101 (4.5%) 255 (12.0%) - - 
SGA (<10th percentile) c 
OR (95% CI) 
REFERENT OR 1.51 (1.24, 1.85)* - REFERENT 
OR 2.90 
 (2.24, 3.77)* - <0.01
d 
SI (95% CI) e 
0.86 (0.67, 1.05)  
Risk factors =Black race and smoking 0.89 
*= p<0.01, †= p≤0.05.   Values are means and standard error unless otherwise specified. P values reported are for interaction in additive scale unless otherwise specified 
aReduced sample size due to missing values (missing=3% length, PI & head circumference, 12% chest circumference & HCC and 15% placental weight & FPR models). 
bDerived from linear regression models adjusting for infant sex infant, gestational age at delivery and maternal age,  pre-pregnancy body mass index (BMI ) and SES. 
cDerived from logistic regression models adjusting for infant sex and maternal age, pre-pregnancy body mass index (BMI), and socioeconomic status. 
d p-value for interaction in multiplicative scale. 
e A synergy index of 1.0 = no interaction, <1 indicates antagonism, and >1 indicates synergy 
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Table 11: Influence of a 5 cigarette increase in cigarette consumption per day by Race and Sex on each Growth Measure at 
term. 
Fetal Measures Term Male 
b 
Beta coefficient  (SE) 
Term Female b 
Beta coefficient  (SE) 
Cigarette x SEX 
Interaction p 
Term Black c 
Beta coefficient  (SE) 
Term White c 
Beta coefficient  (SE) 
Cigarette x RACE 
Interaction p  
Birthweight (g) -13.50 (2.69)* -11.35 (2.58)* 0.50 -0.59 (2.89) -19.76 (2.45)* <0.01 
Crown Heel Length 
(cm) a -0.038 (0.015)* -0.044 (0.014)* 0.82 -0.007 (0.016) -0.070 (0.013)* <0.01 
Head Circumference 
(cm) a -0.033 (0.009)* -0.032 (0.008)* 0.80 -0.018 (0.010)  -0.042 (0.007)* 0.05 
Chest Circumference 
(cm) a -0.040 (0.012)* -0.032 (0.012)* 0.49 -0.012 (0.013) -0.052 (0.011)* 0.01 
Placental Weight (g) a 0.500 (0.573) 0.515 (0.583) 0.79 0.826 (0.647) 0.327 (0.529) 0.54 
Ponderal Indexa -0.004 (0.002)† -0.003 (0.002) 0.53 -0.001 (0.002) -0.004 (0.002)* 0.22 
Head- Chest 
Circumference Ratioa 0.0003 (0.0003) 0.00005(0.0003) 0.55 0.0002 (0.0004) 0.0004 (0.0003) 0.20 
Fetal Placental Weight 
Ratioa -0.042 (0.008)* -0.036 (0.008)* 0.76 -0.013 (0.010) -0.057 (0.007)* <0.01 
 
Term Male d 
OR (95% CI) 
Term Female d 
OR (95% CI 
P 
Interaction 
Term Black e 
OR (95% CI) 
Term White e 
OR (95% CI) 
P 
Interaction 
SGA (<10th percentile) 1.07 (1.03, 1.11)* 1.05(1.01, 1.09) † 0.46n 1.02( 0.98, 1.06) 1.10( 1.06, 1.14)* <0.01 f 
SI (95% CI) 5-10 cigs/day g 
1.12 (0.87, 1.38)  
Risk factors=male sex & smoking 
0.94 (0.86, 1.01)       
Risk factors= Black race & smoking 
*=p≤0.01,    †=p≤0.05   The p-values reported are for interaction in additive scale unless otherwise specified 
RReduced sample size due to missing values (missing=3% length, PI & head circumference, 12% chest circumference & HCC and 15% placental weight & FPR models). 
bDerived from linear regression models adjusting for maternal race, pre-pregnancy body mass index (BMI), socioeconomic status and infant gestational age at delivery. 
cDerived from linear regression models adjusting for maternal pre-pregnancy body mass index and socioeconomic status and infant sex and gestational age at delivery. 
dDerived from logistic regression models adjusting for maternal race, pre-pregnancy body mass index (BMI), and socioeconomic status (SES). 
eDerived from logistic regression models adjusting for maternal pre-pregnancy body mass index (BMI), socioeconomic status (SES) and infant sex. 
f p-value for interaction in multiplicative scale. 
g A synergy index of 1.0 = no interaction, <1 indicates antagonism, and >1 indicates synergy 
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3.1 ABSTRACT 
 
We investigated whether the relationship between preeclampsia and fetal growth is modified by 
infant sex. The subjects were offspring of 516 preeclamptic and 8801 normotensive primiparous 
Black and White women enrolled in the Collaborative Perinatal Project (1959 -1965). The 
frequency of small for gestational age (SGA<10th centile), mean birthweight, ponderal index, 
head and chest circumferences were examined.  Interaction terms between sex and preeclampsia 
were evaluated after adjustment for confounders. The results were stratified by preterm status 
(<37 weeks).  Male preterm offspring of preeclamptic mothers had greater reductions in head 
and chest circumferences than preterm female offspring of preeclamptic women (p=0.02, 
p=0.01; interaction respectively). The influence of preeclampsia on growth of offspring born at 
term was more modest, and the influence of sex was opposite that in preterm infants. Compared 
to term offspring of normotensive women, the reduction in mean ponderal index was greater for 
female vs. term male offspring of preeclamptic women (p<0.01, interaction). Fetal growth was 
more impaired among male vs. female preterm infants born to preeclamptic women. This 
suggests that preterm males born to preeclamptic women may be more prone to neonatal 
complications.  Sex differences in fetal growth may help explain sex differences in neonatal and 
long term health outcomes. 
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3.2  INTRODUCTION 
 
Preeclampsia is a pregnancy specific disease that is diagnosed by new-onset proteinuria and 
increased blood pressure. It affects 3-5% of pregnancies (36), and is associated with abnormal 
remodeling of the maternal vessels supplying the placenta and reduced fetal and placental 
growth. The infant faces detrimental effects due to reduced nutrient and oxygen transfer during 
fetal development.  
The effect of preeclampsia on the mother has been well studied. However, there is less 
information on the specific effects of preeclampsia on offspring. It is evident that male fetuses 
are at a disadvantage in pregnancy.  Spontaneous preterm labor (9) and complications of 
pregnancies such as fetal distress during labor and low Apgar scores are more common with 
pregnancies bearing male compared to female fetuses (10, 11). Guided by evidence of sex 
differences in several pregnancy outcomes, we examined whether the relationship between 
preeclampsia and fetal growth is modified by infant sex. 
Fetal growth restriction (FGR) is defined as fetal growth that fails to achieve the genetic 
growth potential. Small for gestational age (SGA) is used to detect FGR. It is commonly defined 
as birthweights below the 10th percentile for babies born at the same gestational age in an 
appropriate reference population.  However, not all SGA infants are small due to impaired 
growth (e.g. small parents have appropriately grown small infants) and not all FGR infants are 
identified using SGA criteria. Infants may fall within the normal range of birth weight but show 
metabolic, hematologic, and neurologic characteristics as seen in growth-restricted infants (235).  
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For this reason we related preeclampsia and fetal sex to several other indicators of fetal 
growth: Fetal placental ratio, ponderal index and head to chest circumference ratio. Our study 
analyzed these markers of fetal growth among infants born to primiparous preeclamptic and 
normotensive women. The study was designed to evaluate whether fetal growth in preeclamptic 
offspring is modified by infant sex. Fetal sex differences that influence placental, fetal and 
maternal physiology may bring us closer to understanding the pathophysiology of preeclampsia 
as well as provide insight into why morbidity and mortality rates differ by sex in pregnancy and 
in adulthood. 
 
3.3 METHODS 
 
 Study Population 3.3.1
 
The subjects were pregnant women and their offspring who were enrolled in the Collaborative 
Perinatal Project (CPP), a prospective study of neurologic disorders and other conditions in 
children. The CPP collected data on 58,806 pregnant women enrolled at 12 study centers during 
1959 to 1965, about half of whom were African American (202, 203).  
The present analysis was limited to primiparous Black and White women with singleton 
births for several reasons. There are pathological and epidemiological findings indicating 
differences between preeclampsia when it occurs in first or later pregnancies (236). Primiparity 
is also associated with increased risks of preeclampsia and preterm birth. Limiting the study to 
primiparous women provided a greater proportion of women with these events. Hispanics and 
Asians were excluded because of small numbers (7.0%, n= 796) (Figure 4).  Women were 
excluded if they had proteinuria only (n=739), chronic or transient hypertension of pregnancy 
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(gestational hypertension without proteinuria (206)) (n=2,686) or were missing hypertension 
status (n=103). Gestational age was limited to 25 to 42 weeks because preeclampsia was defined 
as occurring after 24 weeks and pregnancies longer than 42 weeks may be associated with 
complications that could confound our study (excluded n=1,313). Births with missing gestational 
ages (n=46) and sex of the infant (n=18) were excluded. Women missing the covariates of 
interest were also excluded (n=1,284). 
Gestational age was calculated based on the last menstrual period of the mother. This 
method is known to have error which may result in the misclassification of preterm and term 
status (207-209). Women with long cycles are more likely to have their gestation overestimated 
(misclassified as term) (210) while women with short cycles are more likely to have their 
gestation underestimated (misclassified as preterm). To address this potential limitation, 
gestational age was defined as reliable in a subgroup of women (n=5951, 63%) with a last 
menstrual period that was 26 to 35 days following the beginning of the previous menstrual 
period (211, 212). Analyses were repeated in this group. To further determine if possible bias 
introduced by misclassification of preterm/term infants affected our results, we performed a 
second analysis among infants with gestational ages 39-42 weeks. This was compared to the 
original distribution of term infants (37-42 weeks) to determine if the findings were the same.   
Birth weights (213), birth lengths (213), head (214, 215) and chest circumferences (215) 
were checked for plausibility using comparative reference populations and Tukey’s criteria was 
used to remove extreme outliers(216). The models met the assumptions for normality after 
removal of the following outliers: Among the term infants, 0-24 outliers were removed from 
each model. Among the preterm infants, 0 outliers were removed from each model.  The results 
of the term fetal growth models were not different with the removal of outliers and thus outliers 
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were removed in the analysis reported in this paper. The final study population was 9317 infants 
(from 516 preeclamptic and 8801 normotensive women). Our final study sample had large 
numbers of missing placental weight (n=1433, 15.4%) and chest circumference measures 
(n=1062, 11.4%). Women missing placental data were more likely to be of lower SES, Black and 
non-smokers, while mothers of offspring missing chest circumference data were more likely to 
be normotensive, of higher SES, and White. However it appeared that this was driven by missing 
data from specific study sites and not due to demographic characteristics of the mother (e.g. 70% 
of placental data was missing among women from Tennessee, while 25% and 28% of women 
from Boston and Buffalo sites respectively had chest circumference data missing). 
 
 Definition of Preeclampsia 3.3.2
 
Preeclampsia was determined by gestational hypertension and proteinuria, which terminated in 
the postpartum period. Gestational hypertension was defined as at least 2 measurements of 
systolic blood pressure >=140 mmHg and/or diastolic blood pressure >=90 mmHg with no prior 
occurrence before 24 weeks of gestation. Proteinuria was 2 random urine dipsticks of 1+ protein 
or one dipstick of 2+ protein(237). Preeclampsia was considered preterm with gestational age at 
delivery ranging from 25 to 36 completed weeks. Term preeclampsia was preeclampsia with 
gestational age at delivery ranging from 37 to 42 completed weeks.  
 
 Fetal Growth Variables 3.3.3
 
SGA was considered as birth weight < 10th percentile for gestational age, and sex using the CPP 
population. Head to chest circumference ratio was the head circumference (cm) / chest 
circumference (cm). Ponderal index was 100 x [birth weight (g)/crown-heel length (cm)3]. The 
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fetal placental ratio was the birthweight (g) / placental weight (g). In addition to SGA and birth 
weight, we evaluated ponderal index which is similar to BMI in adults, and provides an estimate 
of the relative thinness of the infant. It indicates those infants who attained insufficient (low 
ponderal index) or excess soft tissue growth (high ponderal index) relative to the skeletal growth. 
The ratio of head circumference to chest circumference indicates compensatory growth. In the 
presence of impaired growth, visceral organ growth is compromised earlier and brain growth is 
spared longer resulting in a higher head to chest circumference (148).  The ratio of fetal weight 
to placental weight (FPR) is often used as a measure of the efficiency of fetal growth relative to 
placental growth (27). Growth restricted infants tend to have lower fetal placental ratios (112, 
161).  These markers can help confirm that an SGA infant is in fact failing to manifest its genetic 
growth potential.  Furthermore, in cases where fetal weight may appear appropriate for 
gestational age, these measures may indicate infants with impaired growth. In addition, using the 
FPR, ponderal index or head chest circumference can overcome some of the limitations of SGA 
by avoiding the influence of genetically mediated differences in birth weight. 
 
 Socio-demographic Variables 3.3.4
 
Maternal smoking, socio-economic status (SES), and race were collected by self-report; BMI 
was calculated from maternal height (measured at enrollment) and self-reported pre-pregnancy 
weight. Maternal smoking during pregnancy was coded as a dichotomous variable (yes/no). The 
socioeconomic status variable was a combined score based upon education, occupation and 
income (202) and was categorized as low, middle and high SES. Maternal pre-pregnancy BMI 
and gestational age were analyzed as continuous variables. 
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Stillbirths are the most severe outcome following fetal growth restriction. We 
hypothesized that if the relationship between preeclampsia and fetal growth is sex-specific, then 
we should find a similar sex-specific relationship with the rates of stillbirth. In addition, previous 
studies suggest that there is an excess of female infants in preterm preeclamptic pregnancies 
(106, 108), perhaps due to excess male stillbirths. 
 
 Statistical Analysis 3.3.5
 
Chi-square tests were used to test for association between variables. Interaction terms between 
sex and preeclamptic status were evaluated to determine if the influence of preeclampsia on fetal 
growth varied with fetal sex.  Significant interactions were evaluated using the partial F test for 
linear models and the likelihood ratio test for logistic models (p<0.10). It has been proposed that 
departures from additivity (interaction in the additive scale) are more meaningful for interpreting 
the public health and biological significance than departures from multiplicativity (interaction on 
the multiplicative scale) (185, 219, 220). Therefore departures from additive effects in the SGA 
models were evaluated by calculating the synergy index (SI) (a test of interaction) (221) and its 
95% confidence interval (222).  The SI was calculated as the ratio between the combined effect 
and the sum of the individual effects of the risk factors (187). The synergy index was designed to 
measure risk factors rather than preventive factors. Therefore in the analysis of the SI for the 
multiplicative SGA model for the preterm infants, we remodeled female sex as the risk factor. 
Separate linear and logistic regression models were then fitted for males and females to 
report the estimate of the relationship between preeclampsia and fetal growth by sex.  The results 
were stratified by preterm status because the influence of preeclampsia is more severe among 
preterm infants (40, 41). The results were reported as point estimates of the mean and standard 
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error or estimated odds ratio (OR) and 95% confidence interval (CI). A p value of <0.05 was 
considered statistically significant. We repeated all analysis in the preterm and term births infants 
born to women who had reliable menstrual cycles as well as among term infants 39-42 weeks to 
investigate if the results were consistent with the general analyses. The results were unaffected 
when we performed both secondary analyses. Therefore results are reported for the full study 
sample. Stata Software, version 11 (StataCorp, College Station, TX) was used to calculate 
departures from additivity for the SGA logistic regression models. All other statistical analyses 
were performed using SAS 9.2 software (SAS Institute, Cary, N.C.). 
 
3.4 RESULTS 
 
The cohort was primarily young mothers, with 52% being under 20 years of age. Forty seven 
percent of the women were Black, and the majority of women (78%) were of normal BMI (18.5-
24.9kg/m2) (Table 12).  There were 527 preeclamptic births (5.6% of study population. There 
was a greater percentage of males among the preeclamptic women below 20 years of age but a 
larger percentage of females among preeclamptic women 20-29 years of age (P<0.01). However, 
there were no differences in maternal age by sex among the normotensive (P=0.22). There were 
more smokers among the normotensive women compared to preeclamptic women (P<0.01) and 
more Black women among the preeclamptic compared to normotensive group (P<0.01).  There 
were more overweight, obese, and low SES women as well as more SGA infants among the 
preeclamptic compared to normotensive group (all P≤0.02).  
The male to female sex ratio of live births was modestly different in the normotensive 
and preeclamptic groups. Overall, male offspring were more common among normotensive 
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women but less common among offspring of preeclamptic mothers (male:female sex ratios: 
overall 1.09 vs. 0.94 for normotensive vs. preeclamptic women respectively, P=0.08). As 
expected, we found that among offspring of preeclamptic women, males were less common in 
preterm deliveries than at term (male:female sex ratios preterm vs. term: 0.89 vs. 0.94). In 
contrast, among offspring of normotensive women, males were more common in preterm 
compared to term births (male:female sex ratios preterm vs. term 1.15 vs. 1.08). In addition, we 
also investigated if an excess of male stillbirths among offspring of preeclamptic women could 
explain why males were less common in preterm preeclamptic pregnancies, than among term 
preeclamptic pregnancies. There were 105 stillbirths (stillbirths among preeclamptic women 
n=22) (Table 12). We found higher rates of stillbirths among offspring of preeclamptic women 
than normotensive women (4.10% vs. 0.93%; P<0.01). However, the rate of stillbirth did not 
vary by infant sex (P=0.61, and P=0.87 for normotensive and preeclamptic women respectively).    
 
 Preterm Infants  3.4.1
 
When compared to preterm offspring of normotensive women, there was a greater reduction in 
fetal growth among preterm males compared to preterm females born to preeclamptic women 
(Table 13). When comparing the infants of preeclamptic women with those of normotensive 
women, there was a greater reduction in the crown-heel length (-1.67 vs. -0.25; P=0.06, additive 
interaction), head circumference (-1.06cm vs. +0.10cm; P=0.02, additive interaction), chest 
circumference (-1.61cm vs. -0.05cm; P=0.01, additive interaction) and birthweight (-340 vs. -
60g; P=0.05, additive interaction) of preterm males compared to preterm females.   The synergy 
index 0.38 (95% CI 0.00-0.84) was consistent with the linear models and suggested that females 
are less susceptible than males to exposure to preterm preeclampsia.  When the infants born 
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preterm to women with reliable menstrual cycles only were analyzed, the results were consistent 
with this preterm analysis (data not shown).  
 
 Term Infants  3.4.2
 
The association between preeclampsia and fetal growth among the term infants was more modest 
and the relationship with infant sex appeared to be opposite that observed among the preterm 
infants (Table 14).  When compared to term offspring of normotensive women, females had a 
more significant reduction in the ponderal index compared to male infants of preeclamptic 
women (0.11 vs. 0.04, respectively; P<0.01 additive interaction). The relation of preeclampsia 
with other growth parameters did not appear to be modified by infant sex. 
 
 
3.5 DISCUSSION 
 
Our findings indicate that the influence of preeclampsia on fetal growth was modified by fetal 
sex. These results suggest that preeclampsia may impact fetal growth through different biological 
pathways by infant sex. Among infants born preterm, decreased growth was more prominent in 
male vs. female newborn offspring of preeclamptic compared to normotensive women. In 
contrast, among the term offspring we found a more modest reduction in fetal growth, with 
females being more affected.  
In animal models, studies of insults during fetal development such as dietary under-
nutrition (238), hypoxia (239) and placental insufficiency (240, 241) have a greater negative 
influence on male compared to female animals. In humans studies, low ponderal index (very lean 
 74 
mass) at birth is associated with a greater risk for cardiovascular death in men compared to 
women (p=0.01, for sex interaction) (191). In addition, low birth weight (<2500g) is associated 
with a greater risk for chronic kidney disease among men but not women (p=0.03, sex 
interaction) (192). There is also a growing body of evidence suggesting that there is a sex-
specific fetal response to maternal disease during pregnancy. Our findings are consistent with the 
majority of studies that indicate a male disadvantage in pregnancy outcome in response to in 
utero insults. For example in diabetic (98, 99) and chronic hypertensive (100) pregnancies, male 
infants are at higher risk of morbidity and mortality. Therefore, we speculate that our findings of 
reduced fetal growth among male relative to female offspring of preeclamptic women may be 
indicative of greater susceptibility to later life disease.   
Our findings of differential relationships between preeclampsia and growth reduction 
among males vs. females delivered preterm and term is consistent with studies of asthma and 
fetal growth. Murphy found that among pregnant asthmatic women who did not use inhaled 
steroid for treatment of asthma, the female fetuses showed greater reductions in growth, while 
the growth of the males was unaffected (101). However, among pregnant asthmatic women with 
severe exacerbations that required hospitalization, male infants had greater reductions in 
birthweight(102). This is consistent with the theories proposed by Clifton(94)  and Eriksson(103) 
that when faced with maternal insults, males maximize continued fetal growth while females 
reduce growth to increase chances of survival. However when faced with continued or increased 
in utero insult, males are at greater risk for adverse outcome because they have exhausted their 
placental reserves (94, 103).  This may explain our findings in the preterm and term infants. 
Early onset of preeclampsia is more likely to be severe (242) and in general more likely to be 
associated with growth restriction than preeclampsia that occurs near term (160). As a result, this 
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greater in utero insult among preterm infants may explain the greater reductions in growth 
among male vs. female offspring.  
Among offspring of preeclamptic women, males were less common in preterm deliveries 
than at term. In contrast, among offspring of normotensive women, males were more common in 
preterm compared to term births. This is consistent with at least two large studies that also found 
that male offspring were less common among preterm preeclamptic pregnancies, than among 
term preeclamptic pregnancies (106, 108). We could not demonstrate an excess of stillbirths by 
fetal sex that could explain this finding. However, the number of stillbirths to preeclamptic 
women was small and thus we may not have had sufficient power to detect small sex differences 
in the rates that may explain the difference in live births.  
Our study had several strengths. The Collaborative Perinatal Project (CPP) is a large 
dataset, which allowed the exploration of the relatively rare adverse pregnancy outcome- 
preeclampsia. The CPP also included large numbers of fetal measures collected according to 
standardized research protocols.  To our knowledge, this is the only study of this scale with these 
measurements in the United States. The CPP data allowed us to explore the relationship between 
preeclampsia and fetal growth in a racially diverse population. The management of preeclampsia 
has changed since the 1960s, when there were fewer interventions for fetal indications. This 
allowed us to investigate the natural progression of the disease on fetal growth than would be 
possible in a modern cohort and thus limits our generalizability. However, we expect that the sex 
differences observed in the CPP population are generalizable to a modern population. There is 
little possibility of systematic differences between the biological pathway and management of 
preeclampsia by infant sex. 
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Ultrasound technology which is currently used to monitor fetal growth was not available 
in the 1960s. As a result, the study was limited to measures of fetal measures that were taken at 
birth and therefore does not indicate growth rate throughout pregnancy. Errors that exist in the 
measurement of the anthropometric factors may be amplified in the calculation of the head-chest 
circumference, ponderal index and fetal placental ratio. However there is little possibility of 
systematic differences in these measures and ratios by preeclamptic status or infant sex.  
We repeated the analyses among women whose last menstrual period was 26 to 35 days 
following the previous menses and among births between 39-42 weeks of gestation to check for 
misclassification bias. These results were consistent with the term analysis (37-42 weeks), 
suggesting that potential bias introduced by unreliable gestational ages may be minimal. Our 
findings indicate that preeclampsia may influence fetal growth differently among term and 
preterm infants. Preeclampsia may also influence fetal growth differently in very early (births 
<32 weeks) and late preterm births (32-36 weeks). However, due to small numbers of early 
preterm infants, our study was unable to investigate the influence of preeclampsia on fetal 
growth in early vs. late preterm infants.  
The consistency in the results of the multiple measures of fetal growth in our study 
provides reassurance that impaired growth is subtly different in preeclamptic offspring based on 
sex. This evidence suggests that the relationship between fetal growth and preeclampsia may be 
influenced through different biological pathways by fetal sex. These growth reductions are not of 
a magnitude to justify alterations in current clinical treatment. However, the findings from our 
study indicate the importance of including sex differences in the study of mechanisms of fetal 
growth. The relationship between preeclampsia, fetal growth and fetal sex is complex and 
warrants further study. 
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3.6 Tables and Figures 
 
Figure 4: Study Population (Manuscript 2)
CPP Population 
54,681 
Primiparous 
16,523 
Infants included in 
this study 
9,317 
Normotensive 
offspring 
8,801 
Preeclamptic 
offspring 
516 
EXCLUDED 
  Stillbirths n=105 ( only from fetal growth 
analysis) 
  Hispanics and Asians n=788 
Offspring of mothers with: 
  Transient Hypertension n=2686 
  Proteinuria n= 739 
  Missing Hypertension status n=103 
  Diabetics =194 
  Missing Race n=54 
  Missing SES n=369 
  Missing BMI= 775 
  Missing Smoking status n=39 
Offspring with:  
 Missing gestational age n= 46 
Gestational age <25 &>42 weeks  n=1,299 
 Missing Sex status n=9 
Multiparous 
38,158 
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Table 12: Baseline Characteristics of Population of Primiparous Women with live births (n=9,317) 
Characteristics Preeclampsia 
 N=516 
Normotensive 
N=8801 
 PE vs. Ctrl 
Males 
PE vs. Ctrl 
Females 
 Males 
(N=249) 
 n (%) 
Females 
(N=267) 
n(%) 
P-
Value 
Males 
(N=4597) 
n(%) 
Females 
(N=4204) 
n(%) 
P-value P-value P-value 
Maternal Age         
        <20 165 (66.3%) 164 (61.4%) 
0.02 
2356 (51.3%) 2177 (51.8%) 
0.22 <0.01 <0.01         20-29 76 (30.5%) 102 (38.2%) 2125 (46.2%) 1898 (45.1%) 
        30+ 8(3.2%) 1 (0.4%) 116 (2.5%) 129 (3.1%) 
Maternal Race         
       White 105 (42.2%) 94 (35.2%) 0.10 2483 (54.0%) 2221(52.8%) 0.27 <0.01 <0.01        Black 144 (57.8%) 173 (64.8%) 2114 (46.0%) 1983 (47.2%) 
Smoking         
       Nonsmoker 165 (66.3%) 182 (68.2%) 
0.65 
2587 (56.3%) 2339 (55.6%) 
0.55 <0.01 <0.01         Smoker 84 (33.7%) 85 (31.8%) 2010 (43.7%) 1865 (44.4%) 
BMI (kg/m2)         
Underweight  (<18.5) 26 (10.5%) 29 (10.9%) 
0.95 
619 (13.6%) 532 (12.7%) 
0.36 0.01 <0.01 
Normal (18.5-24.9) 188 (76.1%) 196 (73.7%) 3580 (78.4%) 3270 (78.1%) 
Overweight (25.0- 29.9) 27 (10.8%) 32 (12.0%) 330 (7.2%) 329 (7.8%) 
Obese (>35 ) 8 (3.2%) 10 (3.7%) 68 (1.5%) 73 (1.7%) 
Maternal SES score         
1 (low) 124 (49.8%) 142 (53.2%) 
0.61 
1584 (34.5%) 1497 (35.6%) 
0.49 <0.01 <0.01 2 (medium) 70 (28.1%) 65 (24.3%) 1238 (26.9%) 1126 (26.8%) 
3 (high) 55 (22.1%) 60 (22.5%) 1775 (38.6%) 1581 (37.6%) 
Gestational Age 
(weeks) 
        
        <37  35 (14.1%) 40 (15.0%) 0.77 658 (14.3%) 561 (13.3%) 0.19 0.91 0.45         > 37  214 (85.9%) 227 (85.0%) 3939 (85.7%) 3643 (86.7%) 
SGA <10th centile          
<37 weeks 12 (34.3%) 8 (20.0%) 0.16 60 (9.1%) 55 (9.8%) 0.68  <0.001 0.04 
>37 weeks 46 (21.5%) 51 (22.5%) 0.81 432 (11.0%) 339 (9.3%) 0.02  <0.01 <0.01 
Stillbirths N= 22 (4.1%)  N=83 (0.9%)     
 11 (4.2%) 11 (4.0%) 0.87 41 (0.9%) 42 (1.0%) 0.61  <0.01 <0.01 
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Table 13: Adjusted Means of the Markers of Growth among PRETERM offspring of preeclamptic and normotensive women 
 
Fetal measures Male Normo 
b 
Mean (SE) 
Male PE b 
Mean (SE) 
Male 
Difference Diff p 
Female Normo b 
Mean (SE) 
Female PE b 
Mean (SE) 
Female 
Difference 
Diff 
p 
PExSEX 
Interactio
n p  
Birth weight (g) 2674.34 (25.32) 2333.79(111.32) -340.49 <0.01 2547.52 (25.67) 2487.40 (96.59) -60.12 0.60 0.05 
Crown-Heel Length 
(cm)a 48.02  (0.14) 46.35 (0.58) -1.67 <0.01 47.36 (0.14) 47.11 (0.52) -0.25 0.65 0.06 
Head 
Circumference(cm)a 32.58 (0.08) 31.52 (0.34) -1.06 <0.01 32.03 (0.09) 32.13 (0.31) +0.10 0.77 0.02 
Chest Circumferencea 
(cm) 29.95 (0.13) 28.34 (0.53) -1.61 <0.01 29.51 (0.12) 29.56 (0.44) -0.05 0.91 0.01 
Placental Weight (g) a 388.74 (3.96) 376.09 (18.68) -12.65 0.51 378.29 (4.19) 381.38 (15.22) +3.09 0.85 0.56 
Ponderal Indexa 2.422 (0.012) 2.335 (0.052) -0.087 0.11 2.410 (0.013) 2.309 (0.047) -0.101 0.04 0.78 
Head- Chest 
Circumference Ratioa 1.093 (0.003) 1.119 (0.012) +0.026 0.04 1.086 (0.003) 1.095 (0.010) +0.009 0.36 0.28 
Fetal Placental 
Weight Ratioa 6.94 (0.06) 6.90 (0.30) -0.04 0.89 6.85 (0.07) 6.73 (0.24) -0.11 0.65 0.91 
 Male Normo 
c 
OR (95% CI) 
Male PE c 
OR (95% CI  p 
Female Normo c 
OR (95% CI) 
Female PE c 
OR (95% CI)  p  
SGA (<10th percentile) REFERENT 6.37 (2.90, 14.00) - <0.01 REFERENT 
2.76 (1.18, 
6.47) - 0.02 0.08
d 
Synergy Index  
(95% CI)e 
0.38(0.00, 0.84) 
Risk factors=female sex and preeclampsia 
 
Each fetal measure outcome variable was assessed in a separate regression model. Normo= Normotensive Offspring, PE = Preeclamptic Offspring 
The reported p-values for interaction are for interaction in the additive scale unless otherwise specified. 
a Reduced sample size due to missing measurements (missing=3% length, PI & head circumference, 10% chest circumference & HCC and 20% placental weight 
& FPR models). 
bDerived from linear regression models adjusting for maternal race, socio-economic status (SES), pre-pregnancy body mass index (BMI), maternal smoking, 
and gestational age at delivery. 
cDerived from logistic regression models adjusting for  maternal race, socio-economic status (SES), pre-pregnancy body mass index (BMI), and smoking. 
d p-value for interaction in the multiplicative scale 
e A synergy index of 1.0 = no interaction, <1 indicates antagonism, and >1 indicates synergy. 
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Table 14: Adjusted Means of the Markers of Growth among TERM offspring of preeclamptic and normotensive women 
 
Fetal measures Male Normo b 
Mean (SE) 
Male PE b 
Mean (SE) 
Male 
Difference 
Diff p Female Normo b 
Mean (SE) 
Female PE b 
Mean (SE) 
Female 
Difference 
Diff p PExSEX   
Interaction p 
Birth weight (g) 3220.85 (6.62) 3086.90 (28.49) -133.95 <0.01 3130.46 (6.59) 2958.12 (26.59) -172.34 <0.01 0.40 
Crown Heel Length 
(cm) a 50.37 (0.04) 49.92 (0.15) -0.45 <0.01 49.75 (0.04) 49.64 (0.15) -0.11 0.47 0.12 
Head Circumference 
(cm) a 34.04 (0.02) 33.78 (0.09) -0.27 <0.01 33.50 (0.02) 33.20 (0.08) -0.30 <0.01 0.76 
Chest Circumference 
(cm) a 32.00 (0.03) 31.54 (0.12) -0.46 <0.01 31.74 (0.03) 31.22 (0.12) -0.52 <0.01 0.78 
Placental Weight (g) a 430.55 (1.45) 418.87 (6.40) -11.67 0.08 428.31 (1.51) 414.00 (6.20) -14.31 0.03 0.78 
Ponderal Indexa 2.518 (0.004) 2.477 (0.019) -0.041 0.04 2.542 (0.005) 2.434 (0.019) -0.11 <0.01 0.02 
Head- Chest 
Circumference Ratioa 
1.066 
(0.0008) 1.072 (0.004) +0.006 0.09 1.057 (0.0008) 1.068 (0.003) +0.011 <0.01 0.43 
Fetal Placental 
Weight Ratioa 7.66 (0.02) 7.63 (0.09) -0.03 0.76 7.49 (0.02) 7.38 (0.09) -0.11 0.20 0.57 
 Male Normoc 
OR (95% CI) 
Male PE c 
OR (95% CI)  p 
Female normo c 
OR (95% CI) 
Female pe c 
OR (95% CI)  p  
SGA (<10th 
percentile) REFERENT 2.22 (1.56, 3.16) - <0.01 REFERENT 2.92 (2.06, 4.12) - <0.01 0.30
d 
Synergy Index  
(95% CI)e 
0.81 (0.32, 1.29) 
Risk factors=male sex and preeclampsia  
Each fetal measure outcome variable was assessed in a separate regression model. 
The reported p-values for interaction are for interaction in the additive scale unless otherwise specified.  
Normo= Normotensive Offspring, PE = Preeclamptic Offspring 
a Reduced sample size due to missing measurements (missing=3% length, PI & head circumference, 12% chest circumference & HCC and 15% placental weight & FPR 
models). 
bDerived from linear regression models adjusting for maternal race, socio-economic status (SES), maternal pre-pregnancy body mass index (BMI), maternal smoking, and 
gestational age at delivery. 
cDerived from logistic regression models adjusting for  maternal race, socio-economic status (SES), pre-pregnancy body mass index (BMI), and smoking. 
d p-value for interaction in the multiplicative scale  
e A synergy index of 1.0 = no interaction, <1 indicates antagonism, and >1 indicates synergy. 
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4.1 ABSTRACT 
 
The dimensions of the placenta may provide insight on the influence of placental under perfusion 
in the setting of preeclampsia. We studied the largest and smallest diameters, ratio of the 
diameters, placental thickness and placental weight among offspring of 735 preeclamptic and 
21,185 normotensive, Black and White women enrolled in the Collaborative Perinatal Project 
(1959 -1965). Preeclampsia was associated with lower placental weight and diameters (test of 
trend, p<0.01 placental weight, p<0.01 smaller diameter and p=0.04 larger diameter, 
respectively). After additional adjustment for placental weight, only the smaller placental 
diameter retained an independent relationship with the risk of preeclampsia. When we 
investigated the relationship between placental weight and birthweight, we found that at lower 
(<430grams, p<0.01 interaction) and upper (>495 grams, p=0.04, interaction) ranges of placental 
weight, the rate of increase in birth weight with increasing placental weight was greater among 
offspring of preeclamptic vs. normotensive women. Similarly, we found that at lower ranges of 
both diameters (< 20cm, smaller diameter and < 23 cm, larger diameter), the rate of increase in 
birth weight with increasing diameters was greater among offspring of preeclamptic women 
(smaller diameter <12cm p=0.02; 12-16cm p<0.01; 16-20cm p=0.01; >20cm p=0.88; interaction 
respectively. Larger diameter <15cm p<0.01; 15-19cm p<0.01; 19-23cm p<0.01; >23cm p=0.75 
interaction respectively). We also found that among the offspring of preeclamptic women, 
female offspring with smaller diameters above 20cm, had a reduction in birth weight while males 
did not (p=0.02, interaction). Similarly, we found that among offspring of normotensive women, 
female offspring with larger diameters above 23cm had a reduction in birth weight while males 
did not (p<0.01, interaction). Our study identified the smaller placental diameter as a potentially 
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important marker of placental growth or function beyond the information given by placental 
weight. This relationship may be different in the setting of preeclampsia and infant sex. These 
relationships may be beneficial in directing future research to interpret the relationship between 
placental structure/function, the pathophysiology of preeclampsia and the influence of fetal sex. 
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4.2 INTRODUCTION  
 
Preeclampsia is a pregnancy specific disorder which is diagnosed by proteinuria and increased 
blood pressure that affects 3-5% of pregnancies (36). Unsuccessful remodeling of the spiral 
arteries in the uterus leads to reduced placental perfusion, the root cause of preeclampsia (32). 
Due to the risk of reduced nutrient and oxygen transfer during fetal development (30), reduced 
placental weight may result (25, 30, 164). 
Placental weight is a gross measure of placental growth that summarizes the different 
dimensions of the placenta (28, 171). The placental weight, surface area, largest and smallest 
diameters and thickness are placental measures that can be routinely measured at birth. They 
were designed to capture different aspects of placental growth and the capacity of the placenta to 
exchange nutrients and oxygen with the fetus (27, 171, 177). The larger and smaller diameters 
determine the surface area available for spiral arteries in the uterine wall to perfuse the placenta 
(27). The disc thickness increases with increased branching of the villous capillary bed (27). The 
ratio of the diameters reflects the symmetry of placental growth (171), which is expected to be 
centripetal around the umbilical cord (171, 177).  These dimensions of the placenta may provide 
more insight into the mechanisms of placental growth, beyond the information given vby 
placental weight. Additionally, sophisticated measures of placental growth can estimate the 
influence of placental under perfusion in the setting of preeclampsia.  
A recent study that analyzed the 1934-44 Helsinki Birth cohort reported that 
preeclampsia was associated with a shorter small diameter that result in oval shaped placenta. 
The authors suggested that growth of the placenta may be polarized in the presence of 
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preeclampsia causing differential growth along the larger and smaller diameters (178). We 
investigated if this relationship was detectable in a more contemporary and racially diverse 
population. We also investigated which dimensions of placental growth (thickness, small and 
large diameters and ratio of the diameters) were reduced in association with preeclampsia.  
We also hypothesized that in the presence of term preeclampsia infant birth weight would 
be more sensitive to changes in placental growth than that of the offspring of normotensive 
women, and that this may further vary according to fetal sex. 
  
4.3  METHODS 
 
 Study Population  4.3.1
 
The subjects were pregnant women and their offspring who were enrolled in the Collaborative 
Perinatal Project (CPP), a prospective pregnancy cohort study of neurologic disorders and other 
conditions in children. The CPP collected data on pregnant women enrolled at 12 study centers 
during 1959 to 1965, about half of whom were African American (202, 203).  
There were 54,681 singleton births in the Collaborative Perinatal Project. We limited the 
study to Black and White women. Hispanics and Asians were excluded because of small 
numbers (4.2%, n= 2,302).  We excluded women with missing placental data (14%, n=7,422). 
The rates of missing data varied among Black (17.5%) vs. White women (9.3%), nonsmokers 
(14.6%) vs. smokers (10.7%) and among women with low (15.3%) vs. high socioeconomic 
status (8.5%). However this was driven by large numbers of women with missing placental data 
from specific sites (e.g. 70% of placental data was missing among women from the Tennessee 
site). We excluded women with certain abnormal shaped placentas (e.g. crescent shaped) and 
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multilobate placentas (n=1,779) because the measures of placental diameters and thickness 
would be inaccurate in these placentas (243). Gestational age at delivery was limited to 37 to 42 
weeks and births with missing gestational ages were excluded (n=7,282). The analyses were 
limited to infants delivered at term because we had small numbers of preterm offspring of 
preeclamptic women with placental data (n=123). Gestational age was calculated based on the 
last menstrual period of the mother.  
 
 Definition of preeclampsia 4.3.2
 
Preeclampsia was defined as new-onset gestational hypertension and proteinuria, which resolved 
in the postpartum period. Gestational hypertension was defined as at least 2 measurements of 
systolic blood pressure >=140 mmHg and/or diastolic blood pressure >=90 mmHg with no prior 
occurrence before 24 weeks of gestation. Proteinuria was defined as 2 random urine dipsticks of 
1+ protein or one dipstick of 2+ protein.  
We excluded women with proteinuria only (n=1,696), elevated blood pressure before 24 
weeks of pregnancy (n=3,399), chronic hypertension or transient hypertension of pregnancy 
(gestational hypertension without proteinuria) (206) (n=4,486). We also excluded women with 
missing hypertension status (n=183) and women diagnosed with diabetes (n=472). Pre-existing 
hypertension and diabetes may bias the effect of preeclampsia as the effect of these chronic 
diseases could influence the outcome.  
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 Placental Growth Variables 4.3.3
 
The placentas were collected at delivery and measured by trained pathologists using a 
standardized protocol (244). The larger and smaller placental diameters (straight line segments 
that pass through the center of the placenta) were measured perpendicular to each other and 
recorded in centimeters. The thickness of the placental disc was measured by piercing the 
placenta with a needle calibrated in millimeters. After collecting measures of the placental 
dimensions, the placental membranes were then trimmed, the umbilical cord and any blood clots 
removed before weighing the placenta. 
 
 Statistical Analysis: 4.3.4
 
Chi-square tests were used to test for association between variables. Separate models for each 
placental dimension were used to evaluate the association between placental growth and 
preeclampsia. For the exposure, we created dummy variables of quartiles of the smaller diameter, 
larger diameter and the ratio of the diameters (smaller/larger). For placental thickness, we used 
the clinically significant cut points of 2.0-2.5cm as the range of normal placental thickness (177). 
The association of each quartile of placental dimension with preeclampsia was estimated using 
the largest measure as the referent for each placental measure and 2.0-2.5cm as the referent for 
placental thickness. The results were reported as estimated odds ratios and 95% confidence 
intervals. The likelihood ratio test was used to test for trends between decreasing placental 
dimensions and the risk of preeclampsia. A P value of <0.05 was considered statistically 
significant.  
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In normal pregnancy, the relationship between growth of the placental dimensions and 
birth weight is linear (179). We hypothesized that in the presence of preeclampsia there may be 
deviations from this linear relationship. Splines (piecewise polynomials that join smoothly at 
knots or breakpoints) can be used to assess departures from linearity. Linear regression models 
were fitted with linear splines to investigate the trends in the relationship between placental 
growth and birthweight among term offspring of normotensive and preeclamptic women. Three 
to four equally spaced knots were chosen to examine the linear trend between birth weight and 
placental growth. Statistical interactions between preeclampsia status and each piecewise spline 
were evaluated to determine if growth differed between offspring of normotensive and 
preeclamptic women. Similarly, interactions between infant sex and each piecewise spline were 
evaluated to determine if growth differed by fetal sex among offspring of normotensive and 
preeclamptic women. The linear spline curves in figures 1-2 were estimated by plotting the 
predicted mean birthweight vs. piecewise linear splines based on the unadjusted linear regression 
model for each placental dimension.   
The covariates for multivariate analysis were chosen a priori from the literature. The 
variables selected were maternal smoking status at registration, socio-economic status (SES), 
age, parity and race, which were collected by self-report and maternal pre-pregnancy body mass 
index (BMI). Maternal smoking status at registration was coded as a yes/no dichotomous 
variable. The socioeconomic status variable was a combined score based upon education, 
occupation and income (202) and was categorized as low, middle and high socio-economic 
status. BMI was calculated from height (measured at enrollment) and self-reported pre-
pregnancy weight. Maternal pre-pregnancy BMI was analyzed as a continuous variable. To 
address uncontrolled confounding due to study site, site was included as a confounder in the 
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analyses.  Placental weight was moderately correlated with each placental diameter (r=0.50 and 
r=0.51 smaller and larger diameters respectively), and weakly correlated with placental thickness 
(r=0.34). There were no strong correlations among the placental measures. Therefore in order to 
investigate the relationships independent of placental weight, we performed secondary analyses 
adjusting the models for placental weight. Statistical analysis was performed with SAS 9.2 
software (SAS Institute, Cary, N.C.). Linear splines were plotted using Sigma Plot 12.0 (Systat 
Software Inc, C.A.). 
 
4.4 RESULTS 
 
Preeclamptic women were more likely than normotensive women to be Black, non-smokers, of 
low socioeconomic status, primiparous, overweight and obese (Table 15). Offspring of 
normotensive vs. preeclamptic women had larger birthweights (P<0.01), heavier placentas 
(P=0.05) and consistent with this, greater mean larger (P<0.01) and smaller (P<0.01) diameters 
(Table 16). However, there were no differences in the mean thickness or ratio of the diameters.  
Among offspring of normotensive women, males had heavier placentas and as expected, greater 
mean larger (P<0.01) and smaller (P<0.01) placental diameters. However, there were no 
differences by sex in the mean thickness or ratio of the diameters. When we investigated the 
mean placental measures of offspring born to preeclamptic women, we found that only the mean 
larger diameter was greater in males vs. females (18.9 cm vs. 18.6 cm, P=0.04).  
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 Risk of Preeclampsia by placental measure 4.4.1
 
Preeclampsia was more frequently associated with lower placental weights and lower placental 
diameters (Table 17; test of trend, p<0.01 placental weight, p<0.01 smaller diameter and p=0.04 
larger diameter, respectively). We found no statistically significant relationship between the ratio 
of the diameters (ovalness of the placenta) and the risk of preeclampsia. However there was a 
pattern of increased risk of preeclampsia as the ratio of the diameters increased.  After adjusting 
for confounders, we found no relationship between placental thickness and the odds of 
preeclampsia.  After additional adjustment for placental weight, only the smaller placental 
diameter retained an independent relationship with the risk of preeclampsia.  
  
 Relationship between placental dimensions and birthweight among offspring of 4.4.2
normotensive vs. preeclamptic women 
 
Next we investigated the trends in the relationship between the placental dimensions and birth 
weight among offspring of normotensive and preeclamptic women. The rate of increase in birth 
weight with increasing placental weight was greater among offspring of preeclamptic vs. 
normotensive women with placental weights below  430grams (p<0.01 interaction) and above 
495 grams (p=0.04, interaction) (Figure 5). Next we investigated if the relationship between the 
placental diameters as well as placental thickness were independent predictors of birthweight 
beyond that predicted by placental weight in offspring of preeclamptic vs. normotensive women. 
We found that the relationship between both diameters and birth weight were attenuated with the 
inclusion of placental weight (and placental thickness) but retained an independent relation with 
birth weight (Figure 6 A and B). We found that at lower ranges of both diameters (< 20cm, 
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smaller diameter and < 23 cm, larger diameter), the rate of increase in birth weight with 
increasing diameters was greater among offspring of preeclamptic women (smaller diameter 
<12cm p=0.02; 12-16cm p<0.01; 16-20cm p=0.01; >20cm p=0.88; interaction respectively; 
larger diameter <15cm p<0.01; 15-19cm p<0.01; 19-23cm p<0.01; >23cm p=0.75 interaction 
respectively). In contrast to the diameters however, the relationship between placental thickness 
and birthweight as well as ratio of the diameters and birth weight did not differ between 
offspring of normotensive and preeclamptic women. 
 
 Relationship between the smaller and larger placental diameters and birth weight 4.4.3
by infant sex 
 
We then investigated if the trends in the relationship between both placental diameters and birth 
weight differed by sex among offspring of normotensive and preeclamptic women. After 
adjustment for placental weight, we found that among the offspring of preeclamptic women, 
female offspring with smaller diameters above 20cm, had a reduction in birth weight while males 
did not (p=0.02, interaction) (Figure 7A). Similarly, we found that among offspring of 
normotensive women, female offspring with larger diameters above 23cm had a reduction in 
birth weight while males did not (p<0.01, interaction) (Figure 7B). None of the other placental 
measures were different between male and female fetuses with or without preeclampsia. 
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4.5 DISCUSSION 
  
Our study identified that the smaller placental diameter is a potentially important marker of 
placental growth or function beyond the information given by placental weight. We confirmed a 
previous observation of lower placental weight in preeclampsia. After controlling for the 
influence of placental weight, we found that the smaller but not the larger placental diameter was 
an independent predictor of preeclampsia. In addition, the smaller diameter also had an 
independent relationship with birth weight beyond that predicted by placental weight. This 
relationship may be different in the setting of preeclampsia and infant sex.  
The relationship between the smaller diameter of the placenta and preeclampsia remained 
statistically significant after adjustment for the ratio of the diameters, suggesting that this 
relationship was independent of placental shape.  Unsuccessful remodeling of the spiral arteries 
in the uterus leads reduced placental perfusion, the root cause of preeclampsia (32). The larger 
and smaller diameters indicate the area available for spiral arteries in the uterine wall to perfuse 
the placenta (27). We are unable to explain the association between preeclampsia and the smaller 
but not the larger placental diameter.We agree with Kajantie (178) in speculating that the biologic 
processes responsible for placental perfusion may influence  growth or  function  in the planes 
of the placental diameters differently.  
Our findings of the association between preeclampsia and reduced placental diameters 
are consistent with a study by Kajantie who investigated these associations among infants born in 
1934-1944 as part of the Helsinki Birth Cohort (178). Unlike Kajantie, we did not find an excess 
of ovoid placentas or thicker placentas in preeclamptic pregnancies. The Helsinki birth cohort is 
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25 years older than the Collaborative Perinatal cohort and the infants were born during the 
Second World War during a time of severe food shortages (163).  Poor maternal nutrition may 
have intensified the influence of reduced placental growth in the setting of preeclampsia and thus 
may explain our discrepant results. Our study utilized a racially diverse population, with 
potentially better perinatal nutrition than the Helsinki Birth cohort and thus may be more relevant 
to a modern population.  
We found that the relationship between placental growth and birth weight differed 
between normotensive and preeclamptic pregnancies. We found higher rates of increase in birth 
weight at lower and higher placental weight for offspring of preeclamptic vs. normotensive 
women. This may indicate that at the extremes of placental weight, the placenta in preeclampsia 
may be more efficient at translating placental weight to fetal weight. Among the placental 
diameters (independent of placental weight), we found a relationship similar to that observed 
between the lower placental weight and birth weight. For lower diameters in both planes of the 
placental disc in preeclamptic pregnancies, the infant birthweight increased more rapidly 
compared to similar placental diameters in normotensive pregnancies.  This observed differential 
growth at the lower range placental weights and placental diameters suggests a “more efficient” 
small placenta in preeclampsia. This observation is consistent with a prior observation of normal 
amino acid transport in SGA infants from preeclamptic pregnancies which is reduced with SGA 
without preeclampsia (245).   
Our findings suggest that the relationship between growth of the smaller placental 
diameter and birth weight may be different by infant sex. In preeclamptic pregnancies, there 
appeared to be a threshold beyond which birthweight was reduced for female but not for male 
offspring as the smaller diameter increased. A similar relationship was observed with the larger 
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placental diameter of offspring of normotensive women. This is consistent with large cohort 
studies that suggest the placentas of male infants are more efficient at translating placental 
growth to fetal growth than placentas of females (103, 179, 246).  Eriksson and Misra both 
reported higher mean fetal placental ratio (birthweight(g)/placental weight(g)) for males vs. 
females (p<0.01) (103, 179), and a greater rate of increase in birth weight for female vs. male 
infants at higher ranges of placental area (179). Our findings also suggest that growth of the 
placental diameters may be influenced through different biological pathways in the setting of 
preeclampsia and by infant sex.   
Our study had several strengths. The Collaborative Perinatal Project (CPP) provided a 
large dataset, which allowed the exploration of the relatively rare adverse pregnancy outcome- 
preeclampsia. The CPP also included large numbers of placental measures collected according to 
standardized research protocols. These methods of placental measurements have not changed 
considerably and thus are still relevant to current measurements.  Placentas for research are 
typically collected for cases of adverse outcome. However, the CPP is one of only a few large 
studies of this scale with measurements of placentas from normal and adverse pregnancy 
outcomes in the United States. The management of preeclampsia has changed since the 1960s. In 
the 1960’s there were fewer interventions for fetal indications. This allowed us to better 
investigate the natural progression of the disease on placental growth than would be possible 
with a more modern cohort.  
The study was limited to placental measures that were taken at birth and therefore do not 
reflect growth rate throughout pregnancy. Placental thickness was measured at the center of the 
placenta. As a result, this measure may not indicate the thickness throughout the placenta, 
especially in placentas with irregular or non-uniformed growth. The placental diameters may not 
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capture true growth of irregular shaped placentas with non-uniformed growth. We attempted to 
limit this bias by removing multilobate and irregular shaped placentas from our analyses.   
Our study provides evidence to suggest that the smaller diameter of the placenta is an 
independent predictor of preeclampsia beyond the influence predicted by placental weight. We 
also found a disparity in the rate of increase in birthweight at the lower range of placental weight 
and placental diameters. We believe that this relationship may be indicative of catch-up (fetal) 
growth for infants with small placentas in preeclamptic pregnancies. Our results also imply that 
the relationship between the growth of the smaller diameter and birth weight may operate 
through different biological pathways by sex and is different in the setting of preeclampsia. 
Moreover, it suggests that the smaller diameter may be a potential biologically relevant marker 
of placental growth/function that may provide information beyond that given by placental 
weight. These findings indicate the importance of incorporating the placental diameters and 
infant sex in the study of mechanisms relating placental and fetal growth. These relationships 
may be beneficial in directing future research to interpret the relationship between placental 
structure/function, the pathophysiology of preeclampsia and the influence of fetal sex.  
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4.6 Tables and Figures 
Table 15: Baseline Characteristics of the population of women (n=21,920) (Primiparous 
and Multiparous)  
Characteristics 
Women (n=21,920) 
Normotensive 
(N=21185) 
n(%) 
Preeclamptic 
(N=735) 
n(%) 
P-value 
Maternal Age    
        <20 4774 (22.5%) 253 (34.4%) 
<0.01         20-29 12937 (61.1%) 345 (46.9%) 
        30-39 3474 (16.4%) 137 (18.6%) 
Maternal Race    
       White 12004 (56.7%) 323 (44.0%) 
<0.01 
       Black 9181 (43.3%) 412 (56.0%) 
Infant Sex    
        Females 10403 (49.1%) 365 (49.7%) 
0.77 
        Males 10782 (50.9) 370 (50.3%) 
Smoking    
       Nonsmoker 10660 (50.3%) 439 (59.7%) 
<0.01 
        Smoker 10525 (49.7%) 296 (40.3%) 
BMI (kg/m2)    
     Underweight  (<18.5) 2108 (10.0%) 40 (5.4%) 
<0.01 
      Normal (18.5-24.9) 15165 (71.6%) 461 (62.7%) 
Overweight (25.0- 29.9) 2985 (14.0%) 140 (19.1%) 
      Obese (>30 ) 927 (4.4%) 94 (12.8%) 
Maternal SES score    
         1 (low) 7369 (34.8%) 346 (47.1%) 
<0.01          2 (medium) 6464 (30.5%) 223 (30.3%) 
         3 (high) 7352 (34.7%) 166 (22.6%) 
Parity    
        Primiparous 6371 (30.1%) 351 (47.8%) 
<0.01         Multiparous 14788 (69.9%) 383 (52.2%) 
Birthweight Mean (SE) Mean (SE)  
 3233.99 (3.22) 3144.70 (17.29) <0.01 
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Table 16: Mean values of placental measurements in preeclamptic and normotensive pregnancies (Term births) 
Placental 
Dimension 
Preeclampsia 
N=735 
 
Normotensive 
N=21185 
 
All 
Mean 
(SE) 
Males Females 
P-Value 
All 
Mean 
(SE) 
Males Females 
P-value 
n 
Mean 
(SE) 
n Mean (SE) n 
Mean 
(SE) 
n Mean (SE) 
placental 
weight 
432.08 
(3.42)* 
357 
434.27 
(4.83) 
356 
429.89 
(4.84) 
0.52 
438.95 
(0.64) 
10454 
441.86 
(0.89) 
10068 
435.94 
(0.91) 
<0.01 
             
Larger 
diameter 
18.73 
(0.08)* 
 
370 
18.88 
(0.11) 
365 
18.57 
(0.11) 
0.04 
18.94 
(0.14) 
10782 
19.02 
(0.02) 
10403 
18.87 
(0.02) 
<0.01 
Smaller 
diameter 
16.26 
(0.07)* 
369 
16.31 
(0.10) 
365 
16.21 
(0.10) 
0.45 
16.47 
(0.13) 
10782 
16.54 
(0.02) 
10403 
16.40 
(0.02) 
<0.01 
             
Ratio of 
Diameters (%)a 
86.92 
(0.32) 
370 
86.50 
(0.44) 
365 
87.34 
(0.45) 
0.18 
87.25 
(0.06) 
10782 
87.26 
(0.08) 
10403 
87.24 
(0.08) 
0.84 
Thickness 2.18 (0.02) 370 
2.19 
(0.02) 
365 
2.18 
(0.03) 
0.74 
2.20 
(0.003) 
10782 
2.20 
(0.005) 
10403 
2.20 
(0.005) 
0.39 
a=Ratio of the small/large diameter (%) 
*= p≤0.05 of comparison of all Preeclamptic vs. all Normotensive Mean Placental Dimension 
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Table 17: Crude and Adjusted models showing risk of Preeclampsia by placental measure 
Marker Term 
Normo 
(n) 
Term PE 
(n) 
Crude OR (95% 
CI) 
*Adjusted 
 OR (95% CI) 
** Additionally 
adjusted for 
placental 
weight 
 OR (95% CI) 
Placental weight (g)      
<375 5169  221 1.33 (1.09, 1.62) 1.39 (1.12, 1.72)  
  375-430 4885 149 0.96 (0.77, 1.19) 1.01 (0.80, 1.27)  
   430-495 5434 181 1.04 (0.85, 1.28) 1.07 (0.86, 1.34)  
  >495  5164 166 Ref Ref  
Test of trend     P<0.01  
Small diameter (cm)      
 <15 6286 255 1.28 (1.06, 1.55) 1.35 (1.11, 1.65) 1.27 (1.01, 1.59) 
    16 4561 161 1.11 (0.90, 1.38) 1.16 (0.93, 1.44) 1.12 (0.89, 1.41) 
   17,18  4406 131 0.94 (0.75, 1.18) 0.98 (0.78, 1.23) 0.94 (0.74, 1.20) 
   >18  5932 187 Ref Ref Ref 
Test of trend     P<0.01 P=0.06 
Large Diameter (cm)      
  <18 4157 131 1.25 (1.00, 1.56) 1.28 (1.02, 1.61) 1.18 (0.90, 1.54) 
   18,19   3645 124 1.20 (0.84, 1.39) 1.18 (0.86, 1.32) 1.14 (0.82, 1.30) 
   20  8426 285 1.01 (0.87, 1.32) 1.01 (0.83, 1.37) 0.98 (0.78, 1.32) 
   >20  4957 195 Ref Ref Ref 
Test of trend     P=0.04 P=0.24 
Ratio of diameters 
Small/Large (%) 
     
<81.82 4887 178 1.14 (0.92, 1.42) 1.17 (0.94, 1.46) 1.12 (0.90, 1.40) 
 81.82-88.24 4771 171 1.12 (0.90, 1.40) 1.14 (0.91, 1.42) 1.08 (0.87, 1.36) 
88.24–94.12 6393 222 1.09 (0.89, 1.34) 1.10 (0.89, 1.35) 1.07 (0.86, 1.32) 
 >94.12 5134 164 Ref Ref Ref 
Test of trend     P=0.54 P=0.78 
Thickness (cm)      
>2.5  2962 104 1.09 (0.88, 1.35) 1.10 (0.89, 1.37) 1.17 (0.93, 1.48) 
2.0-2.5    14238 459 Ref  Ref Ref 
<2.0       3985 172 1.34 (1.12, 1.60) 1.16 (0.96, 1.40) 1.11 (0.92, 1.34) 
Test of trend     P=0.26 P=0.28 
*Models adjusted for maternal race, pre-pregnancy BMI, age, smoking status at 
registration, infant sex, parity, gestational age at delivery and site of study. 
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Figure 5: Mean birth weight vs. Placental weight among offspring of Preeclamptic vs. 
Normotensive women.   
 
Figure 5: Mean birth weight vs. Placental weight among offspring of Preeclamptic 
vs. Normotensive women.  Curves were estimated by calculating predicted mean birthweight 
based on unadjusted spline regression models 
p=0.04 
p=<0.01 
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Figure 8: Mean birth weight vs. Smaller and Larger diameters among offspring of Preeclamptic vs. Normotensive women 
B 
p=0.02 
p<0.01 
p=0.01 
A 
p<0.01 
p<0.01 
p<0.01 
Figure 6: Mean birth weight vs. Smaller and Larger diameters among offspring of Preeclamptic vs. 
Normotensive women.  Curves were estimated by calculating predicted mean birthweight based on unadjusted spline 
regression models 
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Figure 10: Mean birth weight vs. Smaller and Larger  placental diameter by infant sex 
A B 
p<0.01 p=0.02 
Figure 7: Mean birth weight vs. Smaller placental diameter by infant sex among offspring of Preeclamptic (A) women. 
Mean birth weight vs. Larger placental diameter by infant sex among offspring of Normotensive (B) women. Curves 
were estimated by calculating predicted mean birthweight based on unadjusted spline regression models 
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5.0 CONCLUSION 
 
In this study we used data from the National Collaborative Perinatal Project and investigated 3 
important features: 1) the influence of fetal sex and maternal race on maternal pre-pregnancy 
body mass index, smoking and socio-economic status; 2) the influence of preeclampsia on fetal 
growth and the influence of infant sex; 3) the influence of preeclampsia on placental growth and 
the interaction with infant sex. These areas have not been extensively studied. Our results add to 
the growing literature on the differential influence of fetal sex and race in pregnancy outcome.  
Despite the anthropometric measures indicating reduced growth among Black vs. White 
infants born to normotensive women, the differential rate of SGA between Black and White 
infants was not evident using race adjusted growth charts. Given the well-established lower mean 
birthweight and higher mortality rate among Black vs. White infants, it is reasonable to expect 
that growth restriction and not physiology contributes to these higher rates in Blacks. Our 
findings, which are consistent with the large body of evidence that offspring of Black women are 
at greater risk for fetal growth restriction than offspring of White women (142, 233, 234), 
supports the use of non-race adjusted growth curves.  
Our findings lead us to agree with Eriksson and Clifton who theorize that female and 
male fetuses have different responses to the same maternal environment (94, 103). In our first 
paper we found that in the absence of in utero insults, females were more responsive to the 
maternal environment. They had greater increases in fetal growth in response to increasing 
maternal pre-pregnancy BMI. In our second and third papers we found that females were also 
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more responsive in the setting of mild insults. In the setting of term preeclampsia, female infants 
had lower ponderal index. In addition, the female infants also had reduced birth weight at higher 
ranges of the smaller diameter while boys had continued growth. This finding is consistent with 
an asthma study by Murphy which found that among pregnant women with mild asthma who did 
not use inhaled steroids to treat asthma during pregnancy, female infants had greater reductions 
in growth, while males were unaffected (101).  
The findings in our second paper further agree with the theories of Clifton and Eriksson 
(94, 103) which suggest that the inadequate response of male infants to minor insults makes them 
more susceptible to severe insults. In the setting of preterm preeclampsia, females again had 
better adaptation to the maternal environment. Because males are less responsive and adapt less 
readily to the maternal environment, the severe insults of preterm preeclampsia had a greater 
negative impact on male vs. female infants. This is again consistent with another asthma study 
by Murphy which found that among pregnant asthmatic women with severe exacerbations that 
required hospitalization, male infants had greater reductions in birth weight (102). 
Despite the fact that the growth reductions in our study were subtle, our results raise the 
possibility that fetal and placental growth may be influenced through different biological 
pathways by fetal sex. The one-time measures of fetal and placental growth at birth in our study 
may have limited our findings. However our findings still support the need for further research 
into the influence of sex and race on fetal and placental growth and birth outcomes, especially in 
the setting of preeclampsia. They further suggest that mechanistic studies of fetal growth should 
investigate the influence in each sex.  Future studies are needed to clarify the influence of infant 
sex and race on both growth promotion and growth reduction during fetal development. This 
may be beneficial in creating future biological research to interpret the pathways involved in the 
 104 
pathophysiology of preeclampsia, as well as help to explain the mechanisms for sex differences 
in pregnancy outcomes and fetal origins of adult disease.  
 
5.1 FUTURE RESEARCH 
 
Our findings of differential fetal growth by fetal sex and race in normotensive pregnancies and 
differential fetal and placental growth in preeclamptic pregnancies warrant further investigation. 
Studies of differential outcome of fetal sex and race on birth outcomes have been limited to one 
time measures at birth. Future studies to clarify the influence of preeclampsia, sex and race on 
growth promotion/reduction during fetal development will need to identify the relevant 
biological pathways by 1) designing studies with large and diverse sample sizes, as many studies 
of preeclampsia are small and/or lack ethnic diversity; 2) recruiting women early in pregnancy in 
order to follow them and obtain measures throughout pregnancy; 3) recognizing the value of sex 
differences and analyze males and females separately; 4) exploring sex specific effects of 
biological effectors  such as placental growth factors as well as other endothelial growth factors 
to identify potential biological pathways; 5) obtaining ultrasound measures of fetal and placental 
anthropometry throughout pregnancy; 6) exploring the long term effects on pediatric growth.  
Identification of these pathways may be beneficial in creating future biological research 
to increase growth among infants that are identified to be at risk for growth restriction or who are 
found to have growth restriction early in utero. Those findings may bring us closer to 
understanding the pathophysiology of preeclampsia as well as explain why morbidity and 
mortality rates differ by sex in pregnancy complications. These pathways may also help to 
explain the mechanisms for sex differences in birth outcomes as well as fetal origins of adult 
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disease. Continuous ultrasound measures of growth in utero may also prove to be beneficial in 
creating new scales of growth to identify and distinguish infants who are constitutionally small 
from those who are growth restricted. 
 
 
5.2 APPLICATION TO PUBLIC HEALTH  
 
 
Neonatal and perinatal mortality and morbidity resulting from fetal growth restriction and 
preeclampsia, result in great economic and social burdens to the national health care system and 
the families involved. Our study contributes new insight into the complex relationship among 
preeclampsia, fetal growth, placental growth, infant sex and maternal race. Not all small-for-
gestational age (SGA) infants are small due to impaired growth (e.g. small parents have 
appropriately grown small infants) and not all growth restricted infants are identified using SGA 
criteria. Infants may fall within the normal range of birth weight but show metabolic, 
hematologic, and neurologic characteristics as seen in growth-restricted infants (235). Our study 
adds new contribution by examining in addition to SGA, several other indicators of fetal growth: 
ponderal index, head to chest circumference ratio and fetal placental ratio to capture reduced 
fetal growth. Additionally, these measures provide support that using non-race adjusted weight 
for gestational age tables are more appropriate than race adjusted tables.  
Our study also contributes important information on racial disparities in smoking in 
pregnancy and fetal growth. We also provided evidence to suggest that the smaller diameter may 
be a potential biologically relevant marker of placental growth/function that may provide 
information beyond that given by placental weight. In a more general sense this provides 
evidence that measurement of placental shape can yield information not provided by placental 
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weight alone. Our work builds on the emerging evidence that in utero insults negatively impact 
fetal and placental growth and additionally may also be influenced by infant sex.  
Identification of these biological pathways that operate differently by maternal factors, 
smoking, race, preeclampsia and infant sex may be beneficial in creating future biological 
research to increase growth among infants that are identified to be at risk for growth restriction. 
Based on the Fetal Origins of Adult Disease Hypothesis, this may also prove to be invaluable in 
reducing the rates of later life diseases such as hypertension, cardiovascular disease, chronic 
kidney disease and diabetes in future generations.  
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APPENDIX A: SUPPLEMENTARY TABLES FOR MANUSCRIPT 1 
 
 
Table 18: Influence of 1 kg/m2 increase in BMI by Fetal sex and Race on each Growth Measure among preterm infants. 
Maternal Pre-pregnancy 
BMI 
Male b 
Beta coefficient ±SE 
Female b 
Beta coefficient ±SE 
SEXxBMI 
Interaction p 
Black c 
Beta coefficient ±SE 
White c 
Beta coefficient ±SE 
RACExBMI 
Interaction p 
Birthweight (g) 29.92 (8.50)* 19.92 (8.63)† 0.39 20.36 (7.17)* 33.66 (11.34)* 0.38 
Crown Heel Length (cm) 0.167 (0.047)* 0.127 (0.048)* 0.43 0.135 (0.041)* 0.151 (0.060)† 0.89 
Head Circumference (cm) 0.109 (0.028)* 0.081 (0.029)* 0.43 0.091 (0.025)* 0.097 (0.034)* 0.94 
Chest Circumference (cm) 0.104 (0.047)† 0.083 (0.039)† 0.73 0.092 (0.035)* 0.098 (0.062) 0.98 
Placental Weight (g) 4.384 (1.310)* 3.627 (1.335)* 0.79 4.143 (1.171)* 3.810 (1.557)† 0.80 
Ponderal Index 0.007 (0.004) 0.004 (0.004) 0.65 0.005 (0.004) 0.009 (0.005) 0.52 
Head- Chest 
Circumference Ratio 
-0.0003 (0.001) -0.0003 (0.0009) 0.77 0.0002 (0.0008) -0.0007 (0.0014) 0.64 
Fetal Placental Weight 
Ratio 
-0.004 (0.021) -0.01 (0.02) 0.40 -0.023 (0.019) -0.020 (0.025) 0.21 
 Male d 
OR (95% CI) 
Female d 
OR (95% CI 
P 
Interaction 
Black e 
OR (95% CI) 
White e 
OR (95% CI) 
P 
Interaction 
SGA (<10th percentile) 0.95 (0.87, 1.06) 0.97 (0.88, 1.08) 0.89 0.97 (0.89, 1.06) 0.94 (0.83, 1.06) 0.64 
*=p<0.01,    †=p≤0.05 
bDerived from linear regression models adjusting for maternal age, race, maternal smoking, SES and infant gestational age at delivery. 
cDerived from linear regression models adjusting for infant sex and gestational age at delivery and maternal age, SES and smoking. 
dDerived from logistic regression models adjusting for  maternal age, race, socioeconomic status (SES), and smoking. 
eDerived from logistic regression models adjusting for infant sex infant and maternal age, smoking and socioeconomic status (SES). 
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Table 19: Differential Influence of Smoking by race among preterm infants. 
 
Non Smoker 
Mean (SE) 
Smoker 
Mean (SE) 
 
Nonsmoker 
Mean (SE) 
Smoker 
Mean (SE) 
 
SMOKER x 
RACE  
Interaction p 
 Blackb difference Whiteb difference  
Birthweight (g) 2648.77 (28.56) 2528.15 (34.52) -120.63* 2690.65 (54.44) 2596.68 (43.29) -93.97 0.74 
Crown Heel Length (cm) 47.95 (0.16) 47.23 (0.19) -0.72* 47.99 (0.30) 47.59 (0.24) -0.40 0.47 
Head Circumference (cm) 32.47 (0.09) 32.00 (0.11) -0.47* 32.50 (0.18) 32.29 (0.15) -0.21 0.33 
Chest Circumference (cm) 29.96 (0.13) 29.45 (0.16) -0.51* 29.68 (0.27) 29.63 (0.22) -0.05 0.25 
Placental Weight (g) 375.19 (4.70) 388.33 (5.32) +13.14 385.73 (8.01) 392.91  (6.67) +7.18 0.63 
Ponderal Index 2.408 (0.014) 2.400 (0.017) -0.008 2.427 (0.026) 2.453 (0.021) +0.026 0.38 
Head- Chest Circumference 
Ratio 
1.088 (0.003) 1.089 (0.004) +0.001 1.097 (0.006) 1.094 (0.005) -0.004 0.58 
Fetal Placental Weight Ratio 7.159(0.076) 6.701  (0.086) -0.458* 6.919  (0.131) 6.616 (0.108) -0.303 0.44 
 
Blackc 
OR (95% CI) 
 
Whitec 
OR (95% CI) 
  
SGA (<10th percentile) REFERENT 1.92 (1.17, 3.15)  REFERENT 1.51 (0.75, 3.02)  0.69 
*= p<0.01, †= p≤0.05 
bDerived from linear regression models adjusting for infant sex, gestational age at delivery and maternal age, pre-pregnancy body mass index (BMI) and SES. 
cDerived from linear regression models adjusting for infant sex, maternal age, pre-pregnancy body mass index (BMI), and socioeconomic status. 
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APPENDIX B: SUPPLEMENTARY TABLES FOR MANUSCRIPT 3 
 
 
Table 20: Results of unadjusted linear regression analysis with linear splines of 
placental predictors vs. birthweight in offspring of preeclamptic vs. normotensive 
women.  
Variables Slope  Normoa  Slope PE b Interaction (p) 
Placental weight (g)    
<375 4.08 4.63 <0.01 
375 3.09 5.30 <0.01 
430 3.26 1.99 0.05 
495 2.44 3.19 0.02 
Large diameter   (cm)    
<15 68.94 431.73 <0.01 
15 122.77 124.96 <0.01 
19 82.32 122.00 <0.01 
23 -21.75 31.86 0.03 
Small diameter  (cm)    
<12 -76.30 24.42 0.13 
12 112.86 149.57 <0.01 
16 102.59 121.31 0.02 
20 68.18 43.09 0.72 
Smaller/larger diameter 
ratio (%) 
   
<60 3.47 1.03 0.32 
60 0.27 21.22 0.02 
75 3.33 9.36 0.12 
85 -0.13 -3.46 0.88 
95 -2.99 -17.48 0.26 
Thickness (cm)    
<1.5 78.58 202.92 0.60 
1.5 259.36 275.17 0.99 
2.5 161.83 23.51 0.45 
3.5 -102.38 156.16 0.07 
anormo= offspring of normotensive women,  bPE= offspring of preeclamptic 
women 
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Table 21: Results of adjusted linear regression analysis with linear splines of placental 
predictors vs. birthweight in offspring of preeclamptic vs. normotensive women.  
 Adjusted  
 
Additionally adjusted for placental 
weight 
Additionally 
adjusted for 
placental 
weight and 
thickness 
Variables Slope  
Normoa 
Slope 
PEb 
Interacti
on (p) 
Slope 
Normoa 
Slope 
PEb 
Interaction 
(p) 
Interaction 
(p) 
Placental weight (g)        
<375 3.92 4.53 <0.01     
375 2.79 4.83 <0.01     
430 3.16 1.91 0.05     
495 2.28 2.86 0.04     
Large diameter (cm)          
<15 67.84 430.94 <0.01 47.85 374.09 <0.01 <0.01 
15 113.04 115.77 <0.01 46.16 51.19 <0.01 <0.01 
19 77.55 121.87 <0.01 20.28 65.36 <0.01 <0.01 
23 -17.41 -14.07 0.14 -11.08 -77.66 0.73 0.75 
Small diameter (cm)         
<12 -69.12 -15.19 0.22 -30.77 140.72 0.02 0.02 
12 103.94 136.61 <0.01 48.76 80.39 <0.01 <0.01 
16 99.05 114.55 0.04 30.68 39.06 0.01 0.01 
20 68.62 14.06 0.91 22.77 -54.55 0.89 0.88 
Smaller/larger 
diameter ratio (%) 
       
<60 4.45 13.49 0.28 2.77 9.63 0.30  
60 -0.48 16.24 0.03 0.85 15.49 0.06  
75 4.09 9.04 0.24 2.01 2.41 0.80  
85 0.85 -4.60 0.64 1.06 -5.80 0.26  
95 -2.93 -6.78 0.46 -2.66 5.35 0.87  
Thickness (cm)        
<1.5 92.83 354.83 0.34 65.15 218.53 0.45  
1.5 174.63 180.41 0.96 -35.41 -73.32 0.93  
2.5 162.68 12.12 0.29 -88.49 -168.62 0.27  
3.5 -100.35 75.39 0.25 27.00 -540.67 0.10  
Adjusted for infant sex, maternal race, pre-pregnancy BMI, age, Socio-economic status, smoking, parity, site, 
(placental weight), (thickness).    anormo= offspring of normotensive women,  bPE= offspring of preeclamptic 
women  
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Table 22 : Results of unadjusted linear regression analysis with linear splines of 
placental predictors vs. birthweight in male vs. female offspring of preeclamptic 
women.  
Variables Slope  Males (PE) Slope Females (PE) Interaction (p) 
Large diameter      
<15 406.78 461.42 0.70 
15 113.75 132.95 0.67 
19 134.21 99.51 0.99 
23 -51.46 182.88 0.10 
Small diameter      
<12 219.01 -53.58 0.63 
12 141.76 162.27 0.90 
16 126.92 110.78 0.35 
20 156.26 -85.73 0.08 
 
 
 
 
Table 23: Results of adjusted linear regression analysis with linear splines of 
placental predictors vs. birthweight in male vs. female offspring of preeclamptic 
women.  
Variables Slope  Males  Slope Females  Interaction (p) additionally adjusted 
for placental weight 
interaction (p) 
Large diameter       
<15 345.58 511.23 0.36 0.63 
15 104.33 128.84 0.71 0.88 
19 148.38 87.87 0.41 0.51 
23 -89.31 123.27 0.25 0.92 
Small diameter       
<12 299.47 -48.40 0.49 0.81 
12 126.63 144.53 0.93 0.67 
16 129.88 100.71 0.13 0.10 
20 128.61 -120.42 0.03 0.02 
Adjusted for maternal race, pre-pregnancy BMI, age, socio-economic status, smoking, parity, site, 
(placental weight).    
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Table 24: Results of unadjusted linear regression analysis with linear splines of placental 
predictors vs. birthweight in male vs. female offspring of normotensive women. 
Variables Slope  Males  Slope Females  Interaction (p) 
Large diameter  (cm)    
<15 80.77 58.82 0.43 
15 126.38 118.52 0.33 
19 78.12 83.39 0.93 
23 -10.83 -29.67 0.26 
Small diameter  (cm)    
<12 -81.27 -52.88 0.79 
12 117.20 106.47 0.41 
16 97.30 105.35 0.10  
20 51.21 93.30 0.05 
 
 
Table 25: Results of adjusted linear regression analysis with linear splines of placental 
predictors birthweight in male vs. female offspring of normotensive women. 
Variables Slope  Males Slope Females  Interaction (p) Additionally adjusted 
for  placental weight 
interaction (p) 
Large diameter  (cm)     
<15 77.14 58.66 0.49 0.85 
15 117.22 109.65 0.48 0.15 
19 74.06 80.79 0.85 0.51 
23 -5.85 -28.17 0.16 <0.01 
Small diameter  (cm)      
<12 -77.41 -58.60 0.83 0.86 
12 108.42 98.90 0.57 0.72 
16 94.91 103.50 0.11 0.20 
20 54.80 93.17 0.06 0.44 
Adjusted for maternal race, pre-pregnancy BMI, age, socio-economic status, smoking, parity, site, (placental 
weight).    
 
  
 113 
 
BIBLIOGRAPHY 
 
 
1. Maulik D. Fetal growth compromise: definitions, standards, and classification. Clin 
Obstet Gynecol 2006;49(2):214-8. 
2. Garite TJ, Clark R, Thorp JA. Intrauterine growth restriction increases morbidity and 
mortality among premature neonates. Am J Obstet Gynecol 2004;191(2):481-7. 
3. Verkauskiene R, Beltrand J, Claris O, et al. Impact of fetal growth restriction on body 
composition and hormonal status at birth in infants of small and appropriate weight for 
gestational age. Eur J Endocrinol 2007;157(5):605-12. 
4. Bryan SM, Hindmarsh PC. Normal and abnormal fetal growth. Horm Res 2006;65 Suppl 
3:19-27. 
5. Barker DJ, Osmond C, Simmonds SJ, et al. The relation of small head circumference and 
thinness at birth to death from cardiovascular disease in adult life. BMJ 
1993;306(6875):422-6. 
6. Barker DJ, Bull AR, Osmond C, et al. Fetal and placental size and risk of hypertension in 
adult life. BMJ 1990;301(6746):259-62. 
7. Phillips DI. Insulin resistance as a programmed response to fetal undernutrition. 
Diabetologia 1996;39(9):1119-22. 
8. McCance DR, Pettitt DJ, Hanson RL, et al. Birth weight and non-insulin dependent 
diabetes: thrifty genotype, thrifty phenotype, or surviving small baby genotype? BMJ 
1994;308(6934):942-5. 
9. Brettell R, Yeh PS, Impey LW. Examination of the association between male gender and 
preterm delivery. Eur J Obstet Gynecol Reprod Biol 2008;141(2):123-6. 
10. Sheiner E, Levy A, Feinstein U, et al. Risk factors and outcome of failure to progress 
during the first stage of labor: a population-based study. Acta Obstet Gynecol Scand 
2002;81(3):222-6. 
11. Bekedam DJ, Engelsbel S, Mol BW, et al. Male predominance in fetal distress during 
labor. Am J Obstet Gynecol 2002;187(6):1605-7. 
12. Kautzky-Willer A, Handisurya A. Metabolic diseases and associated complications: sex 
and gender matter! Eur J Clin Invest 2009. 
13. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart Disease and Stroke Statistics--2009 
Update: A Report From the American Heart Association Statistics Committee and Stroke 
Statistics Subcommittee. Circulation 2009;119(3):e21-181. 
14. Verdecchia A, Guzzinati S, Francisci S, et al. Survival trends in European cancer patients 
diagnosed from 1988 to 1999. European Journal of Cancer 2009;45(6):1042-66. 
15. McArdle CS, McMillan DC, Hole DJ. Male gender adversely affects survival following 
surgery for colorectal cancer. British Journal of Surgery 2003;90(6):711-5. 
16. Onishi T, Oishi Y, Goto H, et al. Gender as a prognostic factor in patients with renal cell 
carcinoma. BJU International 2002;90(1):32-6. 
17. Haaxma CA, Bloem BR, Borm GF, et al. Gender differences in Parkinson's disease. 
Journal of Neurology, Neurosurgery & Psychiatry 2007;78(8):819-24. 
 114 
18. Wooten GF, Currie LJ, Bovbjerg VE, et al. Are men at greater risk for Parkinson's 
disease than women? Journal of Neurology, Neurosurgery & Psychiatry 2004;75(4):637-
9. 
19. Patel JD, Bach PB, Kris MG. Lung cancer in US women: a contemporary epidemic. 
JAMA 2004;291(14):1763-8. 
20. Odegard RA, Vatten LJ, Nilsen ST, et al. Preeclampsia and fetal growth. Obstet Gynecol 
2000;96(6):950-5. 
21. Xiong X, Mayes D, Demianczuk N, et al. Impact of pregnancy-induced hypertension on 
fetal growth. Am J Obstet Gynecol 1999;180(1 Pt 1):207-13. 
22. Eskenazi B, Fenster L, Sidney S, et al. Fetal growth retardation in infants of multiparous 
and nulliparous women with preeclampsia. Am J Obstet Gynecol 1993;169(5):1112-8. 
23. Chappell LC, Enye S, Seed P, et al. Adverse perinatal outcomes and risk factors for 
preeclampsia in women with chronic hypertension: a prospective study. Hypertension 
2008;51(4):1002-9. 
24. Rasmussen S, Irgens LM. The effects of smoking and hypertensive disorders on fetal 
growth. BMC Pregnancy Childbirth 2006;6:16. 
25. Dahlstrom B, Romundstad P, Oian P, et al. Placenta weight in pre-eclampsia. Acta Obstet 
Gynecol Scand 2008;87(6):608-11. 
26. Hafner E, Metzenbauer M, Hofinger D, et al. Placental growth from the first to the 
second trimester of pregnancy in SGA-foetuses and pre-eclamptic pregnancies compared 
to normal foetuses. Placenta 2003;24(4):336-42. 
27. Salafia CM, Charles AK, Maas EM. Placenta and fetal growth restriction. Clin Obstet 
Gynecol 2006;49(2):236-56. 
28. Salafia CM, Zhang J, Charles AK, et al. Placental characteristics and birthweight. 
Paediatr Perinat Epidemiol 2008;22(3):229-39. 
29. AbouZahr C. Global burden of maternal death and disability. Br Med Bull 2003;67:1-11. 
30. Roberts DJ, Post MD. The placenta in pre-eclampsia and intrauterine growth restriction. J 
Clin Pathol 2008;61(12):1254-60. 
31. Thorngren-Jerneck K, Herbst A. Perinatal factors associated with cerebral palsy in 
children born in Sweden. Obstet Gynecol 2006;108(6):1499-505. 
32. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. 
Placenta 2009;30 Suppl A:S32-7. 
33. Lain KY, Roberts JM. Contemporary concepts of the pathogenesis and management of 
preeclampsia. JAMA 2002;287(24):3183-6. 
34. Warrell DA. Oxford textbook of medicine. 4th ed. Oxford ; New York: Oxford University 
Press; 2003. 
35. Gaugler-Senden IP, Berends AL, de Groot CJ, et al. Severe, very early onset 
preeclampsia: subsequent pregnancies and future parental cardiovascular health. Eur J 
Obstet Gynecol Reprod Biol 2008;140(2):171-7. 
36. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 
2001;357(9249):53-6. 
37. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension 2005;46(6):1243-
9. 
38. Roberts JM. Pre-eclampsia a two-stage disorder: what is the linkage? Are there directed 
fetal/placental signals? In: Lyall, F, Belfort M, editors. Pre-eclampsia: Etiology and 
Clinical Practice. Cambridge ; New York: Cambridge University Press, 2007:183-94. 
 115 
39. Melchiorre K, Wormald B, Leslie K, et al. First-trimester uterine artery Doppler indices 
in term and preterm pre-eclampsia. Ultrasound Obstet Gynecol 2008;32(2):133-7. 
40. Sibai BM. Preeclampsia as a cause of preterm and late preterm (near-term) births. Semin 
Perinatol 2006;30(1):16-9. 
41. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 
2005;308(5728):1592-4. 
42. Irgens HU, Reisaeter L, Irgens LM, et al. Long term mortality of mothers and fathers 
after pre-eclampsia: population based cohort study. BMJ 2001;323(7323):1213-7. 
43. Ogden CL CM, McDowell MA, Flegal KM. . Obesity among adults in the United States- no 
change since 2003-2004.   . National Center for Health Statistics 2007;NCHS data brief no 1. 
44. Lee CJ, Hsieh TT, Chiu TH, et al. Risk factors for pre-eclampsia in an Asian population. 
Int J Gynaecol Obstet 2000;70(3):327-33. 
45. Coonrod DV, Hickok DE, Zhu K, et al. Risk factors for preeclampsia in twin 
pregnancies: a population-based cohort study. Obstet Gynecol 1995;85(5 Pt 1):645-50. 
46. Odegard RA, Vatten LJ, Nilsen ST, et al. Risk factors and clinical manifestations of pre-
eclampsia. BJOG 2000;107(11):1410-6. 
47. Stamilio DM, Sehdev HM, Morgan MA, et al. Can antenatal clinical and biochemical 
markers predict the development of severe preeclampsia? Am J Obstet Gynecol 
2000;182(3):589-94. 
48. Khan KS, Daya S. Plasma glucose and pre-eclampsia. Int J Gynaecol Obstet 
1996;53(2):111-6. 
49. Dekker GA, Robillard PY, Hulsey TC. Immune maladaptation in the etiology of 
preeclampsia: a review of corroborative epidemiologic studies. Obstet Gynecol Surv 
1998;53(6):377-82. 
50. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: Current concepts. 
American Journal of Obstetrics and Gynecology 1998;179(5):1359-75. 
51. Chan A, Keane RJ, Robinson JS. The contribution of maternal smoking to preterm birth, 
small for gestational age and low birthweight among Aboriginal and non-Aboriginal 
births in South Australia. Med J Aust 2001;174(8):389-93. 
52. Kleijer ME, Dekker GA, Heard AR. Risk factors for intrauterine growth restriction in a 
socio-economically disadvantaged region. J Matern Fetal Neonatal Med 2005;18(1):23-
30. 
53. Ananth CV, Savitz DA, Bowes WA, Jr., et al. Influence of hypertensive disorders and 
cigarette smoking on placental abruption and uterine bleeding during pregnancy. Br J 
Obstet Gynaecol 1997;104(5):572-8. 
54. Cnattingius S, Mills JL, Yuen J, et al. The paradoxical effect of smoking in preeclamptic 
pregnancies: smoking reduces the incidence but increases the rates of perinatal mortality, 
abruptio placentae, and intrauterine growth restriction. Am J Obstet Gynecol 
1997;177(1):156-61. 
55. Savitz DA, Zhang J. Pregnancy-induced hypertension in North Carolina, 1988 and 1989. 
Am J Public Health 1992;82(5):675-9. 
56. Collins JW, Jr., David RJ. Racial disparity in low birth weight and infant mortality. Clin 
Perinatol 2009;36(1):63-73. 
57. Stone JL, Lockwood CJ, Berkowitz GS, et al. Risk factors for severe preeclampsia. 
Obstet Gynecol 1994;83(3):357-61. 
 116 
58. Zhang J, Meikle S, Trumble A. Severe maternal morbidity associated with hypertensive 
disorders in pregnancy in the United States. Hypertens Pregnancy 2003;22(2):203-12. 
59. Frisbie WP, Biegler M, de Turk P, et al. Racial and ethnic differences in determinants of 
intrauterine growth retardation and other compromised birth outcomes. Am J Public 
Health 1997;87(12):1977-83. 
60. Salihu HM, Fitzpatrick L, Aliyu MH. Racial disparity in fetal growth inhibition among 
singletons and multiples. American Journal of Obstetrics and Gynecology 
2005;193(2):467-74. 
61. Cohen GR, Curet LB, Levine RJ, et al. Ethnicity, nutrition, and birth outcomes in 
nulliparous women. American Journal of Obstetrics and Gynecology 2001;185(3):660-7. 
62. Martin JA, Kung H-C, Mathews TJ, et al. Annual Summary of Vital Statistics: 2006. 
Pediatrics 2008;121(4):788-801. 
63. Tanaka M, Jaamaa G, Kaiser M, et al. Racial disparity in hypertensive disorders of 
pregnancy in New York State: a 10-year longitudinal population-based study. Am J 
Public Health 2007;97(1):163-70. 
64. Reagan PB, Salsberry PJ. Race and ethnic differences in determinants of preterm birth in 
the USA: broadening the social context. Soc Sci Med 2005;60(10):2217-28. 
65. Catov JM, Ness RB, Kip KE, et al. Risk of early or severe pre-eclampsia related to pre-
existing conditions. Int J Epidemiol 2007;36(2):412-9. 
66. Rosenberg TJ, Garbers S, Lipkind H, et al. Maternal Obesity and Diabetes as Risk 
Factors for Adverse Pregnancy Outcomes: Differences Among 4 Racial/Ethnic Groups. 
Am J Public Health 2005;95(9):1545-51. 
67. Agustin Conde-Agudelo, José M. Belizán. Risk factors for pre-eclampsia in a large 
cohort of Latin American and Caribbean women. BJOG: An International Journal of 
Obstetrics & Gynaecology 2000;107(1):75-83. 
68. Bodnar LM, Catov JM, Klebanoff MA, et al. Prepregnancy body mass index and the 
occurrence of severe hypertensive disorders of pregnancy. Epidemiology 2007;18(2):234-
9. 
69. Bodnar LM, Ness RB, Markovic N, et al. The risk of preeclampsia rises with increasing 
prepregnancy body mass index. Ann Epidemiol 2005;15(7):475-82. 
70. Jahromi BN, Husseini Z. Pregnancy outcome at maternal age 40 and older. Taiwan J 
Obstet Gynecol 2008;47(3):318-21. 
71. Bianco A, Stone J, Lynch L, et al. Pregnancy outcome at age 40 and older. Obstet 
Gynecol 1996;87(6):917-22. 
72. Ros HS, Cnattingius S, Lipworth L. Comparison of Risk Factors for Preeclampsia and 
Gestational Hypertension in a Population-based Cohort Study. Am J Epidemiol 
1998;147(11):1062-70. 
73. Wikstrom AK, Stephansson O, Cnattingius S. Tobacco Use During Pregnancy and 
Preeclampsia Risk. Effects of Cigarette Smoking and Snuff. Hypertension. 
74. Engel SM, Janevic TM, Stein CR, et al. Maternal smoking, preeclampsia, and infant 
health outcomes in New York City, 1995-2003. Am J Epidemiol 2009;169(1):33-40. 
75. Akishita M, Hashimoto M, Ohike Y, et al. Low testosterone level as a predictor of 
cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis 
2010;210(1):232-6. 
 117 
76. Costarella CE, Stallone JN, Rutecki GW, et al. Testosterone causes direct relaxation of 
rat thoracic aorta. Journal of Pharmacology and Experimental Therapeutics 
1996;277(1):34-9. 
77. Honda H, Unemoto T, Kogo H. Different Mechanisms for Testosterone-Induced 
Relaxation of Aorta Between Normotensive and Spontaneously Hypertensive Rats. 
Hypertension 1999;34(6):1232-6. 
78. English KM, Jones RD, Jones TH, et al. Gender Differences in the Vasomotor Effects of 
Different Steroid Hormones in Rat Pulmonary and Coronary Arteries. Horm Metab Res 
2001;33(11):645-52. 
79. Tep-areenan P, Kendall DA, Randall MD. Testosterone-induced vasorelaxation in the rat 
mesenteric arterial bed is mediated predominantly via potassium channels. Br J 
Pharmacol 2002;135(3):735-40. 
80. White RE, Darkow DJ, Falvo Lang JL. Estrogen Relaxes Coronary Arteries by Opening 
BKCa Channels Through a cGMP-Dependent Mechanism. Circ Res 1995;77(5):936-42. 
81. Gilligan D, Badar D, Panza J, et al. Acute vascular effects of estrogen in postmenopausal 
women. Circulation 1994;90(2):786-91. 
82. Yeap BB, Hyde Z, Almeida OP, et al. Lower Testosterone Levels Predict Incident Stroke 
and Transient Ischemic Attack in Older Men. J Clin Endocrinol Metab 2009;94(7):2353-
9. 
83. Khaw K-T, Dowsett M, Folkerd E, et al. Endogenous Testosterone and Mortality Due to 
All Causes, Cardiovascular Disease, and Cancer in Men: European Prospective 
Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. 
Circulation 2007;116(23):2694-701. 
84. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in 
older men. J Clin Endocrinol Metab 2008;93(1):68-75. 
85. Gordon T, Kannel WB, Hjortland MC, et al. Menopause and coronary heart disease. The 
Framingham Study. Ann Intern Med 1978;89(2):157-61. 
86. Drevenstedt GL, Crimmins EM, Vasunilashorn S, et al. The rise and fall of excess male 
infant mortality. Proc Natl Acad Sci U S A 2008;105(13):5016-21. 
87. Eogan MA, Geary MP, O'Connell MP, et al. Effect of fetal sex on labour and delivery: 
retrospective review. BMJ 2003;326(7381):137. 
88. Sheiner E. The relationship between fetal gender and pregnancy outcome. Arch Gynecol 
Obstet 2007;275(5):317-9. 
89. Hershkovitz R, Silberstein T, Sheiner E, et al. Risk factors associated with true knots of 
the umbilical cord. Eur J Obstet Gynecol Reprod Biol 2001;98(1):36-9. 
90. Lieberman E, Lang JM, Cohen AP, et al. The association of fetal sex with the rate of 
cesarean section. Am J Obstet Gynecol 1997;176(3):667-71. 
91. Stevenson DK, Verter J, Fanaroff AA, et al. Sex differences in outcomes of very low 
birthweight infants: the newborn male disadvantage. Arch Dis Child Fetal Neonatal Ed 
2000;83(3):F182-5. 
92. Quinones JN, Stamilio DM, Coassolo KM, et al. Is fetal gender associated with adverse 
perinatal outcome in intrauterine growth restriction (IUGR)? Am J Obstet Gynecol 
2005;193(3 Pt 2):1233-7. 
93. Migeon BR, Axelman J, Jeppesen P. Differential X reactivation in human placental cells: 
implications for reversal of X inactivation. Am J Hum Genet 2005;77(3):355-64. 
 118 
94. Clifton VL. Review: Sex and the human placenta: mediating differential strategies of 
fetal growth and survival. Placenta 2010;31 Suppl:S33-9. 
95. Sood R, Zehnder JL, Druzin ML, et al. Gene expression patterns in human placenta. Proc 
Natl Acad Sci U S A 2006;103(14):5478-83. 
96. Seckl JR, Holmes MC. Mechanisms of Disease: glucocorticoids, their placental 
metabolism and fetal 'programming' of adult pathophysiology. Nat Clin Pract End Met 
2007;3(6):479-88. 
97. Stark MJ, Wright IM, Clifton VL. Sex-specific alterations in placental 11beta-
hydroxysteroid dehydrogenase 2 activity and early postnatal clinical course following 
antenatal betamethasone. Am J Physiol Regul Integr Comp Physiol 2009;297(2):R510-4. 
98. Bracero LA, Cassidy S, Byrne DW. Effect of gender on perinatal outcome in pregnancies 
complicated by diabetes. Gynecol Obstet Invest 1996;41(1):10-4. 
99. Evers IM, de Valk HW, Visser GHA. Male Predominance of Congenital Malformations 
in Infants of Women With Type 1 Diabetes. Diabetes Care 2009;32(7):1194-5. 
100. Zetterstrom K, Lindeberg SN, Haglund B, et al. The association of maternal chronic 
hypertension with perinatal death in male and female offspring: a record linkage study of 
866,188 women. BJOG 2008;115(11):1436-42. 
101. Murphy VE, Gibson PG, Giles WB, et al. Maternal Asthma Is Associated with Reduced 
Female Fetal Growth. Am J Respir Crit Care Med 2003;168(11):1317-23. 
102. Murphy VE, Gibson P, Talbot PI, et al. Severe asthma exacerbations during pregnancy. 
Obstet Gynecol 2005;106(5 Pt 1):1046-54. 
103. Eriksson JG, Kajantie E, Osmond C, et al. Boys live dangerously in the womb. Am J 
Hum Biol 2010;22(3):330-5. 
104. Ghidini A, Salafia CM. Gender differences of placental dysfunction in severe 
prematurity. BJOG 2005;112(2):140-4. 
105. Ingemarsson I. Gender aspects of preterm birth. BJOG 2003;110 Suppl 20:34-8. 
106. Vatten LJ, Skjaerven R. Offspring sex and pregnancy outcome by length of gestation. 
Early Hum Dev 2004;76(1):47-54. 
107. Zeitlin J, Saurel-Cubizolles MJ, De Mouzon J, et al. Fetal sex and preterm birth: are 
males at greater risk? Hum Reprod 2002;17(10):2762-8. 
108. Elsmen E, Kallen K, Marsal K, et al. Fetal gender and gestational-age-related incidence 
of pre-eclampsia. Acta Obstet Gynecol Scand 2006;85(11):1285-91. 
109. Stark MJ, Dierkx L, Clifton VL, et al. Alterations in the maternal peripheral 
microvascular response in pregnancies complicated by preeclampsia and the impact of 
fetal sex. J Soc Gynecol Investig 2006;13(8):573-8. 
110. Stark MJ, Clifton VL, Wright IM. Neonates born to mothers with preeclampsia exhibit 
sex-specific alterations in microvascular function. Pediatr Res 2009;65(3):292-5. 
111. Naeye RL, Demers LM. Differing effects of fetal sex on pregnancy and its outcome. Am 
J Med Genet Suppl 1987;3:67-74. 
112. Heinonen S, Taipale P, Saarikoski S. Weights of placentae from small-for-gestational age 
infants revisited. Placenta 2001;22(5):399-404. 
113. Kurjak A, Chervenak FA. Textbook of perinatal medicine. 2nd ed. Abingdon: Informa; 
2006. 
114. Zeitlin JA, Ancel PY, Saurel-Cubizolles MJ, et al. Are risk factors the same for small for 
gestational age versus other preterm births? Am J Obstet Gynecol 2001;185(1):208-15. 
 119 
115. Beard JR, Lincoln D, Donoghue D, et al. Socioeconomic and maternal determinants of 
small-for-gestational age births: patterns of increasing disparity. Acta Obstet Gynecol 
Scand 2009;88(5):575-83. 
116. Abrams B, Newman V. Small-for-gestational-age birth: maternal predictors and 
comparison with risk factors of spontaneous preterm delivery in the same cohort. Am J 
Obstet Gynecol 1991;164(3):785-90. 
117. Kramer MS, Olivier M, McLean FH, et al. Determinants of fetal growth and body 
proportionality. Pediatrics 1990;86(1):18-26. 
118. Aliyu M, Lynch ON, Wilson R, et al. Association between tobacco use in pregnancy and 
placenta-associated syndromes: a population-based study. Archives of Gynecology and 
Obstetrics 2010:1-6. 
119. Dubois L, Girard M. Determinants of birthweight inequalities: population-based study. 
Pediatr Int 2006;48(5):470-8. 
120. Schaefer-Graf UM, Kjos SL, Kilavuz O, et al. Determinants of fetal growth at different 
periods of pregnancies complicated by gestational diabetes mellitus or impaired glucose 
tolerance. Diabetes Care 2003;26(1):193-8. 
121. Bernstein IM, Horbar JD, Badger GJ, et al. Morbidity and mortality among very-low-
birth-weight neonates with intrauterine growth restriction. The Vermont Oxford Network. 
Am J Obstet Gynecol 2000;182(1 Pt 1):198-206. 
122. Surkan PJ, Hsieh CC, Johansson AL, et al. Reasons for increasing trends in large for 
gestational age births. Obstet Gynecol 2004;104(4):720-6. 
123. Wu YW, Croen LA, Shah SJ, et al. Cerebral palsy in a term population: risk factors and 
neuroimaging findings. Pediatrics 2006;118(2):690-7. 
124. Barker DJ, Osmond C, Golding J, et al. Growth in utero, blood pressure in childhood and 
adult life, and mortality from cardiovascular disease. BMJ 1989;298(6673):564-7. 
125. Jaquet D, Gaboriau A, Czernichow P, et al. Insulin resistance early in adulthood in 
subjects born with intrauterine growth retardation. J Clin Endocrinol Metab 
2000;85(4):1401-6. 
126. Kramer MS, Olivier M, McLean FH, et al. Impact of intrauterine growth retardation and 
body proportionality on fetal and neonatal outcome. Pediatrics 1990;86(5):707-13. 
127. Boog G, Sagot F, Winer N, et al. Brachmann-de Lange syndrome: a cause of early 
symmetric fetal growth delay. Eur J Obstet Gynecol Reprod Biol 1999;85(2):173-7. 
128. Pavlopoulos PM, Konstantinidou AE, Agapitos E, et al. Cell proliferation rate and 
nuclear morphometry in Roberts syndrome. Clin Genet 1998;54(6):512-6. 
129. Perin E, Cacciaguerra G, Lapenna R, et al. Primary hyperparathyroidism in pregnancy. 
Fertil Steril 2008;90(5):2014 e13-5. 
130. Barker DJ, Fall CH. Fetal and infant origins of cardiovascular disease. Arch Dis Child 
1993;68(6):797-9. 
131. Barker DJ. The developmental origins of adult disease. J Am Coll Nutr 2004;23(6 
Suppl):588S-95S. 
132. Kajantie E, Eriksson JG, Osmond C, et al. Pre-eclampsia is associated with increased risk 
of stroke in the adult offspring: the Helsinki birth cohort study. Stroke 2009;40(4):1176-
80. 
133. Tenhola S, Rahiala E, Halonen P, et al. Maternal preeclampsia predicts elevated blood 
pressure in 12-year-old children: evaluation by ambulatory blood pressure monitoring. 
Pediatr Res 2006;59(2):320-4. 
 120 
134. Williams S, Poulton R. Birth Size, Growth, and Blood Pressure between the Ages of 7 
and 26 Years: Failure to Support the Fetal Origins Hypothesis. Am J Epidemiol 
2002;155(9):849-52. 
135. Huxley R, Neil A, Collins R. Unravelling the fetal origins hypothesis: is there really an 
inverse association between birthweight and subsequent blood pressure? The Lancet 
2002;360(9334):659-65. 
136. Lucas A, Fewtrell MS, Cole TJ. Fetal origins of adult disease-the hypothesis revisited. 
BMJ 1999;319(7204):245-9. 
137. Alexander BT. Placental Insufficiency Leads to Development of Hypertension in 
Growth-Restricted Offspring. Hypertension 2003;41(3):457-62. 
138. Woods LL, Ingelfinger JR, Rasch R. Modest maternal protein restriction fails to program 
adult hypertension in female rats. Am J Physiol Regul Integr Comp Physiol 
2005;289(4):R1131-6. 
139. Woods LL, Weeks DA, Rasch R. Programming of adult blood pressure by maternal 
protein restriction: Role of nephrogenesis. Kidney Int 2004;65(4):1339-48. 
140. Vehaskari VM, Aviles DH, Manning J. Prenatal programming of adult hypertension in 
the rat. Kidney Int 2001;59(1):238-45. 
141. Zhang J, Bowes WA, Jr. Birth-weight-for-gestational-age patterns by race, sex, and parity 
in the United States population. Obstet Gynecol 1995;86(2):200-8. 
142. Kramer MS, Ananth CV, Platt RW, et al. US Black vs White disparities in foetal growth: 
physiological or pathological? Int J Epidemiol 2006;35(5):1187-95. 
143. Akram DS, Arif F. Ponderal index of low birth weight babies--a hospital based study. J 
Pak Med Assoc 2005;55(6):229-31. 
144. Obed S, Patience A. Birth weight and ponderal index in pre-eclampsia: a comparative 
study. Ghana Med J 2006;40(1):8-13. 
145. Fay RA, Dey PL, Saadie CM, et al. Ponderal index: a better definition of the 'at risk' 
group with intrauterine growth problems than birth-weight for gestational age in term 
infants. Aust N Z J Obstet Gynaecol 1991;31(1):17-9. 
146. Patterson RM, Pouliot MR. Neonatal morphometrics and perinatal outcome: who is 
growth retarded? Am J Obstet Gynecol 1987;157(3):691-3. 
147. Walther FJ, Ramaekers LH. The ponderal index as a measure of the nutritional status at 
birth and its relation to some aspects of neonatal morbidity. J Perinat Med 
1982;10(1):42-7. 
148. Barker D. Fetal and Infant Origins of Adult Disease. London: BMJ Books; 1993. 
149. Ounsted M, Moar VA, Scott A. Proportionality of small-for-gestational age babies at 
birth: perinatal associations and postnatal sequelae. Early Hum Dev 1986;14(2):77-88. 
150. Campbell S, Thoms A. Ultrasound measurement of the fetal head to abdomen 
circumference ratio in the assessment of growth retardation. Br J Obstet Gynaecol 
1977;84(3):165-74. 
151. Dashe JS, McIntire DD, Lucas MJ, et al. Effects of symmetric and asymmetric fetal 
growth on pregnancy outcomes. Obstet Gynecol 2000;96(3):321-7. 
152. Lin CC, Su SJ, River LP. Comparison of associated high-risk factors and perinatal 
outcome between symmetric and asymmetric fetal intrauterine growth retardation. Am J 
Obstet Gynecol 1991;164(6 Pt 1):1535-41; discussion 41-2. 
 121 
153. Vik T, Markestad T, Ahlsten G, et al. Body proportions and early neonatal morbidity in 
small-for-gestational-age infants of successive births. Acta Obstet Gynecol Scand Suppl 
1997;165:76-81. 
154. Wulff C, Weigand M, Kreienberg R, et al. Angiogenesis during primate placentation in 
health and disease. Reproduction 2003;126(5):569-77. 
155. Kingdom J, Huppertz B, Seaward G, et al. Development of the placental villous tree and 
its consequences for fetal growth. Eur J Obstet Gynecol Reprod Biol 2000;92(1):35-43. 
156. Wallace JM, Aitken RP, Milne JS, et al. Nutritionally mediated placental growth 
restriction in the growing adolescent: consequences for the fetus. Biol Reprod 
2004;71(4):1055-62. 
157. Moore KL, Persaud TVN. The developing human : clinically oriented embryology. 5th 
ed. Philadelphia: Saunders; 1993. 
158. Pardi G, Marconi AM, Cetin I. Placental-fetal interrelationship in IUGR fetuses--a 
review. Placenta 2002;23 Suppl A:S136-41. 
159. Jacquemyn Y, Osmanovic F, Martens G. Preeclampsia and birthweight by gestational age 
in singleton pregnancies in Flanders, Belgium: a prospective study. Clin Exp Obstet 
Gynecol 2006;33(2):96-8. 
160. Xiong X, Demianczuk NN, Saunders LD, et al. Impact of preeclampsia and gestational 
hypertension on birth weight by gestational age. Am J Epidemiol 2002;155(3):203-9. 
161. Molteni RA. Placental growth and fetal/placental weight (F/P) ratios throughout 
gestation--their relationship to patterns of fetal growth. Semin Perinatol 1984;8(2):94-
100. 
162. Eriksson J, Forsen T, Tuomilehto J, et al. Fetal and childhood growth and hypertension in 
adult life. Hypertension 2000;36(5):790-4. 
163. Barker DJ, Thornburg KL, Osmond C, et al. The surface area of the placenta and 
hypertension in the offspring in later life. Int J Dev Biol 2010;54(2-3):525-30. 
164. Baptiste-Roberts K, Salafia CM, Nicholson WK, et al. Maternal risk factors for abnormal 
placental growth: the national collaborative perinatal project. BMC Pregnancy Childbirth 
2008;8:44. 
165. Kliman HJ, Segel L. The placenta may predict the baby. J Theor Biol 2003;225(1):143-5. 
166. Bortolus R, Chatenoud L, Di Cintio E, et al. Placental ratio in pregnancies at different 
risk for intrauterine growth. Eur J Obstet Gynecol Reprod Biol 1998;80(2):157-8. 
167. Lao TT, Tam KF. Placental ratio and anemia in third-trimester pregnancy. J Reprod Med 
2000;45(11):923-8. 
168. Williams LA, Evans SF, Newnham JP. Prospective cohort study of factors influencing 
the relative weights of the placenta and the newborn infant. BMJ 1997;314(7098):1864-. 
169. Perry IJ, Beevers DG, Whincup PH, et al. Predictors of ratio of placental weight to fetal 
weight in multiethnic community. BMJ 1995;310(6977):436-9. 
170. Lao TT, Wong W. The neonatal implications of a high placental ratio in small-for-
gestational age infants. Placenta 1999;20(8):723-6. 
171. Salafia CM, Zhang J, Miller RK, et al. Placental growth patterns affect birth weight for 
given placental weight. Birth Defects Res A Clin Mol Teratol 2007;79(4):281-8. 
172. Bonds DR, Gabbe SG, Kumar S, et al. Fetal weight/placental weight ratio and perinatal 
outcome. Am J Obstet Gynecol 1984;149(2):195-200. 
 122 
173. Burkhardt T, Schaffer L, Schneider C, et al. Reference values for the weight of freshly 
delivered term placentas and for placental weight-birth weight ratios. Eur J Obstet 
Gynecol Reprod Biol 2006;128(1-2):248-52. 
174. Hemachandra AH, Klebanoff MA, Duggan AK, et al. The association between 
intrauterine growth restriction in the full-term infant and high blood pressure at age 7 
years: results from the Collaborative Perinatal Project. Int J Epidemiol 2006;35(4):871-7. 
175. Janthanaphan M, Kor-Anantakul O, Geater A. Placental weight and its ratio to birth 
weight in normal pregnancy at Songkhlanagarind Hospital. J Med Assoc Thai 
2006;89(2):130-7. 
176. Little WA. The significance of placental/fetal weight ratios. Am J Obstet Gynecol 
1960;79:134-7. 
177. Benirschke K, Kaufmann P, Baergen RN. Pathology of the human placenta. 5th ed. New 
York: Springer; 2006. 
178. Kajantie E, Thornburg KL, Eriksson JG, et al. In preeclampsia, the placenta grows slowly 
along its minor axis. Int J Dev Biol 2010;54(2-3):469-73. 
179. Misra DP, Salafia CM, Miller RK, et al. Non-linear and gender-specific relationships 
among placental growth measures and the fetoplacental weight ratio. Placenta 
2009;30(12):1052-7. 
180. Burton GJ, Jauniaux E, Charnock-Jones DS. The influence of the intrauterine 
environment on human placental development. Int J Dev Biol 2010;54(2-3):303-12. 
181. Ahlbom A, Alfredsson L. Interaction: A word with two meanings creates confusion. Eur 
J Epidemiol 2005;20(7):563-4. 
182. Knol MJ, Egger M, Scott P, et al. When one depends on the other: reporting of 
interaction in case-control and cohort studies. Epidemiology 2009;20(2):161-6. 
183. de Mutsert R, Jager KJ, Zoccali C, et al. The effect of joint exposures: examining the 
presence of interaction. Kidney Int 2009;75(7):677-81. 
184. Rothman KJ. Epidemiology : an introduction. Oxford: Oxford University Press; 2002. 
185. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-
Raven; 1998. 
186. Rothman KJ. The estimation of synergy or antagonism. Am J Epidemiol 
1976;103(5):506-11. 
187. Knol MJ, Vanderweele TJ, Groenwold RH, et al. Estimating measures of interaction on 
an additive scale for preventive exposures. Eur J Epidemiol 2011. 
188. Li R, Chambless L. Test for additive interaction in proportional hazards models. Ann 
Epidemiol 2007;17(3):227-36. 
189. Catalano PM, Drago NM, Amini SB. Factors affecting fetal growth and body 
composition. Am J Obstet Gynecol 1995;172(5):1459-63. 
190. Storms MR, Van Howe RS. Birthweight by Gestational Age and Sex at a Rural Referral 
Center. J Perinatol 2004;24(4):236-40. 
191. Kajantie E, Osmond C, Barker DJ, et al. Size at birth as a predictor of mortality in 
adulthood: a follow-up of 350 000 person-years. Int J Epidemiol 2005;34(3):655-63. 
192. Li S, Chen SC, Shlipak M, et al. Low birth weight is associated with chronic kidney 
disease only in men. Kidney Int 2007;73(5):637-42. 
193. Hindmarsh PC, Geary MP, Rodeck CH, et al. Factors predicting ante- and postnatal 
growth. Pediatr Res 2008;63(1):99-102. 
 123 
194. Hindmarsh PC, Geary MP, Rodeck CH, et al. Intrauterine growth and its relationship to 
size and shape at birth. Pediatr Res 2002;52(2):263-8. 
195. Aber JL, Bennett NG, Conley DC, et al. The effects of poverty on child health and 
development. Annu Rev Public Health 1997;18:463-83. 
196. Rogers I, Emmett P, Baker D, et al. Financial difficulties, smoking habits, composition of 
the diet and birthweight in a population of pregnant women in the South West of 
England. ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. 
Eur J Clin Nutr 1998;52(4):251-60. 
197. Yekta Z, Ayatollahi H, Porali R, et al. The effect of pre-pregnancy body mass index and 
gestational weight gain on pregnancy outcomes in urban care settings in Urmia-Iran. 
BMC Pregnancy and Childbirth 2006;6(1):15. 
198. Ay L, Kruithof CJ, Bakker R, et al. Maternal anthropometrics are associated with fetal 
size in different periods of pregnancy and at birth. The Generation R Study. BJOG 
2009;116(7):953-63. 
199. da Veiga PV, Wilder RP. Maternal smoking during pregnancy and birthweight: a 
propensity score matching approach. Matern Child Health J 2008;12(2):194-203. 
200. Sprauve ME, Lindsay MK, Drews-Botsch CD, et al. Racial patterns in the effects of 
tobacco use on fetal growth. Am J Obstet Gynecol 1999;181(1):S22-7. 
201. Visscher WA, Feder M, Burns AM, et al. The Impact of Smoking and Other Substance 
Use by Urban Women on the Birthweight of Their Infants Substance Use & Misuse. 
Taylor & Francis Ltd, 2003. (Article. 
202. Friedman EA, Neff RK, National Institute of Neurological and Communicative Disorders 
and Stroke. Perinatal Research Branch. Pregnancy hypertension : a systematic evaluation 
of clinical diagnostic criteria. Littleton, Mass.: PSG Pub. Co.; 1977. 
203. Niswander KR, Gordon M, National Institute of Neurological Diseases and Stroke. The 
women and their pregnancies; the Collaborative Perinatal Study of the National Institute 
of Neurological Diseases and Stroke. Washington]: National Institute of Health; for sale 
by the Supt. of Docs., U.S. Govt. Print. Off.; 1972. 
204. Wilcox MA, Chang AMZ, Johnson IR. The effects of parity on birthweight using 
successive pregnancies. Acta Obstetricia et Gynecologica Scandinavica 1996;75(5):459-
63. 
205. Bai J, Wong FW, Bauman A, et al. Parity and pregnancy outcomes. Am J Obstet Gynecol 
2002;186(2):274-8. 
206. Gifford RW AP, Cunningham G, Green LA, Lindheimer MD,, McNellis D RJ, Sibai BM, 
Taler SJ. Report of the National High Blood Pressure Education Program Working Group 
on High Blood Pressure in Pregnancy. American Journal of Obstetrics and Gynecology 
2000;183(1):S1-S22. 
207. Dietz PM, England LJ, Callaghan WM, et al. A comparison of LMP-based and 
ultrasound-based estimates of gestational age using linked California livebirth and 
prenatal screening records. Paediatr Perinat Epidemiol 2007;21 Suppl 2:62-71. 
208. Klebanoff MA. Gestational age: not always what it seems. Obstet Gynecol 
2007;109(4):798-9. 
209. Kramer MS, McLean FH, Boyd ME, et al. The validity of gestational age estimation by 
menstrual dating in term, preterm, and postterm gestations. JAMA 1988;260(22):3306-8. 
210. Berg AT. Menstrual cycle length and the calculation of gestational age. Am J Epidemiol 
1991;133(6):585-9. 
 124 
211. Allsworth EJ, Clarke J, Peipert FJ, et al. The Influence of Stress on the Menstrual Cycle 
among Newly Incarcerated Women. Women's health issues : official publication of the 
Jacobs Institute of Women's Health 2007;17(4):202-9. 
212. De Souza MJ, Toombs RJ, Scheid JL, et al. High prevalence of subtle and severe 
menstrual disturbances in exercising women: confirmation using daily hormone 
measures. Hum Reprod 2009. 
213. Wigglesworth JS, Singer DB. Textbook of fetal and perinatal pathology. 2nd ed. Malden, 
Mass.: Blackwell Science; 1998. 
214. Fenton TR. A new growth chart for preterm babies: Babson and Benda's chart updated 
with recent data and a new format. BMC Pediatr 2003;3:13. 
215. Britton JR, Britton HL, Jennett R, et al. Weight, length, head and chest circumference at 
birth in Phoenix, Arizona. J Reprod Med 1993;38(3):215-22. 
216. Sheskin D. Handbook of parametric and nonparametric statistical procedures. 3rd ed. 
Boca Raton, Fla.: Chapman & Hall/CRC; 2004. 
217. Moodie EE, Stephens DA. Using Directed Acyclic Graphs to detect limitations of 
traditional regression in longitudinal studies. Int J Public Health 2010;55(6):701-3. 
218. Bassan H, Stolar O, Geva R, et al. Intrauterine Growth-Restricted Neonates Born at Term 
or Preterm: How Different? Pediatric Neurology 2011;44(2):122-30. 
219. VanderWeele TJ, Robins JM. The identification of synergism in the sufficient-
component-cause framework. Epidemiology 2007;18(3):329-39. 
220. Flanders WD. On the relationship of sufficient component cause models with potential 
outcome (counterfactual) models. Eur J Epidemiol 2006;21(12):847-53. 
221. Skrondal A. Interaction as departure from additivity in case-control studies: a cautionary 
note. Am J Epidemiol 2003;158(3):251-8. 
222. Zou GY. On the estimation of additive interaction by use of the four-by-two table and 
beyond. Am J Epidemiol 2008;168(2):212-24. 
223. Lampl M, Gotsch F, Kusanovic JP, et al. Sex differences in fetal growth responses to 
maternal height and weight. Am J Hum Biol 2010;22(4):431-43. 
224. Lindeboom M, Portrait F, van den Berg GJ. Long-run effects on longevity of a nutritional 
shock early in life: the Dutch Potato famine of 1846-1847. J Health Econ 
2010;29(5):617-29. 
225. Grigore D, Ojeda NB, Alexander BT. Sex differences in the fetal programming of 
hypertension. Gender Medicine 2008;5(Supplement 1):S121-S32. 
226. Cliver SP, Goldenberg RL, Cutter GR, et al. The effect of cigarette smoking on neonatal 
anthropometric measurements. Obstet Gynecol 1995;85(4):625-30. 
227. Alameda_County_Low_Birth_Weight_Study_Group. Cigarette smoking and the risk of low birth weight: a 
comparison in black and white women. Alameda County Low Birth Weight Study Group. 
Epidemiology 1990;1(3):201-5. 
228. Windham GC, Hopkins B, Fenster L, et al. Prenatal Active or Passive Tobacco Smoke 
Exposure and the Risk of Preterm Delivery or Low Birth Weight. Epidemiology 
2000;11(4):427-33. 
229. Fichtner RR, Sullivan KM, Zyrkowski CL, et al. Racial/ethnic differences in smoking, 
other risk factors, and low birth weight among low-income pregnant women, 1978-1988. 
MMWR CDC Surveill Summ 1990;39(3):13-21. 
 125 
230. Aagaard-Tillery KMDP, Spong CYMD, Thom EP, et al. Pharmacogenomics of Maternal 
Tobacco Use: Metabolic Gene Polymorphisms and Risk of Adverse Pregnancy 
Outcomes. Obstetrics & Gynecology 2010;115(3):568-77. 
231. Hong YC, Lee KH, Son BK, et al. Effects of the GSTM1 and GSTT1 polymorphisms on 
the relationship between maternal exposure to environmental tobacco smoke and neonatal 
birth weight. J Occup Environ Med 2003;45(5):492-8. 
232. Chen CL, Liu Q, Relling MV. Simultaneous characterization of glutathione S-transferase 
M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. 
Pharmacogenetics 1996;6(2):187-91. 
233. Alexander, Kogan, Himes, et al. Racial differences in birthweight for gestational age and 
infant mortality in extremely-low-risk US populations. Paediatric and Perinatal 
Epidemiology 1999;13(2):205-17. 
234. Okah FA, Cai J, Dew PC, et al. Risk Factors for Recurrent Small-for-Gestational-Age 
Birth. Amer J Perinatol;27(01):001-7. 
235. Resnik R. One size does not fit all. Am J Obstet Gynecol 2007;197(3):221-2. 
236. Fisher KA, Luger A, Spargo BH, et al. Hypertension in pregnancy: clinical-pathological 
correlations and remote prognosis. Medicine (Baltimore) 1981;60(4):267-76. 
237. Zhang J, Klebanoff MA, Roberts JM. Prediction of adverse outcomes by common 
definitions of hypertension in pregnancy. Obstet Gynecol 2001;97(2):261-7. 
238. Kwong WY, Wild AE, Roberts P, et al. Maternal undernutrition during the 
preimplantation period of rat development causes blastocyst abnormalities and 
programming of postnatal hypertension. Development 2000;127(19):4195-202. 
239. Hemmings DG, Williams SJ, Davidge ST. Increased myogenic tone in 7-month-old adult 
male but not female offspring from rat dams exposed to hypoxia during pregnancy. Am J 
Physiol Heart Circ Physiol 2005;289(2):H674-82. 
240. Ojeda NB, Grigore D, Robertson EB, et al. Estrogen Protects Against Increased Blood 
Pressure in Postpubertal Female Growth Restricted Offspring. Hypertension 
2007;50(4):679-85. 
241. Ojeda NB, Grigore D, Yanes LL, et al. Testosterone contributes to marked elevations in 
mean arterial pressure in adult male intrauterine growth restricted offspring. Am J Physiol 
Regul Integr Comp Physiol 2007;292(2):R758-63. 
242. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens 
Pregnancy 2003;22(2):143-8. 
243. Salafia CM, Maas E, Thorp JM, et al. Measures of placental growth in relation to birth 
weight and gestational age. Am J Epidemiol 2005;162(10):991-8. 
244. Benirschke K. Examination of the Placenta. Obstet Gynecol 1961;18:309-33. 
245. Shibata E, Hubel CA, Powers RW, et al. Placental system A amino acid transport is 
reduced in pregnancies with small for gestational age (SGA) infants but not in 
preeclampsia with SGA infants. Placenta 2008;29(10):879-82. 
246. Forsen T, Eriksson JG, Tuomilehto J, et al. Growth in utero and during childhood among 
women who develop coronary heart disease: longitudinal study. BMJ 
1999;319(7222):1403-7. 
 
 
